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Abstract
Background/aims
The macula is a specialised part of the retina responsible for detailed central and colour
vision. The carotenoids lutein, zeaxanthin and meso-zeaxanthin are uniquely
concentrated in the inner and central layers of the primate macula, where they are
collectively known as macular pigment (MP). Macular pigment confers potent
antioxidant and anti-inflammatory effects in the eye. Many studies have suggested that
these carotenoids are lower in age-related macular degeneration (AMD) and that
increased levels of MP may confer protection against AMD, especially the late form
of the disease. Research is now beginning to focus on MP optical density (MPOD) and
carotenoid intake in diabetes mellitus, a condition which similar to AMD, is known to
cause oxidative damage and inflammation in the retina.
Methods
The optical density of MP was measured in a group of participants with diabetes (Type
1 and Type 2) and findings compared with normal healthy controls. A comprehensive
review was performed to investigate the putative causal mechanisms and metabolic
perturbations associated with lower MP in diabetes. Surrogate biomarkers for the
prediction of low MP in participants with Type 2 diabetes and older adults free of
ocular pathology, including clinical [blood pressure], plasma [lipoproteins,
inflammatory markers] and anthropometric [waist (cm), hip (cm), height (cm), weight
(kg)] parameters, were investigated and identified as part of a large randomly selected
sample from the Republic of Ireland (as part of The Irish Longitudinal Study on
Ageing [TILDA]).
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Results
The optical density of MP was lower among Type 2 diabetes subjects (0.33 ± 0.21)
compared with Type 1 subjects (0.49 ± 0.23) and normal controls (0.48 ± 0.35) (p=
0.01). A comprehensive review of MP and diabetes, Type 2 diabetes, in particular,
revealed that MP may become depleted through at least four possible causal
mechanisms in this condition including overweight/obesity, dyslipidaemia, oxidative
stress and inflammation. Research performed on the TILDA cohort confirmed that
participants with Type 2 diabetes had significantly lower MPOD compared with nondiabetic controls (p=0.047). In-depth analysis on this Type 2 diabetes cohort revealed
that MP was significantly lower in diabetes participants who were deficient in plasma
vitamin D (<50 nmol/L) (p=0.006); who had a raised triglyceride (TG) over highdensity lipoprotein (HDL) ratio (TG/HDL) [>1.74 mmol/L; p=0.039]; who had
hypertension (p=0.043); who were current smokers (p=0.022); or who had cataracts
(p=0.049). Among older adults who were free of ocular pathology (i.e. AMD,
glaucoma, diabetes, pre-diabetes), MPOD was significantly lower among participants
with an elevated waist circumference (WC) (p=0.034), those who had low plasma
HDL (p=0.038), those with a raised plasma TG/HDL ratio (p=0.003) and those with a
raised total cholesterol (TC) over HDL ratio (TC/HDL) (p=0.030).
Conclusion
Overall, our findings suggest that individuals with Type 2 diabetes have lower MP
relative to healthy controls. The metabolic correlates associated with Type 2 diabetes,
in

particular,

i.e.

oxidative

stress,

inflammation,

overweight/obesity and

dyslipidaemia, may have important implications for MPOD in the retina. Surrogate
biomarkers associated with lower MP in Type 2 diabetes include low plasma levels of
2

vitamin D (25(OH) D), dyslipidaemia (i.e. raised TG/HDL ratio), hypertension,
cataracts and smoking. While an altered lipoprotein profile (i.e. low HDL, raised
TG/HDL ratio, raised TC/HDL ratio), may affect the transport, uptake, and
stabilisation of carotenoids in the retina of older adults free of ocular pathology, it
appears that WC is a more robust predictor of lower MPOD in this patient cohort.
However, its effect size appears to be small and therefore its clinical applicability is
questionable.

Keywords: dyslipidaemia; high-density lipoprotein; macular pigment; triglycerides;
vitamin D (25(OH) D), waist circumference.
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1. INTRODUCTION
1.1 Background
The hydroxyl-carotenoids lutein, zeaxanthin and the retinal metabolite of lutein, mesozeaxanthin, concentrate at the macula where they are collectively known as macular
pigment (MP).1 The selective accumulation of only three specific dietary carotenoids,
to the exclusion of all other carotenoids in nature, suggests an exquisite biological
function at the site of best vision and indicates a role that is uniquely suited to this
anatomic location. It has been shown that MP can influence the quality of visual
performance through the selective absorption of short-wavelength light before
photoreceptor light capture.2 Macular pigment also protects the retina from photooxidative damage by means of its optical filtration and/or antioxidant properties.2, 3
Evidence is now emerging that these carotenoids exhibit a neuroprotective and antiinflammatory function in the retina.4 While there is a growing body of evidence to
suggest that MP is lower in patients with age-related macular degeneration (AMD),
and that increased levels of MP may confer protection against this disorder,3, 5 only a
small number of studies have focused on carotenoid intake and MP optical density
(MPOD) in diabetes mellitus.6,

7

Diabetic retinopathy is one of the primary

microvascular complications of diabetes and the leading cause of blindness in the
working-age population.8 There is strong evidence to suggest that oxidative stress
and its associated inflammation

10

9

play an important role in the development of

diabetic retinopathy. Macular pigment may, therefore, through its antioxidant, antiinflammatory and/or pre-receptoral filtration properties;

2-4

confer protection against

diabetic eye disease. This is the focus of the current research.
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1.2 Rationale
The condition diabetes mellitus is explored in detail. Whilst diabetes is characterised
by having higher than normal blood glucose levels, the pathogenesis and development
of the two main forms of the disease, Type 1 and Type 2 diabetes, differ, and may,
therefore, have unique and independent relationships with MP. While there is no cure
for diabetic retinopathy, new approaches are now being taken to understand the
pathophysiology of the disease to help improve its detection, prevention, and
treatment. Current treatment paradigms for diabetic retinopathy include laser
photocoagulation,11 intravitreal injections,12 and vitreoretinal surgery,13 all of which
focus on the advanced form of the disease, often after permanent damage has occurred.
Newer treatments which are preventative in nature or which address early pathological
changes are therefore highly desirable. Research is now beginning to examine the
possible beneficial effects of dietary supplemental lutein, zeaxanthin, and mesozeaxanthin in protecting ocular tissues and cells, including retinal neurons, in the hope
that these phytochemicals may retard disease progression, a concept explored in
section one.14, 15

An initial evaluation of the available evidence suggested that MP appears to be
generally lower in populations with diabetes compared with healthy controls,6 in
particular amongst patients with Type 2 diabetes.7 A comprehensive review of the
available evidence pertaining to the relationship between diabetes mellitus and MPOD
was undertaken, therefore, with the primary focus to explore the putative causal
mechanisms and metabolic perturbations which might explain any associations
between diabetes, (Type 2 diabetes in particular) and MP status. Metabolic correlates
associated with Type 2 diabetes include overweight/obesity,16, 17 dyslipidaemia,18, 19
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oxidative stress,9 and inflammation;10 mechanisms which may have both independent
and synergistic relationships with MP, a concept which is explored in detail in the
review.

In addition to the review evidence, a body of experimental work was also designed
and executed to; a) explore MP levels in a group of participants with diabetes mellitus
(Type 1 & Type 2) relative to normal healthy controls; b) explore this concept further
in Type 2 diabetes participants derived from a large representative population of older
adults as part of the Irish Longitudinal Study of Aging (TILDA), with specific focus
on the identification of surrogate biomarkers for the prediction of low MP in these
Type 2 diabetes subjects; and c) identify proxy biomarkers associated with lower MP
in a group of older Irish adults in TILDA who are free of ocular pathology (i.e. AMD,
glaucoma, diabetes, pre-diabetes).
1.3 Research benefits
Macular pigment has several important functions in the eye including blue light
filtration and potent antioxidant activities.2, 3 More recently, research has suggested
that MP also has neuroprotective and anti-inflammatory effects in the eye.4 Diabetic
retinopathy is the leading cause of blindness in the working-age population,8 and
chronic disease progression is believed to be linked to the interaction between
inflammation 10 and oxidative stress.9 There is a growing body of evidence to suggest
that increased levels of MP may confer protection in AMD,3,

5

and there is also

preliminary evidence from animal studies to suggest a similar protective effect in
diabetes.14, 20 In humans, a recent randomised control trial (RCT) in this area has also
yielded promising data which suggests that higher MP levels may prevent or retard
the progression of diabetic retinopathy.21
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Optometrists and eye care practitioners can play an important role in preventative eye
care. At a community level, screening for lutein, zeaxanthin and MP levels in the
macula would help identify patients at risk of low MPOD and stratify those patients
requiring appropriate dietary intervention and/or additional supplementation. The
density of MP can be augmented by eating foods rich in these carotenoids (i.e. green
leafy vegetables, fruits, and legumes).22 Supplements rich in these phytonutrients are
also widely available. The MPOD can be measured in vivo 23 and represents a longterm measure of dietary carotenoid accumulation over months to years. However,
MPOD is not routinely measured in clinical practice. Consequently, there may be
value in exploring commonly measured surrogate biomarkers for the prediction of
patients at risk of low MP, given that higher levels of MP may be beneficial to the
retina. Clinical benefits may be realised by using these proxies to identify patients at
increased risk of MPOD depletion (i.e. patients with Type 2 diabetes, older adults free
of ocular pathology), and the use of early intervention protocols to address these
MPOD deficits.

Given the myriad of mechanisms which may contribute to MPOD depletion in Type
2 diabetes, and the ocular risks putatively associated with lower MPOD in diabetes,
lifestyle modification which involves a comprehensive dietary approach is a logical
first step to optimise MPOD status and ocular health outcomes. De novo synthesis of
MP is not possible in humans, therefore, the importance of diet cannot be
overemphasised in the management of diabetic eye disease risk. Nutritional advice on
the inclusion of foods rich in the carotenoids lutein and zeaxanthin (i.e. fruit,
vegetables, legumes), and other dietary strategies to optimise lipoprotein status (i.e.
triglycerides (TGs), high-density-lipoprotein (HDL), low-density-lipoprotein (LDL))
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may, therefore, have long-term clinical impacts on disease prevention and progression.
Dietary advice and lifestyle modifications which are also applicable to older adults
identified with MP deficits.

Although the long-term benefits of maintaining high MP density during life are not
yet known, there is the possibility that a more robust MP status over the full life course
may retard disease progression in later years. Research has shown that neuroretinal
changes can occur long before retinal signs of pathology become visible (i.e. microaneurysms, dot and blot haemorrhages in diabetic retinopathy). Therefore, increased
awareness of the ocular risks associated with certain metabolic disturbances, (i.e.
increased visceral fat, dyslipidaemia) and lifestyle choices (i.e. tobacco use) may yield
behavioural changes which ultimately confer long-term visual health benefits, not only
in patients with diabetes mellitus but also in older adults free of ocular pathology.
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2. THE RETINA
2.1 Introduction
Diabetes mellitus is a group of metabolic disorders characterised by hyperglycaemia,
arising from defects in either insulin secretion, insulin action or both.24 Diabetic
retinopathy is the most frequent microvascular complication of the disease and the
most common cause of blindness in the working-age population.25 The main reasons
for vision loss are diabetic macular oedema and proliferative diabetic retinopathy. The
likelihood of developing retinopathy is related to the duration of disease,
hyperglycaemia, hypertension and possibly dyslipidaemia.26 Type 1 and Type 2
diabetes are the two main forms of the disease.27 Type 2 diabetes has an insidious
onset and can go unnoticed for many years. As a result, patients may already have
diabetic retinopathy at the time of diagnosis.25 Conversely, Type 1 diabetes patients
are diagnosed promptly and typically do not develop retinopathy until years after the
diagnosis is made. Approximately 60% of Type 2 diabetes patients and nearly all Type
1 patients, however, will show some signs of retinopathy 20 years after disease
diagnosis.25 Although the incidence and progression of the potentially blinding
complications of retinopathy can be reduced with tighter glucose control,28 the
fundamental causes of diabetic retinopathy remain uncertain. The unique anatomy and
physiology of the retina may even make it uniquely susceptible to the metabolic
stresses of diabetes.29 In this regard, an understanding of the anatomy and physiology
of the normal retina may give us better insight into what can go wrong in diabetes, and
how these pathological mechanisms can be averted. The pathological sequelae of
diabetes which are relevant to ocular health will be explored in this chapter.
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2.2 The retina
The retina is the light-sensitive layer that extends over the inner surface of the back of
the eyeball, lying in contact with the vitreous matter internally and with the vascular
layer, the choroid, externally. The retina is a transparent layer of neural tissue. The
gross anatomy of the retina is divided into the outer pigmented epithelial layer and the
inner neural sensory layers. These layers form a functional unit essential for vision.

Figure 2.1: Schematic drawing of the human eye (Adapted from Morello 30).

Normal vision depends on cell to cell communication between the neuronal, glial,
microglial, vascular, and pigmented epithelial cells of the retina.29 The major functions
of the retina are to capture photons of light, convert this photochemical energy into
electrical energy, integrate the resulting action potentials and transmit them to higher
brain centres where they are interpreted into recognisable images.29 The neural
components of the eye are an extension of the forebrain and thus form part of the
central nervous system.

The structure of the retina consists of ten distinct layers, of which there are two
synaptic layers. The lamellar cellular architecture of the retina (Figure 2.2), has
alternating layers of neurons (outer and inner nuclear layers and ganglion cell layer)
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interposed with two plexiform layers where neurons communicate and where visual
signals must synapse as they emerge from the rods and cones on their way to the optic
nerve.

Figure 2.2: Light micrograph of a vertical section through central human retina
(Adapted from Kolb et al, 31).

Abbreviations: OLM-outer limiting membrane; ONL-outer nuclear layer; OPL-outer
plexiform layer; INL-inner nuclear layer; IPL-inner plexiform layer; GCL-ganglion
cell layer; ILM-inner limiting membrane.

The anatomy of the retina in Figure 2.3 is described in relation to optical coherence
tomography (OCT), a technique currently used in the diagnosis and follow-up of
diabetic retinopathy. It allows the multiple layers of the retina and choroid to be seen
according to the classification laid down by the international panel of experts in
vitreoretinal diseases.32
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Figure 2.3: Nomenclature for normal anatomic landmarks seen on spectral-domain
OCT images proposed and adopted by the International Nomenclature for OCT Panel.
Healthy retina imaged using Zeiss Cirrus.32
Abbreviation: RPE = retinal pigment epithelium.
2.3 The macula
The macula represents the central part of the retina which is specialised for high spatial
resolution and colour vision. The term macula derives from the presence of
xanthophyll pigments, lutein, zeaxanthin, and meso-zeaxanthin, appearing as a yellow
spot (macula lutea) when viewed in red-free light.33 The macula is approximately 5.85
mm in diameter and is centered about 4 mm temporal and 0.8 mm inferior to the centre
of the optic disc.34 Based on microscopic anatomy, the macular area can be subdivided
into several zones: the macula lutea (~5.85 mm diameter), fovea centralis (~1.85 mm
diameter) and the foveola (~0.35 mm diameter) 35 (Figure. 2.4).
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Figure 2.4: Schematic drawing of human foveolar (Adapted from Kanski et al,36).

The macular area can also be described and divided in terms of its different areas: the
fovea containing the foveola; the parafovea and the perifovea
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(Figure. 2.5). The

foveola is surrounded by a wide ring zone where the ganglion cell layer, inner nuclear
layer and outer plexiform layer of Henle are thickest. This is called the parafoveal
area.38 This area has a relatively low density of retinal vessels and below-average
spatial density of rods.39 The perifovea circumscribes the parafovea. The high rod:
cone ratio and the high density of the retinal vasculature are features common to this
area.39
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Figure 2.5: An anatomical view of the macula region as viewed through cross-section
(Adapted from Thibos et al,37 ).
2.3.1 Specialisation of the macula
The central retina has evolved to enable us to see better i.e. to resolve fine spatial detail
and allow colour perception. This is possible because of the unique structure of the
macula which includes close packing and elongation of photoreceptors (especially
cones), ‘midget’ circuitry which dominates the macular region, and refinement and
specialisation of the central retinal vasculature.40 The fovea accounts for almost all of
our useful photopic vision, even though it comprises less than 4% of the total retinal
area. The fovea has the highest cone density and the central 100 µm of the foveola
contains only red and green cones.39 Blue cone density is highest in a zone between
100 and 300 µm from the centre of the fovea, and the foveola is entirely rod free.39
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An important factor contributing to foveal morphology is the predominance of a
‘midget’ circuitry, in which the majority of bipolar cells are ‘midget bipolar cells’
which each connects to a single cone in the outer nuclear layer and a single ganglion
cell in the ganglion cell layer.40 These ‘midget’ pathways are distinctive in the absence
of convergence of photoreceptor signals onto bipolar and ganglion cells.41 Conversely,
‘parasol’ cell circuits in the periphery are converging, and a single parasol ganglion
cell receives input from multiple ‘diffuse’ bipolar cells and numerous receptors in the
outer nuclear layer.40 The foveola coincides with an area which is devoid of retinal
blood vessels, called the ‘foveal avascular zone’ (FAZ). Most layers of the sensory
retina are displaced sideways at the foveola to create the foveal pit, thus,
photoreceptors have unimpeded stimulation from light forming the retinal image
(Figure 2.6). This anatomic specialisation serves to maximise visual function by
removing angioscotomas from the visual image at fixation.42 Outside the fovea, rod
photoreceptors dominate and second (horizontal, bipolar and amacrine cells) and third
(ganglion cells) order neurons are present.
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Figure 2.6: A comparison of histological and OCT images of the cross-sectional
appearance of the human retina, at the fovea centralis (Adapted from Provis et al,40).

Abbreviations: NFL-nerve fibre layer; GCL-ganglion cell layer; IPL-inner plexiform
layer; INL-inner nuclear layer; OPL-outer plexiform layer; ONL-outer nuclear layer;
ELM-external limiting membrane; IS-inner segment; OS-outer segment; RPE-retinal
pigment epithelium.
2.4 Macular pigment
Although MP is found throughout the tissue of the eye, it is concentrated in the macula
lutea region of the retina. The primary localisation of human MP is in the inner retinal
layers, in the fibres of Henle of the fovea, and parafoveally MP is located in the inner
and outer plexiform layers.43 The unique distribution of MP within the retina implies
that these carotenoids play an important role in vision and macular health, and are
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biologically relevant to the eye.44,
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Carotenoids lutein, zeaxanthin and meso-

zeaxanthin are collectively referred to as MP.46 De novo synthesis of MP is not
possible in humans, therefore, must be obtained from dietary sources. Current studies
indicate an ability to influence concentrations of carotenoids in MP by increasing
concentrations ingested from foods 17, 47 and/or supplements.48 Individual responses to
dietary intake and/or supplementation, however, is quite variable and may change with
time. Investigators have examined and identified possible predictors of MPOD, and
found associations with age, 49, 50 sex,51 overweight/obesity status,52-54 and smoking,52
among others, and will be discussed herein.
Age
Several lines of evidence suggest that MP may play a protective role against AMD,
however, the association between age and MPOD remains unclear. Some studies have
demonstrated a decline in MPOD with age,
increase

57, 58

49, 55, 56

while others have shown an

and yet other studies have shown no such relationship.59, 60 Research

reporting on the association between age and MP is variable possibly due to differing
methodologies being used to measure MPOD, differences in sample sizes and/or
inconsistencies in age ranges. One recent study demonstrated that MPOD appeared to
increase during adulthood (peak at 45-50 years) followed by a gradual reduction after
60 years.61 This study postulated that if these findings can be confirmed in larger
studies then it would be important to recommend supplementation, using lutein and
zeaxanthin, in older populations as prophylaxis against age-related maculopathy.61
Longitudinal data in larger cohorts, however, is required to satisfactorily investigate
the relationship between the optical density of this pigment and age.
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Gender
Gender differences in MPOD have also been reported.16, 17 Hammond et al.51 found
that males had an average of 38% more MP than females and suggested that lutein
might accumulate in the retina more readily in men than in women. While there was a
positive correlation between plasma carotenoids and the density of MP for both sexes
the relationship was stronger for men (males r=0.62, females r=0.3).51 Another study
found a significant negative correlation between adipose tissue lutein concentrations
and MP for women and a significant positive correlation was found for men.17 These
researchers suggested that sex differences in lutein metabolism may be an important
factor in tissue interactions and in determining MP density,17 and that adipose tissue
may compete for carotenoids more effectively in women than men. Not all research,
however, supports these findings. A relative lack of MP was associated with adiposity
in men, and these researchers suggested that this link might underlie the association
between body fat and risk for AMD progression in males.16
Smoking
Several investigations have reported an association between cigarette smoking and
MP.49, 62 55, 63 Hammond et al.64 compared MP measurements in participants who were
current smokers compared with non-smokers, matched for age, sex, dietary patterns
and overall pigmentation. Tobacco users had significantly lower MP (MPOD 0.16)
compared with the controls (MPOD 0.34). Nolan et al.52 reported not only a significant
difference in MP between current and non-smokers but also an inverse dose-response
relationship between MP and the number of cigarettes smoked per day. Research
suggests that current smoking may lead to lower MP levels in the eye as smoking is
associated with increased oxidative stress, not only through the increased systemic
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production of free radicals but also though the weakening of the antioxidant system
and/or poor diet.65 Of interest, cigarette smoking is an established and important
modifiable risk factor for AMD.66 It is possible that the lack of macular carotenoids
among smokers may shift the oxidant/antioxidant balance in favour of AMD.
Overweight/obesity
Studies have reported an inverse relationship between overweight/obesity and MPOD
16, 54

with the observed relationships largely attributable to participants with a BMI >

29 kg/m2.54 Although BMI measures do not provide a precise measure of adiposity it
is likely that higher BMI levels are reflective of excess adipose tissue. Lutein,
zeaxanthin and meso-zeaxanthin, the major components of MP, are fat-soluble
pigments and adipose tissue is a major storage site of the macular carotenoids.67 As
body weight increases, it is suggested that more dietary xanthophyll carotenoids will
be absorbed into adipocyte, thereby, making these carotenoids less available to the
macula.68 Also, increased adipose tissue, visceral fat, in particular, is associated with
a state of chronic low-grade inflammation, which in turn leads to increased oxidative
stress,69 factors which may exert an even greater demand on antioxidant defences
within the body, including MPOD.

Concentrations of carotenoids in the macular are highly variable. Apart from dietary
intake, age, gender, current smoking and overweight/obesity, MP levels may also be
influenced by other factors including the effective absorption of these
phytonutrients,70 competition among carotenoids for absorption,
71

metabolic status,

6

17

dyslipidaemia, 18,

and genetic variation.72 Macular pigment will be discussed in

more detail in chapter four.
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2.5 Cell types in the retina
The retinal tissue contains both neuronal and non-neuronal elements which work
together to enable vision and maintain retinal homeostasis. The five major cell types
in the retina perform sensory, nutritional, regulatory and immunomodulatory
functions.
2.5.1 The neurons
The neurons (photoreceptors, bipolar, horizontal, amacrine and ganglion cells)
perform sensory functions and define colour perception, spatial resolution and contrast
discrimination.73 The laminated organisation of the retina generates two streams of
visual information: a main or vertical pathway, from the photoreceptors to bipolar cells
and from bipolar cells to ganglion cells; and a secondary lateral pathway, comprising
local feedback circuits from horizontal cells back to photoreceptors,74 and from
amacrine cells back to bipolar cells.75 Neurons mediate phototransduction and
modulate and convey nerve impulses which are ultimately transmitted to the brain
through the axons of the ganglion cells which comprise the nerve fibre layer and the
optic nerve.76 The distribution and variable density of photoreceptors and ganglion
cells across the retina, the differential light sensitivity of photoreceptors and the
convergence of information from the extra-foveal retina mean that a hierarchy exists
in the architecture of retinal processing and that foveal information is given higher
priority.2 This hierarchy continues back to the striate cortex, where a high percentage
of cortical cells are dedicated to foveal information 2 (i.e. cortical magnification).The
fovea is particularly important for functional vision and blindness results when this
area is lost to disease. The concept of neurodegeneration as an early component of
diabetic retinopathy and the potential neuroprotective effects of MP in preserving the
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integrity of the neural retina will be explored in more detail in chapters three and four.
2.5.2 Retinal glial cells
Three main types of glial cells are found in the mammalian retina which serves to
maintain retinal homeostasis. These include macroglial retinal cells (Muller cells and
astrocytes) and microglial cells. Glial cells exhibit distinct morphological and
antigenic characteristics which not only provide structural support for the retina but
which are also involved in metabolism, phagocytosis of neuronal debris and the release
of certain trophic factors and neurotransmitters (reviewed by Vecino et al,77). Glial
cells have intrinsic signalling systems which can spread in the form of calcium ion
(Ca2+) waves, and these are correlated with glutamate release.77 This signalling process
plays an important role in immunity, angiogenesis, and neuroprotection.77 Neuroglia
respond to injury as part of the defence to restore homeostasis; however, when they
malfunction, these cells can become a primary pathogenic element.77
2.5.2.1 Müller cells
Müller cells are the predominant macroglial element, representing 90% of retinal
glia.77 These cells span from the pigment epithelium to the internal limiting membrane,
and their cell bodies sit in the inner nuclear layer. Müller cells have intimate contact
with both the retinal blood vessels and the retinal neurons and serve a variety of
important functions. Müller cells are involved in; 1) the control of metabolism and
supply of nutrients to the retina; 2) the uptake and recycling of neurotransmitters,
retinoic acid compounds and ions (such as potassium (K+)); and 3) the regulation of
blood flow and maintenance of the blood-retinal barrier (reviewed by Coughlin et
al,78).
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Müller cells play an essential role in the normal function of a healthy retina. These
cells maintain glucose and neurotransmitter homeostasis by removing glucose and the
main retinal neurotransmitters glutamate and gamma-aminobutyric acid (GABA) from
the extracellular space.79 Müller cells synthesise, store and degrade glycogen,
therefore, when nutrient supplies are low Müller cells utilise glycogen to provide
metabolites for other cell types in the retina
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including photoreceptors which

preferentially take up lactate (partially-metabolised glucose produced by Müller cells)
as fuel for their oxidative metabolism.81 Müller cells transform GABA and glutamate
into glutamine, which is then returned to the extracellular space and re-utilised by
neurons.81 Additionally, Müller cells induce blood-barrier properties in retinal
endothelial cells.82 While Müller cells play a critical role in maintaining a healthy and
functioning retina, abnormalities in any of these functions can result in neuronal
dysfunction, cell death, retinal swelling (i.e. macular oedema) and break-down of the
blood-retinal barrier.78
2.5.2.2 Astrocytes
Astrocytes are the second type of macroglial cell and are almost exclusively confined
to the innermost retinal layers. A difference between astrocytes and Müller cells is that
while Müller cells are distributed throughout the retina independently of
vascularisation,83 astrocytes are present only in vascularised regions.77 Astrocytes
wrap around blood vessels and contact both ganglion and amacrine cells.77 Like Müller
cells, they are key regulators of neuronal nutrition as they store glycogen and provide
glucose to neurons. They also serve a role in ionic homeostasis in regulating
extracellular K+ levels and in metabolising neurotransmitters like GABA. Astrocytes
also contribute to the integrity of the blood-retinal barrier (reviewed by Wang &
Bordey84). Of key importance, astrocytes are the main producers of vascular
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endothelial growth factor (VEGF) during both normal and pathological vessel
formation (reviewed by Penn et al,85). Astroglial cells are therefore strongly implicated
in vascularisation. While these cells perform essential tasks for the normal physiology
of the retina, in response to injury or disease these same astrocytes express several
proteins which compromise the integrity of the blood-retinal barrier, upregulate the
expression of various genes encoding cytokines, chemokines and elements of the
complement cascade, and promote retinal degeneration.86
2.5.3 Microglial cells
Microglial cells are found in every layer of the human retina and provide an
immunomodulatory function. These cells migrate through the extracellular space
between retinal layers and contribute to the healing of degenerating neurons, thereby
protecting the functional and structural integrity of the retina.87 Microglial cells share
some of the same properties as circulating and resident macrophages, such as
phagocytic activity and the release of various cytokines.87 Microglial cells are
extremely sensitive to changes in their microenvironment and become activated by
extracellular signals such as neuronal damage, chronic neurodegeneration, cell death
and ischaemia.87 Once activated, microglia undergo morphological and functional
changes, developing into one of two possible phenotypes: an activated proinflammatory M1 phenotype which releases inflammatory molecules including
cytokines (tumour necrosis alpha (TNF-α), interleukin 1 beta (IL-1β) and interleukin
6 (IL-6)) and toxic metabolites like glutamate. Alternatively, activated microglia can
develop an M2 phenotype. These cells are primarily involved in neuroprotection by
releasing anti-inflammatory cytokines (IL-4 and IL-10).88, 89 In summary, microglial
activity initially contributes to neuronal protection and tissue regeneration; however,
continuous stimulation from exogenous and endogenous stressors can lead to chronic
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over activation and loss of these auto-regulatory mechanisms, changes which are
detrimental to local neurons.87, 90 Figure 2.7 is a schematic of the various types of
retinal cells, both neuronal and non-neuronal (adapted from Gardner et al,91).

Figure 2.7: Schematic of the major types of retinal cells: vascular; macro glial cells
(Müller cells and astrocytes); neurons (photoreceptors, bipolar cells, amacrine, and
ganglion cells); and microglia (Adapted from Gardner et al,91).
2.5.4 The retinal pigment epithelium
Morphologically the RPE forms a highly polarised epithelial sheet that separates the
choroid from the retina. This layer of cells is divided into a basal half which faces the
choroid, and an apical half which faces the retina. The basal end of each cell is much
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in folded and rests on the basement membrane which forms part of Bruch’s membrane.
The apical ends of the cells have multiple microvilli and these project between and
surround the outer segments of the rods and cones 92 (Figure 2.8). The epithelial cells
are joined together by tight junctions which prevent diffusion of large toxic molecules
from the choroid capillaries to the photoreceptors; therefore, the RPE acts as a barrier
(the outer blood-retinal barrier).93 The RPE also provides the principal route for the
transfer of nutrients to the retina. It takes up nutrients such as glucose, retinol and fatty
acids from the blood and delivers these nutrients to the photoreceptors.94

Figure 2.8: Diagram showing the relationship between the photoreceptor cells and
the RPE (Adapted from Katz & Robison 95).
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The RPE performs several highly specialised functions essential for homeostasis of
the neural retina. The RPE plays an integral part in the visual cycle, as it is the principal
storage depot for vitamin A.93 In this regard, it supplies the essential visual cycle
intermediate, 11-cis-retinal, to photoreceptors for the regeneration of rhodopsin.96 The
RPE is also involved in the phagocytosis of shed photoreceptor outer segments.97
These segments are digested and essential substances, such as retinal, are recycled and
returned to the photoreceptors.98 Additionally, the RPE is known to produce and
secrete a variety of growth factors as well as factors which are essential for
maintaining the structural integrity of the retina and choriocapillaris, including
pigment epithelium-derived factor (PEDF), insulin-like growth factor-1 (IGF-1) and
VEGF among others (reviewed by Strauss 93). The RPE allows oxygen diffusion from
the choroidal circulation to the outer retina, a process critical in maintaining normal
photoreceptor cell function and survival.94 Furthermore, as a layer of pigmented cells,
the RPE protects the retina from light damage by the absorption of excessive
photons.99 The many complex and unique functions of the RPE play a critical role in
vision. A failure of any one of these functions can lead to degeneration and loss of
visual function; however, to date, the role of the RPE in diabetic retinopathy remains
elusive.
2.5.5 Endothelial cells and pericytes
The fifth class of cells includes vascular endothelial cells and pericytes. Retinal
capillaries are comprised of a single layer of endothelial cells bound by pericytes, and
both cell types are covered by a common basement membrane100 (Figure 2.9).
Interaction between pericytes and vascular endothelial cells is important in the
regulation of vascular function and the maintenance of the retinal homeostatic
environment. Endothelial cells line the vasculature and serve as a physical barrier
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between blood and the surrounding tissue and constitute the inner blood-retinal
barrier.91 The presence of tight junctions prevents the outward flow of macromolecules
and maintains the local microenvironment.101 The endothelium also efficiently
supplies oxygen and nutrients to the neural retina. Under certain conditions such as
hyperglycaemia, however, retinal endothelial cells become particularly vulnerable.

Healthy Retina
Basement
Membrane

Endothelium

Pericyte

Figure 2.9: Endothelial–pericyte interactions in micro vessels. Pericytes surrounding
endothelial cells share the basement membrane with endothelial cells (Modified from
Simo et al,100).

Pericytes are modified smooth muscle cells that line the outer walls of capillaries and
play a critical role in vessel patency by regulating vascular tone and providing
structural support.102 In this way, pericytes regulate retinal vascular flow by dilating
and contracting,91 and provide nutritional support and waste product removal for the
inner retina.29 One of the earliest responses to hyperglycaemia is pericyte apoptosis.103
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Endothelial cells’ and pericytes’ wide-ranging functions include mediating repair of
the vasculature, promoting the blood-retinal barrier and functioning as hypoxic
sensors.104

Retinal microvascular dysfunction is a major component of diabetic retinopathy and
is characterised clinically by dot and blot haemorrhages and micro aneurysms on the
retina in the earlier stages of diabetes. Visible retinal changes have led to the general
assumption that diabetic retinopathy is predominantly a microvascular abnormality,
however, it is now evident that diabetic retinopathy affects all of the major retinal cell
types (including neuronal and non-neuronal cells). Both retinal neurodegeneration and
microvascular complications are therefore implicated in diabetic retinopathy.91 The
interaction and functional integration of all of these cell types is required for normal
vision, however, disruption to any of them may impair vision.
2.5.5.1 The blood-retinal barrier
Metabolic support for the inner retina comes from a vascular network that traverses
the ganglion cell layer and extends down to the outer plexiform layer. Support for the
outer retina is achieved by diffusion from the vascularised choroid across the RPE.
Together, these retinal vessels along with the RPE form the inner and outer bloodretinal barrier.105, 106 The blood-retinal barrier partitions the neural elements of the
retina from the circulation to protect it from circulating inflammatory cells and their
cytotoxic products, and allows the retina to regulate its extracellular composition.105
This functional barrier resides at the level of tight junctions between adjacent
endothelial cells.91 Several unique proteins constitute the vascular endothelial tight
junctions including occludin and claudins.107 These proteins span the plasma
membrane and limit fluid flow between endothelial cells 106 (Figure 2.10).
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Figure 2.10: Schematic presentation of the inner and outer blood-retinal
barriers and their relative location (Adapted from Cuhna-Vaz et al, 106).
Abbreviation: ECF = extracellular fluid.

The cytokine, VEGF, can induce changes in the expression of these proteins and
therefore influence vascular permeability.105 Because all retinal cells (macroglial,
microglial, and neurons) are capable of releasing pro-inflammatory cytokines such as
VEGF, it is likely that they further exacerbate retinal vascular permeability in
diabetes.101
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Figure 2.11: Pathways for solute movements across the inner blood-retinal barrier
(retinal endothelial cells). (A) Normal. (B) Mechanisms of the breakdown of the inner
blood-retinal barrier (Adapted from Cunha-Vaz et al,106).
2.6 Blood supply to the retina
The retina receives vascular supply from two sources: the central retinal artery
supplies the inner retina and the choriocapillaris supplies the RPE and outer retina
(both of which originate from the ophthalmic artery). The retina is one of the most
metabolically active tissues in the body, therefore, the retina must have an extensive
vascular network to maintain proper functioning and to cope with such a high oxygen
demand. The central retinal artery enters the optic nerve some 10 to 15 mm behind the
globe. On entering the eye, the vessels branch into inferior and superior divisions
which continue to subdivide into arterioles (superior, inferior, nasal and temporal),
and extend away from the optic disc to supply the inner two-thirds of the retina
(Figure 2.12).
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Figure 2.12: A fundus photograph showing the retinal blood supply to the superior
temporal (ST), superior nasal (SN), inferior temporal (IT) and inferior nasal (IN)
arcades.

The arterial intra-retinal branches supply three layers of capillary networks: the radial
peri-papillary capillaries and the inner and outer layer of capillaries 108 (Figure 2.13).
The retinal vascular vessels provide blood to the inner retinal neurons which receive
20-30% of the total ocular blood flow.31
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Figure 2.13: Schematic cross-section showing the retinal blood vessels lining the
inner surface of the retina (Adapted from Santiago et al, 101).

Three capillary plexuses are embedded among retinal neurons: the superficial layer
lies within the inner nerve fibre layer (NFL) with branches extending into the ganglion
cell layer (GCL), while the intermediate and deep capillary plexuses align along each
side of the inner nuclear layer (INL). ONL, outer nuclear layer; IPL, inner plexiform
layer; OPL, outer plexiform layer.

The choroidal network supplies the choroid and the outer third of the retina with
oxygen and other necessary nutrients. The choroid receives 65-85% of ocular blood
flow,31 and is vital for the maintenance of the avascular outer retinal layers,
particularly the photoreceptors. The choroid is supplied primarily by the long and short
posterior ciliary arteries (branches of the ophthalmic artery), with a minor contribution
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from the anterior ciliary arteries.31 The choriocapillaris supplies the RPE and the outer
retinal layers. Retinal vessels are absent centrally at the fovea, (i.e. the FAZ) and the
choroid is responsible for blood supply to this region (Figure 2.14). The foveola has
the highest perfusion rate of any vascular bed within the human body reflecting the
high metabolic activity of the photoreceptors.109

Figure 2.14: Image of the FAZ. The calliper measurement of both horizontal and
vertical diameters of superficial (a) and deep (b) capillary plexus of the FAZ (Adapted
from Hussain & Hussain 110).

The retinal venous system exits the eye via the central retinal vein. The corresponding
retinal venous branches have much the same distribution as the retinal arteries.
Choroidal blood is thought to be drained exclusively through the vortex veins, with
one or two vortex veins draining each of the four quadrants of the eye.111 The vortex
veins penetrate the sclera to merge with the ophthalmic vein.
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2.6.1 Retinal oxygen consumption
Retinal oxygen distribution varies across the retina according to retinal cell type and
their associated level of metabolic activity. The highest oxygen tension is found in the
choroid and the lowest at the level of the photoreceptor inner segments.112 While the
choroid has a high oxygen tension, the extraordinarily high oxygen demand of the
photoreceptors, combined with the avascular nature of the foveola, results in a
substantially increased risk of these cells experiencing hypoxic episodes.112
2.7 Vulnerability of the retina to diabetic retinopathy
The physiology of the retina, and the unique structure of the macula, in particular, may
contribute to the eye’s susceptibility and vulnerability to diabetic retinopathy. 29 The
central retina is adapted for high acuity vision. To maximise vision, there is a
requirement for transparency at the macula, and this transparency imparts several
anatomical and physiological constraints in this region including; 1) the central retina
is devoid of blood vessels (i.e. the FAZ), an anatomic specialisation that serves to
enhance visual acuity (VA) by removing angioscotomas; 42 2) the retinal axons are not
ensheathed by myelin, as myelin is opaque and would, therefore, block light
transmission; 29 and 3) there is a reduced number of mitochondria in the inner retina,
as mitochondria contain light-absorbing haem-based cytochrome proteins which
would impede vision.29 These structural arrangements and adaptations are necessary
to ensure undisturbed light transmission at the point of highest VA, at the foveola.
Retinal and neural adaptations, such as these may, however, increase the eye’s
vulnerability to oxidative stress and inflammation.29 The partial oxygen pressure
declines from the outer retina to the inner retina.113 The oxygen tension of the inner
retina is relatively hypoxic because of the reduced density of blood vessels at the
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foveola. Furthermore, the inner retina possesses relatively few mitochondria.
Consequently, the inner retina relies heavily on anaerobic respiration (i.e. glycolysis)
which is a less efficient means of generating energy, compared with aerobic respiration
(i.e. oxidative phosphorylation) which predominates in the outer retina.29 Furthermore,
demyelinated retinal nerves require more energy to maintain membrane potentials
compared with myelinated axons.114

Despite the sparse vascularity and low oxygen tension, the retina has one of the highest
metabolic demands of any tissue in the body.112 Energy is required for
phototransduction, for neurotransmission at synapses, to replenish photoreceptor outer
segment membranes (daily), and to transport proteins and neurotransmitters via axons
to the optic nerve and lateral geniculate body of the thalamus.29 A healthy, visuallyfunctioning retina requires intact cell-cell communication, a specialisation that may,
however, be vulnerable to the hyperglycaemia-induced metabolic perturbations
typical of diabetes, which may result in neurotoxic or pro-inflammatory responses.
Interestingly, the outer retina is relatively protected from the early insults of diabetes
as it receives its oxygen and nutrients by diffusion from the choroid through the
pigmented epithelium. The combination, however, of high metabolic demand of the
retinal neurons, low vascular supply, and the presence of few mitochondria may limit
the inner retina’s ability to adapt to chronic hyperglycaemia in diabetes and its
associated oxidative stress/inflammation in the pathogenesis of diabetic retinopathy.
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3. DIABETES MELLITUS
3.1 Introduction to diabetes mellitus
Diabetes mellitus (diabetes) is a complex metabolic disorder, characterised by the
elevation and dysregulation of blood glucose levels as a result of a lack or
insufficiency of insulin.24 The condition is broadly classified into Type 1 and Type 2
diabetes.27 Type 1 diabetes is less common accounting for approximately 10 % of all
diabetes cases. It results from the autoimmune destruction of pancreatic beta (β)cells,115 leading to complete dependence on exogenous insulin to regulate blood
glucose levels.116 Type 1 diabetes typically presents in childhood or young adulthood.
Type 2 diabetes mellitus is the more common form of the disease accounting for
approximately 90% of patients.117 It normally affects individuals in later life, however,
due to increasing prosperity, lifestyle changes, and obesity, Type 2 diabetes is now
affecting a much younger age group.118 Type 2 diabetes is characterised by insufficient
secretion of insulin from the β-cells of the pancreatic islets, coupled with impaired
insulin sensitivity in target tissues such as muscle, liver and adipose tissue (a condition
termed insulin resistance).119 Therapy for Type 2 diabetes consists initially of dietary
control and lifestyle modification, followed by oral hypoglycaemic agents, which may
reduce insulin resistance, increase insulin secretion or reduce hepatic glucose
output.120 If these treatments fail to control hyperglycaemia, then insulin is given. Both
forms of diabetes (Type 1 and Type 2) are caused by a combination of genetic and
environmental risk factors.

The pathogenesis of Type 1 and Type 2 diabetes is different. Type 1 diabetes is a
chronic disease that destroys the body’s ability to make insulin. Young patients with
suspect Type 1 diabetes require prompt referral and diagnosis or else they risk diabetic
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ketoacidosis, a potentially life-threatening condition. Diabetic ketoacidosis
can develop when the body fails to store blood glucose as glycogen in the fed state
due to a lack of insulin; in this scenario, the body metabolises fat in a nonphysiological manner producing ketones to fuel the brain and other tissues which
normally use glucose. Unabated, this adaptive process results in a build-up of ketones
in the body with toxic effects,121 giving rise to diabetic coma or even death in extreme
circumstances. Once diagnosed, patients with Type 1 diabetes require a lifetime of
treatment with insulin.122

Type 2 diabetes usually develops insidiously in adulthood, although it is now affecting
a much younger age group. In Type 2 diabetes the pancreas usually produces some
insulin, however, the amount produced is not enough to overcome the resistance of
target tissues to its effects. In an insulin resistance state, normal or elevated insulin
levels consequently produce an attenuated biological response.123 The relative timing
of β-cell dysfunction and insulin resistance can, however, vary and it has been shown
that ‘abnormal’ insulin sensitivity can precede the clinical diagnosis of diabetes by up
to 15 years.124 The failure of compensatory hyperinsulinaemia by the pancreas is the
‘hallmark’ of frank hyperglycaemia
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and Type 2 diabetes ensues. At the time of

diagnosis patients with Type 2 diabetes generally present with a series of metabolic
comorbidities, including, insulin resistance, hyperinsulinaemia, hyperlipidaemia,
hypertension and overweight/obesity, features which are less common in Type 1
diabetes at diagnosis.126 Abnormal glucose metabolism can exist for many years in
Type 2 before overt diabetes is diagnosed and there may be no initial symptoms.24
Lifestyle modification early on, however, may not only address the existing
hyperglycaemia and other metabolic abnormalities but may also lead to better visual
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outcomes.
3.2 Epidemiology
With life expectancy and obesity on the rise worldwide, diabetes mellitus is becoming
a major public health problem, approaching epidemic proportions. Globally, an
estimated 422 million adults were living with diabetes in 2014, compared to 108
million in 1980.127 The prevalence (age-standardised) of diabetes worldwide has
nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population.128 The
number of patients with diabetes is predicted to rise to 642 million (uncertainty
interval: 521–829 million) by 2040.127 The International Diabetes Federation Diabetes
Atlas estimated that 207,490 people in the 20 – 79 year age group were living with
diabetes in Ireland in 2013 (prevalence 6.5%).129 A study carried out by TILDA in
2015, estimated that the prevalence of Type 2 diabetes and pre-diabetes was 9.5% and
5.5% respectively, with approximately 10% of cases undiagnosed.130 According to the
Healthy Ireland survey, 854,165 adults over 40 in the Republic of Ireland have Type
2 diabetes or are at increased risk of developing it.131 Furthermore, there are 304,383
people in the 30-39 year age group who are overweight and not taking the
recommended quantum of weekly physical activity, leaving them at an increased risk
of developing Type 2 diabetes.131 Therefore, there are over a million adults in Ireland
who need to make changes to their habitual dietary and physical activity patterns in
order to address their elevated risk of diabetes.131

Diabetic retinopathy, a common and specific microvascular complication of diabetes,
remains the leading cause of blindness in working-aged people.25 Up to 21% of
patients with Type 2 diabetes have retinopathy at the time of diagnosis.25 After 20
years with diabetes, nearly all patients with Type 1 and more than 60% of Type 2
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patients have developed retinopathy,25 and this prevalence increases with advancing
age.132 Early detection of retinopathy in individuals with diabetes is critical in
preventing vision loss.133 Irish statistics show that on average one person with diabetes
goes blind in Ireland each week.134 The National Diabetic Retinal Screening
Programme was developed in Ireland in 2013 and offers free regular diabetic
retinopathy screening to all people with diabetes aged 12 and over. Optometrists play
an important role in ensuring that patients participate. While there is no cure for
diabetic retinopathy, prompt treatment may be effective in preventing, delaying or
reducing vision loss in patients with this diabetes complication.
3.3 Diabetic retinopathy
Diabetic retinopathy is a major complication of diabetes mellitus and remains a
leading cause of preventable blindness.135 Traditionally it has been viewed as a
microvascular disease where microvascular lesions have been used as the major
criterion for evaluating and classifying diabetic retinopathy. Clinically, diabetic
retinopathy can be divided into two stages: non-proliferative and proliferative diabetic
retinopathy.136 Non-proliferative retinopathy is characterised by damage to the retinal
vasculature, increased vascular permeability, thickening of the basement membrane
and loss of pericytes.137 It can be classified into mild (micro-aneurysms), moderate
(micro-aneurysms, retinal haemorrhages or hard exudates) and severe (20
haemorrhages in each of the four quadrants, venous beading in two quadrants or the
presence of intra-retinal microvascular anomalies) 136 (Figure 3.1).
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Figure 3.1: Non-proliferative diabetic retinopathy; retinal micro-aneurysms,
haemorrhages and hard exudates (A and B); intra-retinal microvascular
abnormalities (C arrow); venous beading (D arrow) and venous loop formation (E
arrow) (Modified from Cheung et al,138).

Proliferative diabetic retinopathy is marked by the growth of new vessels on the retina
and posterior surface of the vitreous (angiogenesis), vitreous haemorrhage, retinal
scars and detachment.136 The ischaemic retina contains high levels of VEGF, the
driving force for neovascularisation.139 This stage of the disease can result in profound
and irreversible vision loss (Figure 3.2).
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Figure 3.2: Proliferative diabetic retinopathy; neovascularisation is a hallmark of
proliferative diabetic retinopathy (A, arrows). It can also be identified on fluorescein
retinal angiogram (B, arrows). Resolution of retinopathy with pan-retinal
photocoagulation (C). Progression of retinopathy without treatment (D) (Modified
from Cheung et al,138).

Diabetic macular oedema, a side effect of both non-proliferative and proliferative
diabetic retinopathy, can occur at any stage of the disease.137 It is caused by increased
vascular permeability and leakage of proteins and lipids into the extravascular space
due to functional damage of the retinal vascular epithelium and a breakdown of the
blood-retinal barrier 137 (Figure 3.3).
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Figure 3.3: Diabetic macular oedema; clinical diagnosis of diabetic macular oedema
based on stereoscopic examination of the macula (A, arrow). Diagnosis can also be
supplemented by OCT; three-dimensional topographic maps of the macula from OCT
allow visualisation of macular oedema in relation to internal limiting membrane or
RPE; B; overall topographic image (C), and horizontal (upper image, D) and vertical
(lower image, D). Cross-sectional images of the macula from OCT allow quantitative
and qualitative assessment of macular oedema (Modified from Cheung et al,138).

Improving technology has enabled the detection of more subtle pathologies and neural
layer abnormalities in patients with diabetes. Optical coherence tomography
angiography (OCTA) is a new vascular imaging technique which allows practitioners
to non-invasively investigate the FAZ and perifovea in more detail. Non-perfusion
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indices and FAZ parameters have been found to correlate with glycated haemoglobin
(HbA1c) (a measure of the patient’s average glucose level over the previous 2 to 3
months), in those with non-proliferative diabetic retinopathy.140 Early detection of
diabetic retinopathy can prevent severe loss of vision and even blindness.
3.4 Pathophysiology of diabetic retinopathy
Diabetic retinopathy has long been recognised as a microvascular disease. Chronic
exposure to hyperglycaemia and other causal factors (e.g. hypertension,
dyslipidaemia)

are

believed

to

initiate

a

cascade

of

biochemical

and

pathophysiological events which ultimately lead to microvascular changes and retinal
dysfunction. An understanding of the pathological processes leading to the onset of
diabetic retinopathy may provide the means to better manage and treat the disease. A
summary of these processes are presented here.
3.4.1 Hyperglycaemia
The initial stages of retinopathy collectively relate to endothelial dysfunction (i.e.
leukocyte adhesion, blood flow alterations, capillary closure and formation of leaky
vessels) and are most probably caused by the effects of elevated blood glucose
concentration on microvascular tissues.141 Adverse effects of persistently elevated
glucose levels vary according to cell type. Cells expressing high levels of the glucose
transporter 1 (GLUT 1), such as vascular endothelial cells, are unable to regulate
intracellular glucose concentrations and are, therefore, more susceptible to
hyperglycaemia-induced damage.142 The presence of hyperglycaemia affects various
molecular pathways, ultimately resulting in a breakdown of the blood-retinal barrier,
and damage to cells that make up these structures, including endothelial cells and
pericytes.143 Multiple metabolic pathways have been implicated in hyperglycaemia67

induced microvascular damage and these include the polyol pathway, activation of
advanced glycation end products (AGEs), and the hexosamine and protein kinase C
(PKC) pathways (Figure 3.4).144

Figure 3.4: The four major mechanisms involved in diabetic retinopathy are increased
polyol pathway flux, increased AGE formation, activation of PKC, and hexosamine
pathways (Adapted from Safi et al,144).

These pathways in one way or another result in increased oxidative stress,
inflammation and vascular occlusion, factors which contribute to the pathogenesis of
diabetic retinopathy. Several significant studies have provided strong evidence that
tight control of blood glucose, as assessed by HbA1c, can delay diabetic retinopathy
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onset and progression in patients with Type 1 28 and Type 2 145 diabetes. The Diabetes
Control and Complications Trial (DCCT) showed that intensive glycaemic control
reduced the incidence of retinopathy by 76%, and progression from early to advanced
retinopathy by 54% 28 highlighting that strict glycaemic control is much more effective
in preventing and delaying the onset of diabetic retinopathy in patients with diabetes
without retinopathy, compared with limiting the severity of retinopathy once it occurs.

Notwithstanding these findings, research has also shown that if blood glucose is
rapidly controlled in patients with previously poor control, it can worsen diabetic
retinopathy.146 Furthermore, there are a group of diabetes patients who are unable to
prevent the onset or progression of diabetic retinopathy despite achieving good
metabolic control of the disease.146 These findings highlight that hyperglycaemia does
not fully explain the wide range of functional and cellular changes which appear over
the course of diabetic retinopathy, and that other pathogenic components of diabetes
may also contribute to its progression.
3.4.2 Hypertension
Hypertension and diabetes are common, intertwined, conditions that share a
significant overlap in their underlying risk factors (including familial predisposition,
advancing age, dyslipidaemia and obesity, among others); and in their complications
(microvascular and macrovascular disorders).147, 148 Up to 75% of adults with diabetes
also have hypertension, and patients with hypertension alone often show evidence of
insulin resistance.147 Moreover, as hypertension and diabetes are both components of
the metabolic syndrome, these conditions commonly co-occur.147, 149

Oxidative stress plays an important pathophysiological role in hypertension. Normally
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reactive oxygen species (ROS) are produced in the vessel wall in a controlled and
tightly regulated manner; however, under pathological conditions (i.e. hypertension),
increased production of ROS leads to endothelial dysfunction, impaired vascular
relaxation, increased smooth muscle growth, and hypertrophy.150 Blood flow and
blood pressure can cause internal stresses in vessels (such as endothelial shear stress
and circumferential wall stress respectively).151 Figure 3.5 shows the forces created by
flowing blood.

Figure 3.5: Fluid flow within a tube creates two types of forces: shear stress, which is
a force tangential to the vessel wall, and pressure, which creates a circumferential
stretch perpendicular to the vessel wall (Adapted from Jones et al,152).
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Hypertension exacerbates diabetic retinopathy through increased blood flow (shear
stress) and pressure (circumferential wall stretch) of vascular endothelial cells.151,153,
154

Collectively, oxidative balance regulates the degree of tone or vasodilation, and this

balance is upset in hypertension. Treatment with antioxidants or agents to inhibit
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase has been shown to
decrease ROS production, prevent target-organ cellular damage and decrease blood
pressure in animal models and human hypertension (reviewed by Touyz & Shiffrin
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). Effective treatment of hypertension (goal blood pressure less than 140/85 mmHg)

has been shown to reduce the rate of worsening of diabetic retinopathy by 34 % over
9 years follow-up,156 and to reduce the risk of vision loss by three lines or more by
47%.156 The recommended guidelines, according to the American Diabetes
Association, for systolic blood pressure and diastolic blood pressure levels are <130
mmHg and <85 mmHg respectively.157 The role of hypertension in diabetes will be
explored in more detail in chapter seven.
3.4.3 Dyslipidaemia
Hyperglycaemia and defects in insulin action may also lead to changes in plasma
lipoproteins in patients with diabetes.158 Additionally, the obesity/insulin-resistant
metabolic disarray commonly associated with Type 2 diabetes, may itself, lead to lipid
abnormalities exclusive of hyperglycaemia.158, 159 Dyslipidaemia is characterised by a
moderate elevation in TGs, low HDL cholesterol and the presence of small, dense,
atherogenic LDL particles,160 (reviewed in chapter six). In brief, dyslipidaemia often
arises in untreated or uncontrolled diabetes, or in people who become overweight and
develop insulin resistance.161 Impairment of the biological action of insulin at a
cellular level (insulin resistance) is thought to primarily underlie the metabolic defects
which contribute to the development of dyslipidaemia.161 Insulin plays a central role
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in how the body utilises and stores glucose and fat. Insulin suppresses lipolysis in
adipocytes via its effect on hormone-sensitive lipase (HSL), and it also stimulates the
action of lipoprotein lipase (LpL), an important enzyme in the hydrolysis of plasma
TGs and free fatty acid (FFA) delivery to adipocytes.158 In an insulin-resistant state,
(i.e. Type 2 diabetes, overweight/obesity), there is an increase in intracellular
hydrolysis of TGs and the release of FFAs into circulation from adipose tissue.
Furthermore, insulin activation of LpL is delayed.162 Overall, this culminates in an
increased concentration of FFAs in circulation returning to the liver, where they are
reassembled into TGs. The presence of excess TGs in the liver promotes TG-rich verylow-density lipoprotein (VLDL) production,163,

164

and the accompanying hepatic

insulin resistance fails to effectively suppress the release of TG rich VLDL in
circulation.165

Heterogeneity exists in the size and composition of all classes of lipoproteins. The
core of lipoproteins contain hydrophobic cholesterol ester and TGs, and their
proportions are determined by the enzyme cholesteryl ester transfer protein (CETP).
In the presence of increased concentrations of VLDL in circulation, CETP will
exchange VLDL TGs for cholesteryl ester in the core of LDL and HDL, resulting in
smaller, denser LDL and HDL particles.158 This CETP-mediated exchange is
accelerated in the presence of excess TGs,166 and explains the hypertriglyceridaemia,
reduced HDL and small dense LDL particles commonly observed in diabetes, and
Type 2 diabetes, in particular, (Figure 3.6).158
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Figure 3.6: Plasma lipid exchange. CETP will exchange VLDL triglyceride for
cholesteryl ester in the core of LDL and HDL. The net effect is a decrease in size and
an increase in density of both LDL and HDL (Adapted from Goldberg 158).

Triglyceride levels also correlate with the degree of glycaemic control in patients with
Type 1 diabetes.167 The absolute insulin deficiency in Type 1 diabetes patients
presenting with ketoacidosis leads to hypertriglyceridaemia.168 Additionally, treated
Type 1 diabetes patients with poor or suboptimal control also present with elevated
TGs, similar to their Type 2 diabetic counterparts, due to relative insulin deficiency.169
Metabolic control after insulin administration, however, rapidly improves TG levels
in Type 1 diabetes by normalising LpL activity. In fact, intensely treated Type 1
diabetes patients often have no observed lipid abnormalities, and plasma TGs may
even be lower than non-diabetic individuals.170
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Dyslipidaemia often precedes the overt appearance of Type 2 diabetes by several
years, which suggests that dysregulation of lipoprotein metabolism is an early event
accompanying insulin resistance and precedes β-cell failure in Type 2 diabetes.171 It is
worth noting that centrally-deposited adipose tissue (visceral fat or intra-abdominal
fat) differs considerably in its metabolic activities and clinical consequences compared
with other body fat. Excess subcutaneous fat does not appear to contribute
significantly to elevated TG levels
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compared with visceral adiposity.173 Visceral

adipose tissue is also highly vascular and drains directly into the portal vein.
Furthermore, the ability of insulin to suppress lipolysis and to re-esterify FFAs is
significantly reduced in visceral adipocytes.174 In summary, patients with diabetes
and/or individuals who are overweight/obese have an increased risk of suffering from
dyslipidaemia.
3.4.4 Oxidative stress
While the exact mechanisms by which oxidative stress contributes to diabetic
retinopathy remain elusive, it is thought that chronic hyperglycaemia leads to the
overproduction of free radicals and that hyperglycaemia also impairs the endogenous
antioxidant defence system,175 rendering the affected cells and tissues (i.e. lipids,
protein and de-oxy ribonucleic acid (DNA) constituents) more susceptible to oxidative
damage.176 Under normal physiological conditions, ROS are detoxified by their
interaction with various reducing and sequestering agents. However, when the body
becomes overwhelmed (e.g. by hyperglycaemia), oxidative stress ensues.

Reactive oxygen species can be defined as intermediate oxygen-carrying metabolites
with or without an unpaired electron, (i.e. oxygen-centered free radicals such as
superoxide anions, hydroxyl radicals); and non-radicals (such as hydrogen peroxide,
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and singlet oxygen).177 Free radicals can either donate an electron to or accept an
electron from, therefore, behave as oxidants or reductants.178 Radicals and nonradicals are both capable of oxidising other components, turning them into free
radicals, thereby, causing a chain reaction that can lead to the formation of numerous
new radicals.179, 180
3.4.4.1 Overproduction of reactive oxygen species
Sustained hyperglycaemia and increased chronic local oxidative stress disrupts retinal
metabolism and accelerates premature endothelial cell apoptosis in both Type 1 and
Type 2 diabetic retinopathy.181-183 There is also evidence to suggest that oxidative
damage occurs in non-vascular retinal cells (Muller, bipolar, amacrine, ganglion, and
photoreceptor cells) in the early stages of diabetic retinopathy.184-186 Glial cells
normally produce large amounts of glutathione (GSH), whereas, hyperglycaemia
induces depletion of GSH within these cells, resulting in impaired glutamate
metabolism.187 This culminates in the release of inflammatory substances by glial cells
which damage their close structural relationship with blood vessels.188 These
pathogenic changes are linked to increased vascular permeability and resultant
diabetic macular oedema.

Additionally, Muller cells stimulated by hyperglycaemia increase ROS production
which amplifies AGE formation, contributing directly to neuronal cell apoptosis.189,
Capillary occlusion and retinal ischaemia increase expression and release of growth
factors (i.e. VEGF) and cytokines (discussed in more detail in section 3.4.5). Vascular
endothelial growth factor increases vascular permeability and also favours the growth
of abnormal vessels.190 Pathological angiogenesis driven by VEGF originating from
pericytes, retinal ganglion and glial cells has been implicated in irreversible vision
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loss.190
3.4.4.2 Role of antioxidant defence system
The balance between oxidation and anti-oxidation is believed to be critical in
maintaining healthy biological systems. The endogenous antioxidant defence
mechanisms include enzymatic and non-enzymatic antioxidants. The primary
endogenous antioxidant enzymes are catalase (CAT), glutathione peroxide (GPx) and
superoxide dismutase (SOD).177 Non-enzymatic antioxidants include vitamin E (αtocopherol), β-carotene, GSH compound and lipoic acid.177 The endogenous
antioxidant system is supported by smaller exogenous antioxidant molecules derived
principally from a diet rich in fruit, vegetables and grains, a diet which includes
vitamins C and E, carotenoids (β-carotene, lutein, zeaxanthin, meso-zeaxanthin) and
polyphenols.177 The synergistic action of several ocular antioxidants is what protects
the eye most effectively from oxidative damage.180 While ROS has been linked to
diabetic complications, antioxidants have shown promise as a possible therapy for the
prevention and treatment of the disease (reviewed in more detail in chapters four and
six).
3.4.5 Inflammation
Inflammation is common in many chronic diseases, including diabetes.191 In Type 1
diabetes islet inflammation is thought to be a local phenomenon driven by a focal
autoimmune attack on islet antigens, whereas, in Type 2 diabetes activation of
inflammation results from systemic features such as obesity and insulin resistance.192
The comorbidities of hypertension, dyslipidaemia, insulin resistance, obesity,
(metabolic correlates commonly associated with Type 2 diabetes), have been
incriminated in the maintenance and exacerbation of these inflammatory reactions.192
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Ultimately, inflammatory mediators activate a series of receptors and transcription
factors, such as nuclear factor Kappa B (NF-kB), which leads to impaired insulin
signalling in insulin-sensitive tissues, systemic endothelial dysfunction, and altered
vascular flow.193 Figure 3.7 outlines the association between inflammatory mediators
and anatomical changes to retinal tissue in diabetic retinopathy.194 The role of
inflammation in diabetes mellitus will be reviewed in chapter six.

Figure 3.7: Role of vitreous mediators in diabetic retinopathy progression. In diabetic
retinopathy, several inflammatory vitreous mediators are upregulated and induce
anatomical changes in the retinal tissue. The structural changes enhance retinal tissue
degeneration and mediate pathogenesis of diabetic retinopathy (Adapted from
Semeraro et al,194).
3.4.5.1 Adipose tissue and inflammation
Adipose tissue also contributes importantly to the inflammatory process in
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overweight/obese subjects.195 Pro-inflammatory and pro-coagulant mediators released
by stressed adipose tissue have both local and systemic effects on metabolism and
vascular function.192 Adipose tissue from obese individuals contains activated
macrophages that together with adipocytes produce inflammatory adipokines such as
TNF-α, IL-6, and molecules that may contribute to insulin resistance such as FFAs,
TNF-α, and resistin.196 Overweight/obesity-induced inflammation in association with
diabetes mellitus and MP will be discussed in chapters six, seven and .eight
3.4.6 Retinal neurodegeneration
Diabetic retinopathy has traditionally been described as a microvascular disease of the
retina, however, more recent research suggests that retinal neurodegeneration is an
early event in its pathogenesis. Biochemical and histopathological changes,
characteristic of retinal neurodegeneration have been observed in diabetic patients
before any visible changes in the retina.197-199 It is now widely accepted that structural
and functional damage to nonvascular cells (ganglion cells, glial and microglial cells)
contribute to the pathogenesis of diabetic retinopathy.135,

200,

201

Important

neuroprotective factors include somatostatin (SST) and PEDF. Neurotoxic factors
involve elevated levels of extracellular glutamate, oxidative stress and overexpression
of the renin angiotensin system (RAS).202, 203 The balance between neurotoxic and
neuroprotective factors is what determines the presence of retinal neurodegeneration
in the diabetic retina.

Retinal neurodegeneration has been identified in experimental models on rodent rats
at the very early phase of diabetic retinopathy. Rats with streptozotocin (STZ) induced
diabetes exhibited a high rate of apoptosis in the neuroretina within one month after
inducing diabetes, without any significant apoptosis in endothelial cells.204 Apoptosis
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and glial activation have also been shown to occur in the retina of diabetic patients,
before microvascular abnormalities.197 Retinal ganglion cells appear to be the earliest
cells affected and have the highest rate of apoptosis,205 however, cell death has also
been observed in the outer nuclear layer (photoreceptors),200 and the RPE.206
Neuroretinal damage produces functional abnormalities early in the course of the
disease, as demonstrated by abnormal responses of oscillatory potentials in
electroretinograms (ERGs), findings which reflect malfunctioning of inner retinal
layers.201

It is now believed that carotenoids, lutein, zeaxanthin, and meso-zeaxanthin may
prevent and protect against the development of diabetic retinopathy via
neuroprotective properties, however, the molecular basis for these effects remain
unknown. The neuroprotective properties of these carotenoids will be explored in
more detail in chapter four.
3.5 Current treatment options for diabetic retinopathy
Diabetic retinopathy remains one of the most debilitating complications of diabetes.
Both neuronal and vascular retinal damage occurs as a result of chronic
hyperglycaemia, and this damage is progressive, however, most patients remain
asymptomatic until very late stages of the disease. Regular screening is, therefore,
essential. While there is no cure for diabetic retinopathy, timely treatment may be
effective in delaying or reducing vision loss and remains the gold standard for
ameliorating blindness due to diabetic retinopathy. Clinically significant macular
oedema is the most common cause of moderate vision loss (< 6/12 vision) in all types
of diabetic retinopathy. The majority of severe vision loss (< 6/60 vision) in diabetic
retinopathy is the result of complications from proliferative diabetic retinopathy, either
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from a vitreous haemorrhage, retinal detachment, or neovascular glaucoma. It is
recommended that patients with Type 1 and Type 2 diabetes have an initial dilated and
comprehensive eye examination by an ophthalmologist or optometrist within 3–5
years after onset of diabetes for Type 1 diabetes and yearly after diagnosis for Type 2
diabetes.136 Clinical judgment should, however, be used when applying these
recommendations to individual patients.25

Primary prevention of diabetic retinopathy involves strict control of blood sugars,145
blood pressure,156 and lipids.207 Secondary interventions for diabetic retinopathy
include pan-retinal photocoagulation,208 focal laser photocoagulation,209 and surgical
vitrectomy.13 More recently, intravitreal anti-VEGF injections have demonstrated
their superiority to laser therapy in reducing vision loss and improving rates of vision
gain in eyes with diabetic macular oedema.210 Anti-VEGF therapy has also been
shown to be highly effective in regressing retinal neovascularisation in eyes with
proliferative diabetic retinopathy.211 This form of treatment may, however, not be
optimal for patients who cannot comply with monthly follow-ups and the repeated
intravitreal injections necessary for adequate treatment and prevention of proliferative
diabetic retinopathy. Furthermore, intravitreal injections are invasive, increasing the
likelihood of local complications including uveitis, cataract, retinal detachment, and
endophthalmitis.212 While intravitreal injections are very effective at preventing vision
loss and often result in a visual gain for patients with both diabetic macular oedema
and proliferative diabetic retinopathy, there is a substantial proportion of eyes
(approximately 40-50%) that do not respond fully to anti-VEGF treatment.213
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Improvements in understanding the pathogenesis of diabetic retinopathy and an
increase in diagnostic techniques, including imaging, opens up the possibility of
earlier diagnosis of diabetic retinopathy and will, therefore, optimise efforts toward
more precise management of the disease. While Type 1 diabetes patients tend to be
diagnosed promptly, patients with Type 2 diabetes can be insulin resistant for many
years prior to diagnosis, and can often present with signs of diabetic retinopathy at the
time of diagnosis.25 Lifestyle modifications including an increase in physical activity
and a healthy diet (i.e. diet of fruit, vegetables, legumes), offer potential to manage
diabetes after onset and can even prevent Type 2 diabetes development.214 Early
detection and education on lifestyle behaviours broaden therapeutic objectives beyond
direct suppression of pathological vascular changes.
3.6.2 The role of macular pigment in diabetes
While the Age-Related Eye Disease Study 2 (AREDS2) has established a clear clinical
benefit for dietary carotenoids (lutein and zeaxanthin) supplementation in patients
with AMD,5 their role in another retinal disease putatively associated with oxidative
stress and inflammation (i.e. diabetes) remains comparatively unexplored. Current
treatment paradigms for diabetic retinopathy (laser photocoagulation, intravitreal
injections and vitreoretinal surgery) focus on the treatment of advanced disease, often
after permanent damage has ensued. These treatments are also invasive, expensive and
need to be repeated at frequent intervals. An important conceptual advance in recent
research has been the recognition that diabetic retinopathy is a disease of the
neurovascular unit, with multiple interdependent cell types contributing to the
dysfunction of the retina. Therefore, new therapeutic approaches should adopt a more
holistic view of how diabetes affects the retina. Newer treatments that are preventative
or address early pathology are more appealing. Researchers are now beginning to look
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at the beneficial effects of lutein, zeaxanthin, and meso-zeaxanthin in protecting ocular
tissues and cells, including retinal neurons, and on the prevention of diabetic
retinopathy which has been studied in a variety of experimental animal models 14, 186,
215

and human studies.15,

21

There is increasing evidence that MP levels can be

augmented through increased intake of dietary lutein and zeaxanthin in both healthy
and diseased retinas,5, 216-218 suggesting the possibility that therapeutic intervention in
the form of dietary modification or nutritional supplementation may modulate the risk
of diseases with a relative lack of MP.5, 47 The putative protective role of lutein,
zeaxanthin and meso-zeaxanthin in the pathogenesis of diabetic retinopathy will now
be explored in chapter four.
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4. MACULAR PIGMENT AND DIABETES MELLITUS
4.1 Background
The human macula uniquely concentrates three hydroxyl-carotenoids: lutein,
zeaxanthin, and meso-zeaxanthin, collectively known as MP.46 Lutein and zeaxanthin
cannot be produced endogenously in humans, therefore, these carotenoids must be
obtained from dietary sources such as green leafy vegetables and bright coloured
fruits,22 while meso-zeaxanthin is believed to be mainly formed at the macula through
a poorly understood process of bioconversion.219 Although, meso-zeaxanthin has been
found in specific dietary sources such as turtle, shrimp and fish skin.220 While there
are many hundreds of carotenoids present in the plant world, the primate macula
contains only these three.

The anatomical location of MP has generated a lot of interest in this pigment’s role in
vision and macular health. Macular pigment is highly concentrated in the central retina
(the macula) and concentrations decrease nearly 100-fold with increasing retinal
eccentricity.44 While not considered to be essential micronutrients, MP’s constituent
carotenoids have powerful antioxidant, anti-inflammatory and neuroprotective
properties

2, 4, 221, 222

and these phytonutrients have been studied extensively.

Epidemiological studies and large-scale clinical trials, such as AREDS2, have brought
attention to the functional benefits of these carotenoids in the prevention of retinal
diseases such as AMD.5,

218

The fact that MP is modifiable, through diet and/or

supplementation, means that ongoing research into their role in the prevention or
progression of AMD is important. Researchers are now beginning to focus on the
relationship between MP and diabetes mellitus, a condition similarly known to cause
oxidative damage and inflammation in the retina.9, 10 Studies have shown that MP is
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lower in diabetes,

6, 9

however, the causal mechanisms and metabolic perturbations

associated with lower MP in diabetes have yet to be elucidated. While all humans
appear to have some quantity of MP within their retina, foveal concentrations tend to
vary quite dramatically.223,224 The basic science and clinical research underlying the
assessment of MP and recommendations for nutritional interventions against diabetic
eye disease are under-acknowledged by practitioners and vision researchers alike. This
chapter will explore the structural and functional benefits of MP in the eye, with a
particular focus on MP and diabetic retinopathy.
4.2 Location of macular pigment
The yellow colouration of the macula is attributable to the presence of lutein,
zeaxanthin and meso-zeaxanthin.44 The ratio of lutein to zeaxanthin to mesozeaxanthin is 1:1:1 in the centre of the fovea.1 Near the fovea, there is twice as much
zeaxanthin and meso-zeaxanthin as lutein, and in the peripheral retina, this relationship
is reversed.46, 60 Xanthophylls are highly concentrated within the photoreceptor axons
of the Henle nerve fibre layer centrally, where the inner retinal layers are displaced.43,
44

In the parafoveal region they are located in the inner and outer plexiform layers of

the photoreceptors.43,

44

At 7 degrees retinal eccentricity, it is believed that these

carotenoids become optically undetectable 60 (Figure 4.1).
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A

Figure 4.1: Histology of human MP illustrating the spatial profile and pre-receptoral
location of MP. The main location of MP is in the layer of the fibres of Henle in the
fovea (A) and in the inner nuclear layer at the parafoveal site (B) (Modified from
Trieschmann et al,43).
4.3 Carotenoid chemistry
The MP of primates can be traced to its dietary origins. Around 700 carotenoids exist
in nature, however, only 40 to 50 carotenoids are present in a typical Western diet,45,
225

of which 15 to 30 enter the human bloodstream.45, 225 The most prominent plasma

carotenoids include lycopene, α-carotene, β-carotene, lutein and zeaxanthin.45 The
carotenoid group include phytochemicals with the basic structure C40 H56. These
compounds act as antioxidants as they contain several double bonds and react with
ROS to scavenge free radicals. Carotenoids are classified as carotenes if they are
exclusively hydrocarbons, composed of only carbon and hydrogen, and are classified
as oxo-carotenoids (xanthophylls) when they carry at least one oxygen atom.226-228
Xanthophylls and their hydroxyl (-OH) functional groups permit lutein, zeaxanthin
and meso-zeaxanthin to cross both the blood-ocular and blood-brain barriers.
Carotenes 𝛽-carotene and lycopene contain only carbon and hydrogen atoms and do
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not cross these barriers.229 Lutein, zeaxanthin and meso-zeaxanthin are the only
carotenoids to ultimately reach the human retina.45, 46 Figure 4.2 shows the chemical
structure of lutein, a hydroxyl-carotenoid (C40H56 O2).230

Figure 4.2: Chemical structure of lutein (C40H56 O2); lutein contains double bonds
that scavenge ROS.230

Xanthophylls are a large group of plant pigments responsible for the colour of brightly
coloured fruit and vegetables. Lutein is found in the highest concentrations in dark
green leafy vegetables (spinach, kale, collard greens and others).22 Zeaxanthin is the
major carotenoid found in corn, orange peppers, oranges and tangerines.22 The highest
molar percentage of lutein and zeaxanthin are found in egg yolk and maize. 22 Mesozeaxanthin, was previously thought to be undetectable in the human liver or plasma
and thought to be generated solely at the macula following a biochemical
transformation of lutein.1, 219 The 3:1 ratio of lutein to zeaxanthin in plasma and the
2:1 ratio in the fovea support this theory of conversion.1 Meso-zeaxanthin, however,
has more recently been found in trace amounts in blood plasma,231 and has been
identified in some less commonly consumed foods including fish (e.g. salmon and
trout), shrimp, and turtle.220,

232

Supplementation trials have also demonstrated a

significant increase in MP’s levels after oral supplementation with meso-zeaxanthin,
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suggesting that it can be absorbed after oral administration and transported to the
macula.233 Meso-zeaxanthin accounts for about one-third of total MP at the fovea.
4.3.1 Stereochemistry of macular carotenoids
Macular pigment was shown in 1985 by Bone et al,234 and later by Handleman et al,235
using high-performance liquid chromatography (HPLC) to be composed of two
chromatographically separable components, namely lutein and zeaxanthin. The lutein
component of MP consists of a single stereoisomer of lutein [(3R, 3′R, 6′R)- β, εcarotene-3,3′-diol], whereas, the zeaxanthin component consists of three possible
stereoisomers which include dietary zeaxanthin itself or RR-zeaxanthin [(3R,3′R)β,β- carotene-3,3′- diol], SS-zeaxanthin [(3S,3′S)- β, β- carotene-3,3′-diol] (found only
in trace amounts), and meso- zeaxanthin [(3R,3′S)- β, β- carotene-3,3′-diol].46, 60, 234
Macular pigment refers to the accumulation at the macula of a single isomer of lutein
and 3 stereoisomers of zeaxanthin (RRZ, meso-zeaxanthin, and SSZ).44,

46

The

hydroxyl group at the C-3′ position in lutein (3R, 3′R, 6′R- β, ε- carotene-3,3′-diol) is
configured exactly opposite to that of zeaxanthin (3R, 3′R-β, β -carotene-3,3′-diol),
while the C-3 and C-3′ hydroxyl groups in meso-zeaxanthin (3R, 3′S-β, β, -carotene3,3′-diol) are positioned identically to lutein.226 These hydroxyl groups, one at each
side of the molecule, appear to control the biological function of xanthophylls.219 The
double-bond in lutein at the 4′, 5′ position is shifted to the 5′, 6′ position in zeaxanthin
and meso-zeaxanthin.226 Additionally, there is an extra conjugated double bond in
zeaxanthin and meso-zeaxanthin which makes them more stable and better
antioxidants than lutein.236,237,1 Zeaxanthin is superior in preventing lipid peroxidation
induced by ultraviolet (UV) light,238 while meso-zeaxanthin has a greater capability of
quenching oxygen radicals than lutein, although, lutein has a better filtering
efficacy.239 The functional differences of these carotenoids appear to correlate with
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their spatial distribution in the retina. Zeaxanthin and meso-zeaxanthin predominate in
the centre of the retina where cone density is highest and risk of oxidative damage is
greatest.235, 237 The combination of all three carotenoids and their essential functions,
however, is what reduces oxidative stress in both normal and diseased retinas. Figure
4.3 shows the stereochemistry of all three macular carotenoids.226

Figure 4.3: Chemical structure of macular pigment carotenoids. (a),(b) lutein; (c)
zeaxanthin; (d) meso-zeaxanthin (Adapted from Bernstein et al,226).
4.4 Functional properties of macular pigment
The retina is an ideal environment for the generation of ROS for several reasons; 1)
the retina is subject to high levels of cumulative irradiation; 2) the membranes of the
outer segments of photoreceptors have high concentrations of polyunsaturated fatty
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acids (PUFAs) which are susceptible to photo-oxidation;

240

3) oxygen consumption

by the retina is much greater than by any other tissue and the outer retina has a high
oxygen tension (70 mmHg), almost that of arterial blood; 4) furthermore, the process
of phagocytosis by the RPE itself creates oxidative stress.241 Therefore, a rich oxygen
supply, combined with high-energy short-wavelength light stimulation, and a
vulnerable substrate creates ideal conditions for oxidative damage.242 Some of the
major proposed functions of these ocular carotenoids include blue light filtration
effects, antioxidant, anti-inflammatory and neuroprotective properties, and are
discussed in more detail herein.2, 221, 222, 243, 244
4.4.1 Macular pigment as a blue light filter
Macular pigment reduces sensitivity of the macular region to short-wavelength light
by acting as a broadband filter.245 Most UVC (100-200 nm) radiation is absorbed by
the atmosphere; while UVB (290-320nm) and UVA (320-400nm) radiation are
absorbed by the cornea and crystalline lens. Slightly longer-wavelength light (400-500
nm) is for the most part absorbed by MP, which has a peak absorbance of 460nm. 44,
246

Absorption by MP occurs before light reaches the photoreceptors,44 therefore,

penetration of damaging short-wavelength light is minimised. While macular
xanthophylls reach their highest concentrations in the centre of the fovea, these
carotenoids are also highly distributed throughout the photoreceptor cell. Therefore,
each photoreceptor screens other photoreceptors as well as itself because of the lateral
course of the axons.44

Blue light being a shorter wavelength has more energy and is, therefore, potentially
more damaging to the eye. Chronic exposure to radiation (400-520 nm) can cause
damage to both the intraocular lens and the retina through photo-oxidative reactions.247
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Beyond the first three years of life yellow chromophores develop in the crystalline
lens which are capable of absorbing UV and short-wavelength light.248 Because of
these chromophores the absorbed energy is safely dissipated and the lens and retina
are protected against photo-oxidative damage.249 With advancing age, however, these
chromophores become modified and phototoxic. Absorption of UV and shortwavelength visible light by a phototoxic chromophore causes the chromophore to
become excited, firstly to a singlet state, then a triplet state, and from a triplet state
free radicals and ROS are produced (e.g. singlet oxygen and superoxide), free radicals
which can damage ocular tissue (reviewed by Roberts & Dennison 250), (Figure 4.4).

Figure 4.4: Photo-oxidation (Adapted from Roberts & Dennison 250).

Exposure to UV and short-wavelength blue light is particularly hazardous after the age
of 40 because there is an increase in light-absorbing endogenous phototoxic
chromophores, that efficiently produce singlet oxygen and other ROS. Chromophores
which produce free radicals and singlet oxygen upon photoexcitation are known as
photosensitisers. A single molecule of a photosensitiser is capable of producing
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numerous free radicals and singlet oxygen molecules as long as it is recycled and
photoexcited by subsequent photons. It is thought that increased levels of ROS and the
concomitant decrease in the production of antioxidants and antioxidant enzymes in the
lens leads to DNA damage and cross-linking of proteins, resulting in cataract
formation.251

The continual exposure of the retina to incident light, in addition to the high
concentrations of oxygen, and the presence of photosensitisers, such as vitamin A
derivatives, rhodopsin, cone opsins, lipofuscin and melanin, make the outer retina
inherently susceptible to photo-oxidative damage. Damage induced by chronic
phototoxic reactions over many years has been implicated in the aetiology of AMD.252
Blue light-induced generation of ROS by the lipofuscin chromophore is toxic to
mitochondria and is known to initiate apoptosis in the RPE.253,254 Furthermore, it has
been shown that blue light damage is proportional to the amount of light received and
the amount of lipofuscin within RPE cells.255 Chromophores in photoreceptor outer
segments (rhodopsin and cone opsins) are also susceptible to oxidative damage. While
most UV light is absorbed by the cornea and lens, some fraction of blue light radiation
reaches the retina and may activate potent retinal photosensitisers. Blue light
absorption by MP can, therefore, indirectly be considered an antioxidant action
because it prevents blue light from generating ROS which can potentially damage
photoreceptor cells.256
4.4.1.1 Blue light-filtering effects of MP in diabetes
Several studies have investigated the protective effects of lutein and zeaxanthin
administration against light-induced damage in experimental animal models. Evidence
suggests that zeaxanthin can protect photoreceptors against light-induced apoptosis in
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quail (the retinae of which, like those of primates, selectively accumulate lutein and
zeaxanthin).257 Oral supplementation with zeaxanthin was found to decrease
photoreceptor cell death and activation of microglia in this study, providing
experimental evidence that xanthophyll carotenoids can protect photoreceptor cells in
vivo.257 The effects of lutein in light-induced retinal degeneration has also been
investigated in STZ induced diabetic murine models.186 Functional abnormalities
secondary to diabetes-induced oxidative stress, (i.e. reduction in ERG a and b-wave
amplitudes), were observed before histopathological

changes

in

diabetic

retinopathy.186 These changes were, however, successfully restored following
administration of lutein, suggesting that carotenoids have the potential to normalise
diabetes-induced early functional modifications in the retina.186 The beneficial effects
of MP on diabetes in experimental animal and human studies will be explored in more
detail in chapter six.
4.4.2 Macular pigment as a potent antioxidant
Carotenoids lutein, zeaxanthin and meso-zeaxanthin are part of the antioxidant
defence system. By nature of their biological structure and function, these
phytonutrients help neutralise ROS. Carotenoids interact synergistically with other
antioxidants, minerals and vitamins, thereby, protecting the eye against the cumulative
effects of damage due to light and oxygen.45,258,250 There is increasing evidence that
higher intakes of fruits and vegetables (i.e. carotenoids lutein and zeaxanthin),22, 259
can slow the progression of age-related cataracts and AMD.5, 260 The beneficial effects
of higher intakes of fruit and vegetables in diabetes and diabetic retinopathy is
growing, however, findings are not as definitive.261
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Oxidative damage is one of the underlying causes of diabetic retinopathy. While freeradicals can occur as normal by-products of cellular metabolism,262 the generation of
ROS increases dramatically in the retina during times of local stress (i.e.
hyperglycaemia). De novo synthesis of MP is not possible in humans, therefore, an
important source of theses phytonutrients is a diet which is rich in fruit and
vegetables,22 a diet which may be compromised in diabetes (Type 2 diabetes in
particular).214 Additionally, there is a decline in the production of antioxidants and
antioxidant enzymes with age, (reviewed by Liguori et al,263). Oxidative stress appears
to be caused by both increased production of ROS and/or reductions in antioxidant
defences, thereby, resulting in an altered redox state,264, 265 (reviewed in more detail in
chapter six).

In brief, carotenoids lutein, zeaxanthin and meso-zeaxanthin are powerful quenchers
of singlet molecular oxygen and free radical scavengers.266-268 The quenching of
singlet oxygen is primarily by a physical mechanism rather than a chemical one. The
carotenoid molecule accepts the excitation energy from singlet oxygen. The added
energy causes excitation of the carotenoid molecule, resulting in a triplet state and this
triplet state dissipates energy harmlessly as heat through rotational and vibrational
interactions and finally relaxes into a ground state. The structure of the carotenoid
remains unchanged in this process.229, 267 Xanthophylls lutein, zeaxanthin and mesozeaxanthin can also scavenge ROS (free radicals such as hydroxyl and peroxyl
radicals). The free radical can either obtain its missing electron from the electron-rich
molecule of the carotenoid or the free radical adds itself to the carotenoid molecule to
pair its single electron, thus forming a covalent bond.229, 267 Either way, the electronrich structure of the carotenoid molecule attracts free radicals and spares cell damage
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to lipids, proteins or DNA.269 Figure 4.5 shows the photochemical mechanisms of
protection by lutein and zeaxanthin.250

Figure 4.5: Photochemical mechanisms of protection (Adapted from Roberts &
Dennison 250).

Carotenoids have a ready supply of available electrons that enable them to scavenge
ROS and attenuate oxidative injury. Zeaxanthin, (with 11 conjugated double bonds),
has a higher ability to quench singlet oxygen than lutein (with 10 conjugated double
bonds).229,270 Meso-zeaxanthin, in conjunction with its binding protein, however, is
even more effective.271 Meso-zeaxanthin differs from zeaxanthin in the spatial
orientation of the hydroxyl group on the C3 chiral position, but the conjugated systems
are the same. The order of efficiency of the macular carotenoids in quenching singlet
oxygen is as follows: lutein < zeaxanthin < meso-zeaxanthin < all three combined.272
A mixture of lutein: zeaxanthin: meso-zeaxanthin in a ratio of 1:1:1 however, has
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shown to be the most effective in quenching singlet oxygen.272
4.4.2.1 Antioxidant function of MP in diabetes
Evidence is emerging which suggests that oxidative damage occurs in retinal vascular
cells (endothelial and pericyte cells) as well as non-vascular cells (Muller cells,
photoreceptor, bipolar and ganglion cells) in the early stages of diabetic retinopathy.184
Hydroxyl-carotenoids, lutein, zeaxanthin, and meso-zeaxanthin readily supply
available electrons that enable these carotenoids to scavenge ROS. Although the
evidence exploring MP and diabetes is relatively sparse, it has been shown that plasma
concentrations of lutein and zeaxanthin are lower in diabetes patients with nonproliferative diabetic retinopathy compared with normal controls and that
supplementation with these carotenoids can improve VA, contrast sensitivity and
macular oedema in patients with diabetic retinopathy.15 The putative protective effects
of MP in diabetic retinopathy in human and animal studies will be explored in more
detail in chapter six.
4.4.3 Neuroprotective and anti-inflammatory properties of MP
The presence of lutein and zeaxanthin in substantial concentrations in the primary
visual cortex 273 and the finding of better dark-adapted cone sensitivities in association
with higher MP

274

combine to suggest a key role for MP in ocular and

neurophysiologic health. The retina is part of the central nervous system and once
damaged regenerates poorly, if at all. The majority of studies investigating the effects
of MP augmentation in ocular disease, including AMD and diabetes, have reported
beneficial effects on vision

21, 218

findings which suggest a neuroprotective effect of

these carotenoids. While the exact mechanisms are not clear, there are a number of
plausible explanations to explain why these phytonutrients improve neural function,
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including, enhancement of membrane stability, modulation of synaptic activity and
intracellular communication.256, 275, 276

The orientation of xanthophyll molecules within the phospholipid bilayers not only
protect against oxidative damage but also modulate the physical properties of these
membranes.275 Macular xanthophylls are distributed between the lipid and protein
components of membranes.226 The presence of polar hydroxyl groups at each end of
the xanthophyll molecule ensures a roughly perpendicular orientation within the lipid
bilayer.256, 275 The almost vertical orientation of the dipoles provides good conditions
for macular xanthophylls to act as a blue light filter.275 Concomitantly, such an
organisation has a direct effect on reducing the penetration of molecular oxygen into
the hydrophobic membrane core, thus protecting vulnerable regions against oxidative
damage.256 The high membrane stability and preferential transmembrane orientation
in lipid bilayers of photoreceptor outer segments, in addition to their antioxidant
properties, maximises their protective action in retinal membranes.275

Lutein and zeaxanthin may also play a role in maintaining cell integrity and plasticity,
by binding to tubulin.277 Tubulin has been identified as the major carotenoid binding
protein found in abundance in the receptor axon layer of the fovea.277 Tubulin is also
the main structural protein of microtubules.277,

278

Microtubules form important

cytoskeletal structures that play a role in maintaining neuronal morphology,
transporting cargo, and scaffolding signalling molecules.279 Reduced microtubule
stability has been observed in neurodegenerative diseases such as Alzheimer’s disease
and Parkinson’s disease

279

and research suggests the macular carotenoids modulate

the stability of photoreceptor-axon microtubules, thereby, promoting cell integrity.278
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Particular attention has also been given to the stimulatory effects exerted by
carotenoids on gap junctional communication. While chemical synaptic transmission
(via transmitters, neurotransmitters) is the dominant mode of signal transmission,
inter-neuronal signal transmission is also mediated by gap junctions. Gap junctions
provide low resistance avenues for electrical and/or metabolic communication of
coupled cells.280 Direct coupling through gap junctions has been suggested to mediate
communication between neurons and glial cells.280,281 The regulation of gap junctional
communication is complex and the mechanisms related to carotenoid activity are not,
however, fully understood. It has been suggested that lutein and zeaxanthin increase
processing speed through their facilitative effect on gap junctional communication.282
In theory, a high density of pigment may improve signal transduction in the visual
system.282 The connection between photoreceptors and the visual cortex may also be
strengthened, which could explain improvements in contrast sensitivity function after
three months of supplementation with lutein and zeaxanthin in patients with nonproliferative diabetic retinopathy.15

There is also growing evidence to suggest that lutein and zeaxanthin may prevent the
development of diabetic retinopathy by suppressing ROS induced by inflammation.14,
283

Reactive oxygen species are considered a strong stimulus for the activation of a

number of pro-inflammatory pathways and several intracellular signalling pathways
of inflammation are associated with oxidative damage. In the endotoxin-induced
uveitis (EIU) mouse model, the innate immune system causes intraocular
inflammation which involves the neural retina.185,

284

One effect of retinal

inflammation that impairs visual function is the decreased expression of rhodopsin, an
essential protein that is vital for photo-transduction and photoreceptor function. In the
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EIU mouse model, ERG showed a decrease in a-wave amplitude and photoreceptor
dysfunction.185, 284-286 It is thought that a reduction of rhodopsin is caused by the
upregulation of signal transducer and activator of transcription 3 (STAT3) and
activation of inflammatory signals downstream, (i.e. IL-6). Once STAT3 activation
exceeds a certain threshold, the IL-6-STAT3 pathway enters a vicious cycle, which
exacerbates pathological conditions. It was found that the loss of rhodopsin resulted
in shorter outer segments and a decrease in photoreceptor cell function.287 To
investigate if lutein can protect visual function by suppressing inflammation the EIU
model mice were pre-treated with lutein. Treatment with lutein prevented a reduction
in the rhodopsin protein and preserved ERG a-wave, thereby, protecting photoreceptor
cell function in the inflamed retina.230, 285 Lutein’s effect on rhodopsin preservation
was accompanied by a suppression of STAT3 activation,230 which also suppressed the
IL-6-STAT3 cycle, effectively preventing tissue damage.230 While the interaction
between oxidative stress and inflammation is complex, these findings suggest that
lutein also has an anti-inflammatory effect.230

The benefits of MP are many and may relate to its blue light filtering effects,
antioxidant, anti-inflammatory and neuroprotective properties. The link between
hyperglycaemia and neurodegeneration is, however, not fully understood but various
cues point to altered inflammation and the activation of retinal microglia as early
features of diabetic retinopathy.288,289,

290

The protective effects of lutein and

zeaxanthin in animal and human studies will be reviewed in more detail in chapter six.
4.4.3.1 Polyunsaturated fatty acids
The photoreceptor membranes of both rods and cones contain high quantities of longchain omega 3 PUFAs. Polyunsaturated fatty acids account for about 50% of the lipid
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bilayer of rod outer segment membranes and proteins make up the remaining 50%.
Polyunsaturated fatty acids are particularly susceptible to free radical damage because
their conjugated double bonds are convenient sources of hydrogen atoms, which
contain one electron. The lipid radical combines with oxygen to form lipid peroxyl
radicals and lipid peroxides, which can only achieve a steady-state by stealing
electrons from other PUFAs, thus, creating a cytotoxic cascade of reactions that
consume valuable PUFAs and produce damaged molecules.291, 292 Docosahexaenoic
acid (DHA) is the main omega-3 PUFA in photoreceptors and the most oxidisable
fatty acid in the body.293 Docosahexaenoic acid contains six double bonds so the retina
is inherently susceptible to lipid peroxidation. Lipid peroxidation of membrane
PUFAs results in loss of membrane function and structural integrity.294

Omega-3 fatty acids DHA and eicosapentaenoic acid (EPA) have, however, also been
shown to inhibit a wide range of inflammatory mediators involved in the
pathophysiology of diabetic retinopathy, as well as, decrease the formation of free
radicals and induce the expression of endogenous antioxidant enzymes, (reviewed by
Behl & Kotwani

295

). The anti-inflammatory and anti-angiogenic responses of DHA

appears to be more potent than EPA

296

and DHA is known to regulate immune

function through microglia activation.292,297 Recent studies suggest that PUFAs and
their metabolites could play a significant role in diabetic retinopathy,298 as both EPA
and DHA inhibit the production of both IL-6 and TNF-α,299, 300 and PUFAs also
suppress VEGF production.301, 302 Lutein, zeaxanthin and meso-zeaxanthin are ideally
located in the rod outer segment membranes, suggesting a protective role as potent
antioxidants for these important lipids.303,60,

291,304

Interestingly, the effect of

supplementation with a multi-component nutritional supplement which included
99

omega 3 (EPA and DHA) and lutein/zeaxanthin, among other nutrients have been
shown to exert positive and beneficial ocular effects in those with diabetic eye disease,
(Type 1 and Type 2).21 This concept will be explored in more detail in chapter six.
4.4.3.2 Vitamin D
Vitamin D is also known to have anti-inflammatory and anti-angiogenic properties.305
Evidence is accumulating that higher levels of vitamin D may protect against the
development of diabetic retinopathy,306, 307 and that low plasma vitamin D levels are
associated with increased severity of diabetic retinopathy.308 Abnormalities in many
systemic inflammation markers (i.e. TNF- α, IL-6) have been found in Type 2 diabetes
and it has been reported that vitamin D down-regulates the production of these proinflammatory cytokines (reviewed by Palomer et al,309). Furthermore, the angiogenic
effects of vitamin D deficiency have been shown to contribute to vascular damage in
a group of young adolescents with Type 1 diabetes.310 Due to the cross-sectional nature
of many of these studies, however, it is not known if vitamin D deficiency is a cause
or a consequence of retinopathy. The relationship between vitamin D, MP and Type 2
diabetes will be explored in more detail in chapter seven.
4.5 Absorption, delivery and uptake of carotenoids in the eye
While a diet rich in fruit and vegetables is important for achieving adequate intake of
lutein and zeaxanthin (as well as other nutrients), concentrations of carotenoids in the
retina to form MP are highly variable and reflect not only dietary consumption but
also other factors such as individual efficacy of absorption,70 cholesterol and
lipoprotein status,18, 71 body composition/bodyfat,17, 54 and metabolic status,6 among
others. Individual differences in MP may also be influenced by non-dietary factors
such as genetics,72 demographic and lifestyle characteristics. The bioavailability,
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process of intestinal absorption, transport, and delivery of these phytonutrients to the
retina will now be explored.
4.5.1 Recommended daily intake values for carotenoids
At present there is no official recommended dietary intake level or established
physiologically significant cut off points for lutein/zeaxanthin in plasma above which
‘protection’ or ‘prevention’ against chronic diseases (i.e. AMD, diabetic retinopathy)
are ensured. Based on previous research,259 an intake of 6 mg of lutein and zeaxanthin
per day for men and women has been suggested as a dietary target to reduce the risk
of AMD.311 Mean daily intake of lutein and zeaxanthin combined, ranges from 0.8 mg
to 4 mg per day, depending on the population studied and the method of dietary
assessment used.22,
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An Irish study, involving 826 subjects estimated mean

lutein/zeaxanthin intakes of 0.6 - 2.4mg/day.49 The majority of lutein supplements
contain in the range of 6 - 25mg/day. Many supplements, however, are often well in
excess of the recommended levels of certain minerals and vitamins, with some dosages
carrying potential adverse effects. It is worth noting that while lutein is considered a
very safe compound, an exceedingly high daily ingestion of lutein (e.g. daily 20 mg
supplement of lutein; 4 g of fish oil; and dietary consumption of lutein, which included
a broccoli, kale, spinach, and avocado smoothie every morning) was associated with
a case of crystalline maculopathy.313 In this regard, a comprehensive dietary approach
to optimise carotenoid intake is preferable and would be a positive first step in
maintaining eye health.
4.5.2 Bioavailability, absorption and uptake of macular carotenoids
Many factors can affect the bioavailability and absorption of carotenoids including; 1)
food processing (raw, dehydrated, frozen, cooked); 2) meal composition; 3) activity
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of digestive enzymes; and 4) the effective uptake of carotenoids by enterocytes.314
Carotenoid

metabolism

begins

in

the

stomach.

The

initial

phase

of

digestion/absorption involves the extraction of carotenoids from the food matrix,
followed by their incorporation into lipid droplets, and transfer to mixed
micelles.315,316 The extent to which this happens depends on the quantity and nature of
lipids present in the food bolus.314 Lipids increase the bioavailability of both free and
esterified lutein,317 as they facilitate the extraction of carotenoids from the food matrix
by providing a hydrophobic phase in which carotenoids can solubilise. Dietary
triglycerides stimulate biliary secretion and consequently micelle production,
therefore, can increase carotenoid availability for absorption (reviewed by
Desmarchelier & Borel

314

). Dietary fibre, on the other hand, can inhibit lutein and

zeaxanthin absorption.318 It is also known that some micronutrients compete with
carotenoids regarding their absorption. The presence of β-carotene can lead to
competition for incorporation into mixed micelles and subsequent uptake by
enterocytes.319

Uptake and absorption of dietary carotenoids in the duodenum is by a facilitated
process which utilises scavenger receptor class B member 1 (SR-B1),320 a cell surface
glycoprotein and a member of CD-36 (cluster of differentiation 36) superfamily.321
Once absorbed carotenoids follow the same route as other newly absorbed lipid
molecules (e.g. fatty acids, cholesterol) and are incorporated with them in
chylomicrons in the Golgi apparatus before secretion in the lymph (apolipoprotein B
dependent route).314 As some carotenoids are also found in HDL and since the small
intestine synthesises HDL, it is hypothesised that a fraction of carotenoids are also
secreted into the lymph in HDL (apolipoprotein A dependent route).322
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4.5.3 Plasma transport and effective uptake of carotenoids
Carotenoids that reach the liver via chylomicrons are either stored there, eliminated in
bile, or re-secreted into VLDL to be distributed to peripheral tissues.314 While
carotenoids are detectable in all lipoprotein classes to varying degrees, most
hydrophobic carotenoids such as lycopene and β-carotene are transported on LDL,
whereas, the more hydrophilic xanthophyll carotenoids, such as lutein and zeaxanthin,
are primarily carried by HDL.19,323,324 The Wisconsin hypo-alpha mutant (WHAM)
chicken has very low levels of HDL due to a mutation in the ABCA1 transporter
gene.18 When these chickens are fed a high-lutein diet, lutein levels increase in plasma,
heart, and liver, but not in the retina, suggesting that HDL is critical for the delivery
of carotenoids to retinal tissue.18

Lipoprotein-bound xanthophylls, lutein, zeaxanthin and meso-zeaxanthin, accumulate
in the macula. To reach the neural retina (Muller cells, receptor axons and retinal
ganglion cells) carotenoids cross at the RPE. The RPE is similar to the blood-brain
barrier for the retina in that it serves as a cellular and metabolic interface between the
retina and the blood supply from the choroid.325 It has been suggested that lutein and
zeaxanthin are preferentially take up by human RPE cells via an SR-B1 dependent
mechanism.326 Differentiated ARPE-19 cells express lipoprotein receptors necessary
for lipoprotein delivery (i.e. SR-B1, LDL receptor and CD-36).326 While xanthophylls
are mostly associated with HDL in plasma, recent research suggests that zeaxanthin
and meso-zeaxanthin are more efficiently delivered to ARPE-19 cells via HDL in an
SR-B1-dependent process, whereas, lutein is more efficiently delivered via LDL and
cell uptake is thought to involve the LDL receptor.327 It is possible that these
mechanisms account for the selective accumulation of zeaxanthin and meso103

zeaxanthin over lutein in the central macula.328

Specificity and uptake of xanthophylls in specific regions of the retina may ultimately
be driven by selective binding proteins such as glutathione S-transferase (GSTP1) for
zeaxanthin and steroidogenic acute regulatory protein (a StARD family protein) for
lutein.329 It is thought that tubulin may serve as a secondary high capacity deposition
site for carotenoids within the Henle fibre layer.226, 329 Furthermore, a number of
enzymes that metabolise ocular carotenoids have also been identified, including betacarotene 15,15′ oxygenase-1 (BCO1) which cleaves carotenes, an essential step for
generation of vitamin A, and β-carotene 9′,10′ oxygenase-2 (BCO2) which cleaves
carotenes and xanthophylls.330 The process by which carotenoids and their oxidation
and degradation products are removed from the retina, however, is less clear. It is
known that macular carotenoid levels are remarkably stable even in the face of large
fluctuations in plasma levels that might occur with diet and/or supplementation.
Moreover, non-human primates placed on carotenoid-deficient diets typically take
several years to achieve non-detectable MP.331 Figure 4.6 provides a brief schematic
to describe the current understanding of the whole process of uptake, transport, and
accumulation of MP carotenoids in the human retina (adapted from Li et al,329).
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Figure 4.6: Possible pathway for MP carotenoid uptake, transport, and accumulation
in the human retina, (Adapted from Li et al, 329).
Abbreviations: Choroicapillaris (CH); Bruch's membrane (BM); retinal pigment
epithelium (RPE); inner segments (IS); outer plexiform layer (OPL); inner plexiform
layer (IPL).
4.6 Quantification of macular pigment in clinical practice
The protective effect of MP, if any, can be investigated through the observation of MP
levels. From the findings of epidemiological studies and AREDS2, there has been
great interest in quantifying carotenoid status in the eye.5, 332 Macular pigment levels
can be augmented with dietary modification,47 and/or nutritional supplementation,333
therefore, in measuring MPOD on a wide-scale it may be possible to analyse the
effects of MP augmentation on disease process and progression (i.e. the effects of MP
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augmentation on diabetic retinopathy). It is extremely challenging, however, to
measure MP in vivo and although several measurement modalities have been
proposed, most techniques are only available in a research setting. In humans,
measurement of MP in vivo is typically categorised into one of two groups:
psychophysical (requiring a response from the subject) or objective (requiring minimal
input from the subject), and will be discussed herein.
4.6.1 Psychophysical techniques
Psychophysical techniques include colour matching,9 heterochromatic flicker
photometry (HFP),334 and customised-HFP (c-HFP).335 One of the more common
methods of measuring MP is the HFP technique which is often used as a standard
against which other techniques are validated.336, 337 The HFP method exploits the
spectral absorption properties and retinal location of MP. The MPOD is determined
by presenting a light stimulus of two alternating wavelengths, a green light (not
absorbed by MP) and a blue light (maximally absorbed by MP) and the subject is
required to make isoluminance matches.334 If the colours are alternated at an
appropriate frequency and the luminance of the two colours are not perceived to be
equal then the stimulus will appear as a flickering light.338 The radiance of the blue
light is adjusted by the subject until the observed flicker is minimised.334 The
procedure is performed centrally, typically at 0.50 retinal eccentricity (where MP
peaks) and repeated at a parafoveal locus, typically 70 (where MP is optically
undetectable).339 The log ratio of the amount of blue light absorbed centrally to that
absorbed at a peripheral retinal locus (the reference point) gives a measure of the
subject's MPOD. Customised-HFP enhances the HFP technique by optimising the
flicker frequency for each individual.334, 335 The Macular Densitometer™ (a device
which uses c-HFP) has been validated by comparing MP measurements to known
106

biochemical markers (i.e. plasma concentrations of MP's constituent carotenoids) and
by comparing the data it generates with the in vitro spectral absorption curve of the
macular carotenoids 339 (Figure 4.7). Importantly, HFP and c-HFP have demonstrated
an ability to detect changes in MPOD following supplementation with MP's
constituent carotenoids.333, 340

Figure 4.7: Absorption spectra of lutein (red) and zeaxanthin (blue) in olive oil. A
mixture of lutein plus zeaxanthin (dashed black line) closely approximates the
absorption spectrum of the MP in the living human eye (Adapted from Bernstein et
al,339).

The HFP measurement relies on several assumptions; 1) the amount of yellowing in
the media (e.g. the crystalline lens) would influence the measured MPOD value,
however, the reference measure outside of the fovea cancels this effect. 341
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Consequently, varying degrees of crystalline lens absorption does not affect MP
measurement and; 2) the peripheral reference locus (typically taken at 70 retinal
eccentricity) has a negligible level of MP.339 An advantage of the HFP method is that
pupil dilation is not necessary. A drawback of the technique, however, is that it
requires significant patient training to produce meaningful results. Additionally, some
protocols only take two measurements, centrally and peripherally, therefore, providing
no information on the spatial distribution of MP. It is possible, however, to achieve a
spatial profile of MPOD by altering the size and/or the eccentric position of the test
stimulus. While the extra measurements increase the duration of the test, it produces
a curve that can be used to describe the change in MPOD with increasing eccentricity
from the central fovea 342 (Figure 4.8).

Figure 4.8: Mean spatial profile of MPOD (Adapted from Nolan et al,342).
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More recently researchers have tried to identify other image-based methods which are
less technically demanding and can measure MPOD objectively.
4.6.2 Image-based techniques
Non-invasive methods for assessment of carotenoid status have evolved considerably
over the past few decades. Fundus autofluorescence has gained a lot of interest as the
technique is objective and provides high-resolution and quantitative spatial
distributions of MP. It is rapid and, apart from good fixation on a target, requires
minimal patient cooperation. Fundus autofluorescence exploits the fluorescent
properties of lipofuscin present and the predictable attenuation of the fluorescence by
MP.343 Lipofuscin is excited in vivo between 400 and 590 nm (peak excitation at 490510 nm) and emits autofluorescence at 520-800 nm (peak emission at 590-630 nm).344
At the fovea, excitation light within the absorbance range of MP is partially absorbed
by the carotenoids, resulting in an area of reduced fluorescence. The Heidelberg
Spectralis use the two-wavelength autofluorescence technique to measure MP and
captures sets of images at two excitation wavelengths 226 (Figure 4.9).
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Figure 4.9: Image of macular pigment measured by Heidelberg Spectralis (Left,
excitation wavelength at 488 nm; Right, excitation wavelength at 514 nm) (Adapted
from Bernstein et al,226).

The Spectralis autofluorescence attenuation method is highly reproducible and
provides a lot of spatial data.345 The instrument calculates the average MPOD,
standard deviation (SD) and range of MPOD levels along a series of concentric onepixel width circles. The results are then plotted on a graph 00 to 150 with a red curve
corresponding to the average MPOD at each eccentricity, a green curve corresponding
to the SD of the average MPOD and a blue region corresponding to the high and low
range of MPOD.343 A reference point is typically taken at 90 eccentricity where the
MPOD is defined as zero. Two other analysis eccentricities routinely used are 0.50 and
20 343 (Figure 4.10).
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Figure 4.10: Macular pigment tracing from a healthy subject. (a) Macular pigment
tracing at 0.50 (red), 20 (blue), and 90 (green) demarcated by the solid lines as
indicated. (b) Macular pigment image showing the fovea and the degrees (0.50, red;
20, blue; 90, green) from the centre of the macula lutea (Adapted from Conrady et al,
343

).

A recent study, on subjects free of retinal disease, confirmed that measuring MP using
autofluorescence imaging displays good concordance with c-HFP.337 Furthermore,
MP volume under the curve 90 gave the strongest correlations with lutein, zeaxanthin,
lutein and zeaxanthin, which demonstrates the importance of capturing all of the
carotenoid content of the macula rather than focusing on the MPOD at just one or two
eccentricities.343 Additional work, however, is needed to confirm its reliability across
populations (e.g. patients with AMD and patients with diabetes). With the latest
technology visually significant cataracts do not seem to suppress MP measurements
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excessively especially when using MP under the curve 90.343 Some drawbacks to the
method, however, is the need for specialised equipment which is expensive, its bright
light levels and the need for pupil dilation. Current generation autofluorescence
techniques based on ocular imaging systems, however, look promising and may be
well-suited for busy clinical practice settings in the near future.
4.6.2 Plasma analysis and dietary intake of carotenoids
Systemic measures of carotenoids are also used as a surrogate for ocular
concentrations of these phytonutrients. Methods include HPLC analysis of plasma and
dietary assessment. Plasma HPLC analysis of carotenoids have correlated well with
assessment of ocular carotenoid status,346-348 and are a good way of identifying patients
who are adequately absorbing these phytonutrients. Plasma measurements, however,
involve invasive blood draws and time-consuming analysis and are only available in
a research setting.

Dietary assessment tools have also been used to assess carotenoid intake. Methods
include food frequency questionnaires [FFQs], food diaries and 24-hour recalls.
Owing to their relatively lower administrative costs and their ability to assess usual
and longer-term intake, FFQs have historically been the method of choice for
epidemiological studies.349 Assessment of carotenoid intake in this way, however, has
limitations. A common one is the overestimation of dietary intake as FFQs are greatly
influenced by the accuracy of the portion size reported by the subject. Estimates
obtained are also dependent on the use of accurate nutrient data sources. An issue with
FFQs is that they may not always reflect food eaten by the population being examined.
For example, FFQs developed for assessing lutein and zeaxanthin intake designed for
an American population,350 may not be valid for estimating these carotenoids in, for
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example, an Irish population. Additionally, as lutein and zeaxanthin concentration in
food varies with time and geographical origin, carotenoid databases used to analyse
dietary intake need to be up to date and developed using foods from the country of
origin of the population being studied. An accurate assessment is also difficult given
that current databases generally report lutein and zeaxanthin as a combined value.
When carotenoids are considered together it makes it even more difficult to determine
their respective roles in eye health.351

A promising development in recent times is the ‘lutein/zeaxanthin screener’. This new
tool estimates carotenoid intake and offers advantages over other dietary assessment
tools in that it is easy to use, quick, and cost-effective. Intake of lutein and zeaxanthin
can be calculated (although reported as a combined value) as crude estimates (i.e.
lutein/zeaxanthin score) based on dietary intake and relative bioavailability of four
common xanthophyll containing food groups (eggs, broccoli, maize, and dark leafy
vegetables).352 The range of scores on the “lutein/zeaxanthin screener” is 0-75 and
intake is categorised into low, medium and high. Dietary estimates of lutein and
zeaxanthin combined have been shown to be positively and significantly correlated
with plasma concentrations of these carotenoids (r=0.329,p<0.001), and this
relationship remained after controlling for other variables such as age and body mass
index (BMI).352
4.7 The need for alternative biomarkers
Despite some attempts, there is still no commercially available instrument that can
successfully measure MPOD in vivo in clinical practice.336 While the
‘’lutein/zeaxanthin screener’ looks promising dietary intake assessed using FFQs is
self-reported and only crudely quantified and as a result is subject to both bias and
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error. In addition to, plasma analysis of carotenoids involves complex analysis.
Consequently, there is merit in examining the predictive capacity of a range of more
commonly measured proxy biomarkers; i.e. [clinical (blood pressure), plasma
(lipoproteins, inflammatory markers) and anthropometric (abdominal fat)], which
might be used to identify patients at risk of low MP. The capacity of more commonlymeasured surrogate biomarkers to help identify people at risk of low MP (i.e. patients
with Type 2 diabetes, older adults) will be explored in chapters seven and eight.
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5. MACULAR PIGMENT IS LOWER IN TYPE 2 DIABETES COMPARED
WITH TYPE 1 DIABETES AND NORMAL CONTROLS.
5.1 Abstract
Purpose
This cross-sectional study was designed to investigate the optical density of MP in
Type 1 and Type 2 diabetes subjects relative to normal controls.
Methods
One hundred and fifty subjects were recruited to the study and divided into
one of the three study groups based on their health status, as follows: Group 1:
Healthy controls; Group 2: Type 1 diabetes; Group 3: Type 2 diabetes. Macular
pigment optical density at 0.5° of retinal eccentricity was measured using c-HFP.
Dietary intake of macular carotenoids was quantified using a lutein and zeaxanthin
FFQ. Diabetes type, duration, medication, smoking habits, HbA1c, and plasma lipid
levels were recorded, whereas VA, BMI, and diabetic retinopathy grade were
measured for each participant.
Results
One-way analysis of variance revealed a statistically significant difference in
BMI, age, HDL cholesterol and HbA1c between the three groups (p<0.01 for all). Chisquare analysis revealed a statistically significant difference in diabetic retinopathy
distribution (p<0.01). None of these variables exhibited a statistically significant
correlation with MPOD for any study group (p>0.05 for all). There was no difference
in dietary carotenoid intake between groups. Macular pigment optical density was
lower among Type 2 diabetes subjects (0.33 ± 0.21) compared with Type 1 diabetes
(0.49 ± 0.23) and normal controls (0.48 ± 0.35). General linear model analysis,
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including age, BMI, diabetes duration, diabetic retinopathy status, HDL, and HbA1c
as covariates, revealed a statistically significant effect of diabetes type on MPOD (F =
2.62; p=0.04).
Conclusion
Macular pigment optical density was statistically significantly lower in Type 2
diabetes compared with Type 1 diabetes and normal controls. Although BMI was
higher in the Type 2 diabetes group, the lower MPOD levels observed among Type 2
diabetes seem not to be attributable to differences in the dietary carotenoid intake or
the specific presence of diabetes, diabetic control, duration, or diabetic retinopathy.
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5.2 Introduction
Neurodegenerative diseases of the retina such as AMD and diabetic retinopathy are
leading causes of worldwide blindness.353 Although the relationship between AMD
and MPOD has been widely reported,221, 339 only a small number of studies have
focused on MPOD and carotenoid intake in diabetes mellitus,6, 15 a condition similarly
known to cause oxidative damage in the retina.354

Diabetes, a lifelong progressive disease, is the result of the body’s inability to produce
insulin or use insulin to its full potential and is characterised by high circulating
glucose.355 Diabetic retinopathy represents the most common diabetic eye disease, and
there is strong evidence that oxidative stress plays an important role in its
development.354, 355 Chronic hyperglycaemia causes oxidative stress,355 which results
in microvascular complications at the retina, where the neuronal elements responsible
for vision are located. The relationship between hyperglycaemia, changes in redox
homeostasis, and oxidative stress are key events in the pathogenesis of diabetic
retinopathy.355 Oxidative stress is also involved in the initiation and progression of
obesity and diabetes mellitus.356 The links between Type 2 diabetes and obesity are
ﬁrmly established.357 Type 2 diabetes now also affects a much younger population
because of sedentary lifestyles and increases in caloriﬁc intake and accounts for more
than 90% of all cases of diabetes.358 The development of ocular complications in
diabetes is related to disease control and longevity.11,

359, 360

After 20 years with

diabetes, 75% of patients will have some form of diabetic retinopathy.360 Apart from
good systemic control of blood sugar levels, hypertension, lipid proﬁles, and renal
function, current treatment modalities for diabetic retinopathy are limited to laser
photocoagulation

11

and/or intravitreal injections.12 These are effective modes of
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treatment but they also have their limitations and side effects. New modalities should,
therefore, be preventative in nature and ideally implemented long before overt clinical
symptoms develop. Macular pigment is believed to possess antioxidant properties and
to limit retinal oxidative damage by absorbing harmful short-wavelength blue light.3
Macular pigment is highly concentrated at the central macula and is composed of the
dietary hydroxyl-carotenoids lutein, zeaxanthin, and meso-zeaxanthin.46 These
hydroxyl carotenoids are found in the retina to the exclusion of all other 700
carotenoids found in nature.312 Concentrations of carotenoids in human plasma and
deposition of the macular carotenoids in the retina to form MP are highly variable and
reﬂect not only dietary intake but also factors such as carotenoid chemistry,361
individual efﬁcacy of absorption,70 fat intake,16 competition among carotenoids for
absorption,17 cholesterol and lipoprotein status,18,
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metabolic status,6 body

composition, and BMI.17, 54 The relationship between MP and diabetes is only now
attracting research interest, possibly as a result of the outcomes of clinical trials, which
demonstrate a protective effect of lutein and zeaxanthin supplementation in another
oxidative stress-related condition, AMD.221, 339 One experimental study on diabetic
rats demonstrated a reduction in retinal oxidative damage after carotenoid
supplementation.14 Lutein and zeaxanthin intake has also been shown to improve
macular oedema in diabetic retinopathy patients.15 These results suggest that MP
supplementation has the potential to inhibit or delay the development of macular
disease in patients with diabetes.

This study was designed to investigate the cross-sectional relationship, if any, between
diabetes and central MPOD and to explore the inﬂuence of potential explanatory
factors, including HbA1c, plasma lipid levels, BMI, and dietary carotenoid intake on
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any relationship that might be observed.
5.3 Materials and Methods
Subjects
Diabetic participants and normal control subjects were recruited for this crosssectional, case-control study at the Mater Misericordiae University Hospital in Dublin,
Ireland. The study was approved by the Institutional Research Ethics Committee and
adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained
from all subjects before enrolment and examination. Generic inclusion criteria were
as follows: subjects were to be older than 18 years, not having taken dietary
supplements containing lutein, zeaxanthin or meso-zeaxanthin over the 6-month
period before the study, and logMAR VA better than 0.2 (6/9) in the study eye. For
normal (control) subjects, exclusion criteria included any sign of retinal or ocular
abnormality and the presence of Type 1 or Type 2 diabetes. Patients with diabetes
were excluded if they exhibited signs of ocular comorbidity (e.g. glaucoma, cataract,
AMD), had previously undergone any form of treatment for diabetic retinopathy or
maculopathy, or if they exhibited any signs of proliferative retinopathy or
maculopathy. The study eye was selected using the eye with better VA, or, in cases of
equal acuity, the right eye was selected as standard. Subjects were assigned into one
of three study groups based on their ocular health status and diabetes type as follows:
Group 1: Non-diabetic controls; Group 2: Type 1 diabetes; Group 3: Type 2 diabetes.
Demographic and lifestyle information
Demographic information, including age, gender, race, history of smoking (current
smoker, ex-smoker, and never smoked) and duration of smoking in years was collected
in relation to each subject.
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Diabetes classification and diabetic retinopathy grading
The following diabetes-related information was recorded for each diabetes participant:
diabetes duration, diabetes type, and diabetic retinopathy grade. Subjects were
classified based on their ocular health status and diabetes type as non-diabetic controls,
Type 1 diabetes, and Type 2 diabetes. The duration of disease was recorded in years.
Diabetic retinopathy was graded according to modiﬁed 2-ﬁeld early treatment diabetic
retinopathy study (EDTRS) protocol-grade range R0 M0 to R2 M0 by consultant
ophthalmic surgeon, Mr Paul Connell, Mater Private Hospital. Medications for
diabetes including insulin and oral hypoglycaemics were noted. Glycated
haemoglobin (%) was also recorded.
Anthropometric measurement
Anthropometric measurements including weight and height were obtained using
standardised techniques. Body weight was measured to the nearest 0.2 kg using a Seca
Compact Digital Floor Scale 111, model 888 (Seca Limited), whereas, height was
measured to the nearest 0.5 cm using a collapsible “Leicester Height Measure”
stadiometer (CMS Weighing Equipment). Body mass index was given as weight (in
kilograms)/height (in square metres, (kg/m2)).
Plasma analysis
Plasma blood levels including total cholesterol (TC) in millimoles per litre (mmol/L),
LDL (mmol/L), HDL (mmol/L), TGs (mmol/L) and HbA1c (%) were recorded for
each subject.
Lutein and zeaxanthin intake.
Dietary carotenoid intake was estimated using the lutein/zeaxanthin questionnaire
121

(Carotenoid & Health Laboratory, Jean Mayer USDA Human Nutrition Centre on
Aging, Tufts University, USA).350 Lutein, zeaxanthin and total lutein and zeaxanthin
in micrograms (mg) per day were quantified.
Macular pigment optical density measurement
Macular pigment absorbs blue light and is optically undetectable at 6° to 8°
eccentricity.44 In this study, MPOD was determined using the Macular Metrics
Clinical Densitometer (Macular Metrics, Rehoboth, MA), which is based on the
principle of HFP.334 The basic measurement procedure involves presenting a small test
stimulus that alternates between a measuring wavelength (458 nm), which is absorbed
by MP and a reference wavelength (540 nm) not absorbed by the pigment. The subject
adjusts the intensity of the measuring wavelength (458 nm) luminance until there is
minimum ﬂicker (matching luminance). The luminance of the reference wavelength
(540 nm) remains constant. The ratio of the amount of measuring wavelength (458
nm) light required to achieve the endpoint of matching luminance, or minimum ﬂicker,
for foveal and parafoveal readings is a measure of the amount of pigment present, and
the logarithm of this ratio represents the optical density of MP. Before using the
densitometer, all subjects were shown an explanatory video describing the method for
recording null ﬂicker matches. The measurement was conducted by a single examiner
who was highly skilled and experienced with the technique. All subjects were naive
to the HFP test. The MPOD measurement comprised the average of six readings
(computed as the radiance value at which the subject reported null ﬂicker) taken
centrally at 0.5° retinal eccentricity and again at 7° retinal eccentricity. The target used
for measuring MPOD at 0.5° eccentricity was a solid disc of 0.5° arc radius, and the
parafoveal measurement was taken by asking the subject to ﬁxate on a red light located
precisely at 7° from central ﬁxation. Measurements were deemed reliable and
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acceptable only when the SD of null ﬂicker responses was below 0.1. A c-HFP
procedure was adopted, whereby ﬂicker frequency was optimised for each participant
before the measurement of MPOD. The starting ﬂicker was set at 10 Hz to 11 Hz. If
the subject was unable to ﬁnd no/minimum ﬂicker, this frequency was increased until
no/minimal ﬂicker could be identiﬁed. If the null one was too wide, the ﬂicker
frequency was reduced. The ﬂicker frequency was adjusted until the subject found a
narrow null zone.
Statistical analysis
The statistical software package SPSS for Microsoft Windows (v.21.0; IBM Corp.,
Armonk, NY) was used for analysis. Data are presented as mean ± standard deviation
throughout. The data were tested for normality using the Kolmogorov–Smirnov test.
One-way analysis of variance (ANOVA) was used to test for differences in normally
distributed study parameters between groups, whereas the Kruskal–Wallis test was
used to test for differences in group medians in non-normally distributed data. The
Chi-square test was used to compare categorical data across the three study groups.
Pearson’s product-moment correlation tests were performed to assess the relationship
between MPOD and other study variables where appropriate. A general linear model
approach was used to explore the relationship between diabetes type, other potential
explanatory variables, and the dependent variable, MPOD. The level of statistical
signiﬁcance was set at the standard p<0.05.
5.4 Results
One hundred and ﬁfty subjects were recruited to the study and divided into 1 of the 3
study groups on the basis of their ocular health status and diabetes type, as follows:
Group 1: Non-diabetic controls (n = 48; male = 20, female = 28); Group 2: Type 1
123

diabetes (n = 34; male = 17, female = 17); Group 3: Type 2 diabetes (n = 68; male =
43, female = 25). Kolmogorov–Smirnov analysis revealed that BMI, TC, lutein intake,
zeaxanthin intake, and MPOD data were normally distributed (p>0.05 for each),
whereas all remaining variables exhibited non-normal distributions. Accordingly,
parametric tests were applied, where relevant, to normally distributed data, and
nonparametric equivalent tests to non-normally distributed data. A comparison of the
demographic and clinical characteristics of each group is presented in Table 5.1.
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Table 5.1: Demographic and clinical findings according to classiﬁcation group.
Variable

Non-diabetic controls

Sex

Male = 20; Female =28

Type 1 Diabetes

Type 2 Diabetes

Male = 17; Female = 17 Male = 43; Female = 25

p value
<0.07*

Age (years)

52.48 ± 16.03

43.67 ± 12.98

62.67 ± 11.31

<0.01†

BMI (kg/m2)

27.7 ± 4.8

27.33 ± 4.77

31.44 ± 6.16

<0.01‡

Smoking duration (years)

2.13 ± 0.62

2.35 ± 0.60

2.25 ± 0.65

0.33†

-

22.73 ± 10.85

9.54 ± 7.33

<0.01†

HbA1c (%)

-

7.9 ± 1.08

6.88 ± 1.09

<0.01†

TG (mmol/L)

-

1.37 ± 2.06

1.55 ± 0.85

0.55†

HDL (mmol/L)

-

1.52 ± 0.46

1.14 ± 0.28

<0.01†

LDL (mmol/L)

-

2.37 ± 0.70

2.20 ± 0.74

0.15†

TC (mmol/L)

-

4.31 ± 0.82

4.03 ± 0.89

0.14‡

MPOD (SD)

0.48 ± 0.35

0.49 ± 0.23

0.33 ± 0.21

<0.01‡

Lutein Intake (mg/day)

0.95 ± 0.21

1.06 ± 1.29

0.95 ± 1.73

0.93‡

Zeaxanthin Intake (mg/day)

0.11 ± 0.12

0.16 ± 0.26

0.12 ± 0.25

0.54‡

Total Lutein & Zeaxanthin

1.07 ± 1.25

1.23 ± 1.34

1.07 ± 1.83

0.88‡

-

Yes = 23 (68%)

Yes = 24 (35%)

<0.01*

No = 11 (32%)

No = 44 (65%)

Diabetes

mellitus

duration

(years)

Intake, (mg/day)
Non-Proliferative
Diabetic Retinopathy
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* Chi-square test † Kruskal-Wallis test ‡ One-way Analysis of Variance.
Abbreviations: ANOVA, one way analysis of variance; BMI, body mass index; kg/m 2, kilogrammes per metre squared; HbA1c, glycated haemoglobin level; HDL,
high density lipoprotein; LDL, low density lipoprotein; mg/day; microgrammes per day; mmol/L, millimoles per litre; TC, total cholesterol; TG, triglycerides.
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Post hoc analysis (Tukey test) revealed that MPOD was statistically signiﬁcantly
lower in Type 2 diabetes compared with both normal controls (p=0.02) and Type 1
diabetes (p=0.03), whereas the difference in MPOD between Type 1 diabetes and
normal controls was not statistically signiﬁcant (p=0.99). The distribution of MPOD
for each of the study groups is presented in Figure 5.1

Figure 5.1: MPOD distribution (mean ± 95% confidence intervals) according to
diabetes status, illustrating the substantially lower MPOD levels among Type 2
diabetes subjects.

A general linear model analysis conﬁrmed a signiﬁcant effect of diabetes type on the
dependent variable, MPOD (p=0.04), but no effect of potentially confounding
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variables including age, BMI, diabetic retinopathy status, HDL cholesterol, or HbA1c
on MPOD (p=0.16 – 0.74). While there was a significant difference in age between
the three groups; Type 1 (mean age = 43.67±12.98); Type 2 (mean age = 62.67±11.31)
and non-diabetic controls (mean age = 52.48±16.03) (p<0.01); age was controlled for
in the general linear model and had no effect on MPOD (p=0.128). In addition, age,
including controlling for confounding, was not significantly correlated with MPOD
(r=-0.175; p=0.138). The distribution of MPOD according to diabetic retinopathy
status, which demonstrated no inﬂuence on MPOD in the general linear model analysis
(p=0.45), is presented in Figure 5.2.

Figure 5.2: The distribution of MPOD (mean ± 95% confidence intervals) according
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to diabetic retinopathy status, illustrating the significant overlap between groups.

Body mass index was statistically signiﬁcantly higher in Type 2 diabetes compared
with normal controls (p<0.01) and Type 1 diabetes (p<0.01), whereas the difference
in BMI between Type 1 diabetes and normal controls was not statistically signiﬁcant
(p=0.75). Body mass index, however, including controlling for confounding was not
statistically signiﬁcantly correlated with MPOD (r=0.08, p=0.51). The distribution of
BMI for each of the study groups is presented in Figure 5.3.

Figure 5.3: Body mass index distribution (mean ± 95% confidence intervals)
according to diabetes status, illustrating substantially higher BMI levels among Type
2 diabetes subjects.
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5.5 Discussion
This study demonstrates that MPOD levels are signiﬁcantly lower in Type 2 diabetes
when compared with Type 1 diabetes, which represents an entirely novel ﬁnding. This
observation is signiﬁcant given that similar dietary carotenoid intake was observed
among the study groups and in the context of shorter diabetes duration among the Type
2 diabetes subjects. Similarly, the presence of non-proliferative diabetic retinopathy
seems not to inﬂuence MPOD levels, which are, surprisingly, slightly higher on
average in those with retinopathy compared with those without retinopathy, although
lower in both diabetic groups compared with normal controls. The study further
demonstrates that the MPOD levels in Type 2 diabetes are signiﬁcantly lower than in
normal controls, a ﬁnding, which is in general agreement with those of previous
investigations that have explored the relationship between MPOD and diabetes. It has
been shown, for example, that Type 2 diabetes subjects had lower MPOD when
compared with non-diabetic controls, while Type 2 diabetes with mild nonproliferative retinopathy exhibited similar MPOD levels to Type 2 diabetes without
retinopathy.6 In addition, plasma lutein and zeaxanthin concentrations, which have
been shown to be positively and signiﬁcantly related to MPOD in normal subjects, 49
have been shown to be signiﬁcantly lower in diabetes compared with normal
subjects.15 In more advanced cases of diabetic eye disease, subjects with Grade 2
maculopathy were found to have signiﬁcantly lower MPOD than those without
maculopathy.9 The apparent relationship between low MP levels and increasing
severity of maculopathy prompted those study investigators to implicate oxidative
stress as a causative factor, a concept that merits further discussion here.9
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Macular pigment optical density has a slow biological turnover, as it reﬂects the local
balance between pro-oxidant stresses and antioxidant defences in the retina.49 The
retina is particularly susceptible to oxidative stress because of its high oxygen
consumption, the high proportion of PUFAs, and exposure to visible and shortwavelength blue light.291 There is also considerable evidence that hyperglycaemia
results in the generation of ROS, ultimately leading to increased oxidative stress in the
retina,354,

355

which may play an important role in the aetiology of diabetic

complications. Poor metabolic control and longer duration of diabetes are directly
linked to the prevalence of diabetic retinopathy,359 whereas oxidative stress can be
signiﬁcantly reduced with aggressive control of hyperglycaemia.362 We found no
association, however, between MPOD and either HbA1c or diabetes duration in this
study. Paradoxically, despite their lower MPOD, metabolic control appeared better,
diabetes duration was shorter, and diabetic retinopathy prevalence was lower for Type
2 compared with Type 1 diabetes subjects. Although HbA1c has previously been
shown to be inversely and signiﬁcantly related to MPOD among a smaller sample of
Type 2 diabetes subjects,6 our ﬁndings imply that lower MPOD in Type 2 diabetes is
not attributable to the diabetic condition, duration, or level of control, and suggests a
need to explore alternative explanatory causes. Furthermore, while there was a
significant difference in age between the three groups (p<0.01), and some studies have
demonstrated a decline in MPOD with age, 49, 55, 56 although not all 57, 58 age was not a
predictor of MPOD on general linear model analysis. Also, we found no correlation
between MPOD and age, while controlling for all other variables.

Although BMI measures do not provide a precise indicator of adiposity, it is likely
that the statistically signiﬁcantly higher BMI levels observed in the Type 2 diabetes
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group here, which averaged above World Health Organisation (WHO) deﬁned BMI
levels indicative of obesity (BMI>30),363 are reﬂective of excess adiposity in this
group compared with the normal control and Type 1 diabetes groups. To date, there
has been very little consensus on the relationship between types of obesity and MPOD.
One study reported a lack of an association between MPOD and various obesity
indices, including WC, WHpR, and BMI, in a South-Indian population.364 Conversely,
other studies have shown signiﬁcant inverse relationships between body fat and
MPOD in humans,16, 17, 54 however, these relationships differed between men 16 and
women.17 Lutein and zeaxanthin are known to accumulate in adipose tissue,257 and
lower MPOD values have also been reported among individuals exhibiting body fat
measuring greater than 27% when compared with those with lower body fat.54 Higher
body fat percentage even within relatively healthy limits is associated with lower
tissue lutein and zeaxanthin status 53 and renders the macular carotenoids less available
to retinal tissue.68 Distribution of body fat in the body is also important, and it has been
shown that lutein/zeaxanthin concentrations in adipose tissue differ according to body
site, with levels demonstrably higher in abdominal fat than in the gluteofemoral fat
depot.67 Interestingly, abdominal obesity is now considered an important risk factor
and predictive indicator for the development of Type 2 diabetes and cardiovascular
disease.365 Waist-to-height ratio has more recently been shown to have superior
discriminatory power for detecting cardiovascular risk factors in both sexes 366 and
should be considered as a screening tool for diabetes, hypertension, and cardiovascular
disease in men and women.366 Future studies investigating the link between MPOD
and obesity should, therefore, encompass more reﬁned methods of body fat assessment
including bioelectrical impedance analysis and WHtR,366 because BMI measurements
alone may not be adequate to provide a true indication of adiposity, and this could
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explain the lack of an association between MPOD and BMI in our study. Diets, which
are high in fat and low in carotenoids, have been linked with increased oxidative
stress.367 Obesity is also independently associated with increased oxidative stress
367, 368

69,

and an increased BMI has also been shown to be associated with increased risk

of DNA damage due to oxidative stress.369 Plasma 8-OHdG, for example, a known
sensitive marker of oxidative DNA damage and total systemic oxidative stress in vivo,
has been shown to be positively correlated with BMI in people with Type 2 diabetes
mellitus.370 Adipose tissue produces bioactive substances called adipokines, which
induce the production of ROS by a combination of mechanisms including
mitochondrial and peroxisomal oxidation of fatty acids and overconsumption of
oxygen,69, 368 thereby, initiate a process of oxidative stress.69, 368 Recent studies have
highlighted the role of increased abdominal fat mass as a key driver of inﬂammation
in Type 2 diabetes,371 a state closely associated with increased oxidative stress,69, 368
and macrovascular disease.371 Chronic inﬂammation induces changes in metabolic
pathways and is believed to play a signiﬁcant role in the progression from obesity to
Type 2 diabetes.372, 373 Despite the lack of any direct association between BMI and
MPOD observed herein, it is plausible to suggest that; 1) more reﬁned methods of
body fat assessment such as bioelectrical impedance analysis 374 and WHtR 366 might
reveal an association that could explain the lower MPOD values observed in Type 2
diabetes subjects here and; 2) that the combined effect of increased competition for
lutein/zeaxanthin deposition and increased inﬂammation and oxidative stress levels in
association with higher BMI/body fat might explain, at least in part, the lower MPOD
levels observed in the Type 2 diabetes group. There is no signiﬁcant difference in
MPOD between patients with or without retinopathy indicating that retinopathy status
seems not to be the main driver in inﬂuencing MP levels.
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High-density lipoprotein differences observed between Type 1 and Type 2 diabetes
could also contribute to the lower MP levels observed in the Type 2 diabetes group.
Macular pigment carotenoids are primarily transported by HDL in plasma. 18, 71 It has
been suggested that mechanisms governing the retinal capture and/or stabilisation of
these carotenoids in the retina may be subject to HDL inﬂuence, by affecting receptormediated uptake of these carotenoids from plasma.71 High-density lipoprotein
deﬁciencies are associated with lutein and zeaxanthin tissue deﬁciencies, most notably
in the retina.18 Furthermore, it has been suggested that individuals exhibiting elevated
plasma TG concentrations and concurrently reduced plasma HDL concentrations may
have a related and reduced capacity to transport lutein in plasma.71 Such features are
very characteristic of Type 2 but not Type 1 diabetes.375 Lipoprotein proﬁle is
adversely affected by insulin resistance and might mechanistically explain (by
eliciting a reduced capacity to transport macular carotenoids), why Type 2 diabetes is
associated with lower MP levels compared with Type 1 diabetes where insulin
resistance is much less prominent. A more comprehensive investigation into the
association between lipoprotein proﬁle, MPOD, and dietary carotenoid intake among
diabetes subjects is therefore warranted. Average macular carotenoid intake was
similar for the three study groups (p=0.88) and at levels that are consistent with the
lower limits of average daily carotenoid intake, (ranges from 1.1 to 1.6 mg/day).49
Although dietary intake is the primary driver of tissue carotenoid levels,3 the
relationship between diet and deposition of these pigments in the retina is moderated
by a number of factors. Retinal capture and/or stabilisation of these carotenoids in the
macula, may, for example, be subject to inﬂuence by obesity-induced inﬂammation
and oxidative stress,372, 373 competition between adipose and retinal tissue for the
dietary carotenoids,17, 53, 54 impaired transport of circulating lutein/zeaxanthin,18, 71
134

and/or genetic inﬂuence,224 which may help to explain the signiﬁcant effect of Type 2
diabetes on MPOD.
5.6 Limitations
Limitations to this cross-sectional case-control study include the use of a dietary
questionnaire designed for an American population among European participants, lack
of plasma carotenoid analysis, lack of detailed body fat analysis, and the absence of
other clinical parameters such as inﬂammatory markers. Further research is needed in
the diabetic population to uncover the relationship between disease progression, BMI
including WHtR, body fat composition, plasma cholesterol, inﬂammatory status, and
dietary carotenoid intake, as well as the mechanism of retinal damage in the presence
of low MPOD.
5.7 Conclusion
The effects of the adiposity, insulin resistance, inﬂammation, and HDL suppression,
characteristics that differentiate Type 2 from Type 1 diabetes, on MPOD should be
particularly emphasised. A longitudinal study, comparing MPOD in Type 1 and Type
2 diabetes with parameters such as lipoprotein proﬁle (including LDL, HDL, and
TGs),18, 71 obesity indices (including WHtR, bioelectrical impedance analysis, BMI,
WC, and waist-to-hip ratio (WHpR) measurements),366 and dietary intake of lutein and
zeaxanthin,
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would certainly provide a more holistic understanding of the

relationship between MPOD and BMI in Type 2 diabetes patients over time. Certain
features such as obesity,356 low HDL, and raised TGs are characteristic of Type 2 but
not Type 1 diabetes,375 and these characteristics may indeed affect the transport,
uptake, and stabilisation of these carotenoids in the retina and would, therefore,
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warrant further investigation.
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6. A REVIEW OF THE PUTATIVE CAUSAL MECHANISMS
ASSOCIATED WITH LOWER MACULAR PIGMENT IN
DIABETES MELLITUS.
6.1 Abstract
Purpose
Macular Pigment confers potent antioxidant and anti-inflammatory effects at the
macula, and may therefore, protect retinal tissue from the oxidative stress and
inflammation associated with ocular disease and aging. There is a body of evidence
implicating oxidative damage and inflammation as underlying pathological processes
in diabetic retinopathy, a major cause of vision impairment and blindness. Macular
pigment has therefore become a focus of research in diabetes. This review explores
the currently available evidence pertaining to MP levels in diabetes, and illuminates
the potential metabolic perturbations implicated in MP depletion in diabetic eye
disease.
Methods
This review was carried out in two stages. Firstly we identified all relevant published
articles from human and animal studies which reported on the relationship between
MP (lutein and/or zeaxanthin and/or meso-zeaxanthin) and diabetes (Type 1 & Type
2), up until the year 2019. The second part of the search involved identifying
publications which investigated the relationship between the metabolic perturbations
typically associated with diabetes, and Type 2 diabetes in particular (e.g.
adiposity/dyslipidaemia) and MP. PubMed, Google Scholar, Mendeley, Scopus,
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Cochrane Library and the ISRCTN registry were used to search for literature of
relevance to MP and diabetes. Relevant citations in the literature located through our
search were also appraised.
Results
Metabolic co-morbidities commonly associated with Type 2 diabetes such as
overweight/obesity, dyslipidaemia, hyperglycaemia and insulin resistance, may have
added and independent relationships with MP. Increased adiposity and dyslipidaemia
may adversely affect MP by compromising the availability, transport, and assimilation
of these dietary carotenoids in the retina. Furthermore, carotenoid intake may be
compromised by the dietary deficiencies characteristic of Type 2 diabetes, thereby,
further compromising redox homeostasis.
Conclusion
Candidate causal mechanisms to explain the lower MP levels reported in diabetes
include increased oxidative stress, inflammation, hyperglycaemia, insulin resistance,
overweight/obesity and dyslipidaemia; factors, which may negatively affect redox
status, and the availability, transport and stabilisation of carotenoids in the retina.
Further study in a diabetic population is warranted to fully elucidate these
relationships.
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6.2 Introduction
The macula is an oval shaped area at the centre of the retina which consists of a dense
collection of light-sensitive cone cells responsible for central, high-resolution vision
and colour perception.376 At the centre of the macula lies the fovea, where MP is
located. Macular pigment is comprised of three carotenoids; lutein, zeaxanthin and the
retinal metabolite of lutein, meso-zeaxanthin.46,226 Lutein and zeaxanthin are not
synthesised de novo in humans but are exclusively of dietary origin, typically derived
from a diet rich in coloured fruit and vegetables,22 while meso-zeaxanthin can be
generated by conversion from retinal lutein,
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or may be obtained from dietary

sources such as trout and salmon.220 The highest concentration of MP is found in the
receptor axon layer of the foveola, while in the parafovea, MP is located in the inner
plexiform layers,44,43 an area of the retina which is primed for the generation of ROS
and consequently, oxidative damage.291 These hydroxyl-carotenoids are selectively
located in the macula to the exclusion of all other dietary carotenoids. Figure 6.1
highlights the location of MP and the macula within the eye.

Figure 6.1: Diagram highlighting the location of MP and the macula within the eye.
139

Macular pigment has a number of important functions in the eye. Evidence suggests
that MP contributes to visual performance and/or experience, as it acts as an optical
filter for blue light (peak absorption ≈ 460 nanometres).226, 2 The importance of MP’s
antioxidant and anti-inflammatory properties is supported by its capacity to protect
against the cumulative damaging effects of oxidative stress,291 and inflammation,283
which affect the macula in conditions such as AMD.5,

218, 259, 377

In light of this

evidence, the relatively recent emphasis on MP as a possible ocular-protectant in
diabetes,6 a pathological condition similarly associated with inflammation, oxidative
stress and progressive retinal damage; is logical and represents a natural extension of
previous work in AMD.5, 218, 259, 377

The underlying molecular mechanisms associated with the onset of diabetes and the
potential protective effects of lutein and/or zeaxanthin against retinal oxidative
damage, inflammation and visual function have been explored in diabetic murine
models.14, 20, 186, 215, 378-380 The onset of diabetes in alloxan and STZ diabetic mice and
rats was accompanied by an increase in markers of oxidative stress and inflammation
including: malondialdehyde (MDA), 8-hydroxyguanosine (8-OHdG), NF-𝜅B and
VEGF, with a concomitant decrease in local antioxidants including GSH, and GPx.14,
186, 215

Importantly, treatment with antioxidants (lutein and/or zeaxanthin) have been

shown to lower oxidative stress and inflammation and increase endogenous
antioxidants; findings which in some186,

215

but not all

20

studies occurred

independently of any effects on hyperglycaemia. The beneficial effects of these
carotenoids on retinal function have also been observed in diabetic murine models,
and these include the preservation of ERG b-wave amplitude and prevention of
neurodegenerative effects on the inner retinal layers.14, 186, 215 Findings from these
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studies provide important insights into the potential role that MP may have in
protecting against diabetic retinal disease, however, the observed findings need to be
interpreted with caution, as higher MP dosages have been used in animal studies
compared with those used clinically in humans, and many of these studies have never
conclusively demonstrated retinal uptake of the administered carotenoids beyond the
RPE and choroid.381, 382 A summary of the experimental animal studies examining
MPOD in diabetes is outlined in Table 6.1.

A number of cross-sectional studies,6, 7, 9, 383, 384 including findings from our own study
group,7 and RCTs,15, 21 have explored the relationship between Type 1 and Type 2
diabetes and MPOD in humans. The MPOD is generally found to be lower in diabetes
6, 7, 9

9

with some studies suggesting that oxidative stress is implicated in its depletion.6,

Lower levels of MPOD have also been associated with raised HbA1c levels and the

presence of retinopathy in patients with Type 2 diabetes.6 In another study, patients
with diabetes (Type 1 & 2) with grade 2 diabetic maculopathy, had significantly lower
MPOD compared to those with no maculopathy (p=0.016).9

Although oxidative stress is implicated as a causative factor, the exact reasons why
MP is lower in diabetes, and Type 2 diabetes in particular 6, 7 are not fully understood.
One study found lower levels of MP in Type 2 versus Type 1 diabetes,7 suggesting
that other coincident metabolic and pathological abnormalities which are
characteristic of Type 2 diabetes (e.g. overweight/obesity, dyslipidaemia), may
explain the lower MPOD levels observed. Furthermore, lutein and zeaxanthin
supplementation has been shown to exert positive and beneficial ocular effects in those
with diabetic eye disease, including structural improvements in measures of macular
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oedema and functional improvements in VA and other visual function measures.15, 21
Table 6.2 outlines a summary of the cross-sectional studies and RCTs examining the
relationship between MPOD and diabetes (Type 1 & 2).

Although the evidence exploring MP and diabetes is relatively sparse, the findings
which have been reported are sufficient to suggest that MPOD may be adversely
affected by the condition, and that there is a plausible rationale to explore the possible
benefits of lutein and/or zeaxanthin supplementation for ocular health and visual
function in diabetes, particularly Type 2. The recent generation of such evidence has
prompted this literature review, which is designed to explore and elucidate the
metabolic perturbations and candidate causal mechanisms which may underpin the
likely complex interdependency of MP and diabetic eye disease.
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Table 6.1: Summary of experimental animal studies examining the relationship between lutein and/or zeaxanthin and diabetes.
Author & Year

Design: Animal Model

Lutein and/or Zeaxanthin

Outcome, Evidence & Conclusion

Muriach et al

Albino mice (alloxan

Lutein (70% purity, 0.2 mg/kg

Decrease in oxidative stress (decrease MDA and NF-κB,

(2006).215

induced diabetes mellitus).

body weight).

increase GSH and GPx); ERG b-wave restored.

Kowluru et al

Rats (STZ induced

Zeaxanthin (0.02% or 0.1%

Decrease in oxidative stress (decrease 8-OHdG, nitrotyrosine,

(2008).14

diabetes mellitus).

equivalent to 8.4 mg/kg). Placebo

iNOS, VEGF & ICAM-1 levels).

controlled.
Arnal et al

Rats (STZ induced

Lutein (in combination with DHA).

Decrease in oxidative stress (MDA and nitrotyrosine, increase

(2009).380

diabetes mellitus).

Placebo controlled.

GSH & GPx). Restored ERG b-wave amplitude & latency time.

Sasaki et al

Mice (STZ induced

Lutein (0.1 mg wt/wt). Placebo

Decrease in ROS & ERK activation and apoptosis. Protection

(2010).186

diabetes mellitus).

controlled.

of inner retina from visual impairment.

Tang et al

Mice (db/db) spontaneous

1% (kcal) Wolfberry (lutein &

Lower expression of endoplasmic reticulum stress biomarkers,

(2011).378

diabetes.

zeaxanthin). Placebo controlled.

(BiP, PERK, ATF6, caspase-12) and restored AMPK,
thioredoxin, Mn-SOD, and FOXO3α activities.

Yu et al

Mice (db/db) spontaneous

Wolfberry diet (lutein and

Activation of AMPK in mitochondria which caused

(2013).379

diabetes.

zeaxanthin). Placebo controlled.

retinoprotection in the retina of db/db mice.

Kowluru et al

Rats (STZ induced

Multi-nutritional supplement,

Carotenoids ameliorated capillary cell apoptosis. Improved

(2014).20

diabetes mellitus).

lutein=20 mg; zeaxanthin=40

ERG, a- and b- wave amplitudes. Decrease oxidative damage &

mg/kg of powder diet, in addition

increased antioxidant activity. Inflammatory markers (decrease
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to numerous antioxidants. Placebo

in VEGF, IL-1β & NF-kB).

controlled.
Zhou et al

Rats (High fat diet and low Zeaxanthin (50 mg/kg; 200 mg

Supplementation with zeaxanthin reduced blood glucose,

(2017).385

dose STZ induced diabetes

dissolved in 10 ml corn oil).

improved cognitive deficits, neural cell survival and increased

mellitus).

Placebo controlled.

p-AKT levels. Inhibited cleaved caspase-3 levels and NF-κB
nuclear transcription in the hippocampus.

Abbreviations: mg, milligram; MDA, malondialdehyde; NF-κB, nuclear factor κ B; GSH, glutathione; GPx, glutathione peroxidase; ERG, electroretinogram; STZ- streptozotocin;
8-OHdG, 8-hydroxy-21 – deoxyguanosin; iNOS, inducible nitric oxide synthase; VEGF, vascular endothelial growth factor; ICAM -1, intercellular adhesion molecule; DHA,
docosahexaenoic acid; ROS, reactive oxygen species; ERK, extra cellular receptor kinase; kcal, kilocalorie; BiP, binding immunoglobulin protein; PERK, protein kinase RNAlike ER kinase; ATF6, activating transcription factor 6; AMPK, AMP-activated protein kinase; Mn SOD manganese superoxide dismutase; FOXO3α, forkhead O transcription
factor 3 α; IL-1 β, interleukin 1 beta; p-AKT; phosphorylated serine/threonine kinase.

144

Table 6.2: Summary of cross-sectional studies and RCTs examining the relationship between MPOD and diabetes.
Author & Year

Design

Outcome, Evidence & Conclusion

Davies &

Cross-sectional study to assess MPOD in diabetes (N = 26)

Those with maculopathy had lower levels of MP than those without

Morland (2002).9

vs healthy, non-diabetic controls (N = 30).

maculopathy (p = 0.016).

Zagers et al

Cross-sectional study to assess MPOD in diabetes (N=15)

The density of MP in diabetic participants was not different from that in

(2005).383

vs healthy non-diabetic subjects (N=14).

controls (p = 0.3).

Mares et al

Cross-sectional study on sub-sample of women who

Lower MPOD was associated with diabetes. Relationship of dietary

(2006).384

participated in CAREDS (n = 1698). MPOD measured by

intake of lutein and zeaxanthin to MP differed between diabetic and

HFP.

non-diabetic women.

Lima et al,

Cross-sectional study including: non-diabetic controls

Type 2 diabetic patients, with or without retinopathy, had reduced

(2010).6

(N=14), diabetic patients with (N=12) and without

MPOD vs. non-diabetic subjects. MPOD was inversely correlated with

retinopathy (N=17).

HbA1c levels.

Scanlon et al,

Cross-sectional study assessing MP in Type 1 (N=34) & 2

MPOD levels were lower in diabetic participants vs controls (p =0.04).

(2015).7

(N=68) diabetic participants and healthy controls (N=48).

MPOD was lower in Type 2 vs Type 1 (p = 0.02) and Type 2 vs
controls (p = 0.03).

She et al,

Cross-sectional study assessing MP in diabetic patients

MPOD levels were not significantly different between the three groups

(2016).386

without retinopathy (N=134), with early stage non-

(i.e. diabetic participants with or without retinopathy and controls (p =

proliferative diabetic retinopathy (N=48) and non-diabetic

0.24). MPOD was positively associated with central foveal thickness

controls (N=219).

(p=0.001).
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Moschos et al,

Retrospective study on Type 2 diabetic patients (N=60; 120 MPOD was not measured in this study. OCT showed an increase in the

(2017).387

eyes) without diabetic retinopathy. Patients received

central foveal thickness (p<0.001) and mf-ERG revealed increased

carotenoid supplements containing lutein (10 mg),

retinal response density within the central 13° surrounding the fovea

zeaxanthin (2 mg) and meso-zeaxanthin (10 mg) once a

(rings 1 to 3) (p<0.001) at 2 years after the onset of carotenoids

day for two years.

supplement intake.

Gonzalez-Herrero

Prospective controlled study assessing macular integrity

Significant improvements in macular sensitivity at 90 days (p=0.030) in

et al, (2018).388

and macular sensitivity by microperimetry in patients with

the supplemented group. Total antioxidant capacity levels increased and

non-proliferative diabetic retinopathy. Patients were

plasma IL-6 levels decreased significantly in the DHA + xanthophyll

assigned (1:1) to the DHA + xanthophyll supplementation

supplemented group but not in the control group. MPOD was not

group (N=12; 24 eyes) or the control group (N=12; 24

measured in this study.

eyes).
Cennamo et al,

Prospective controlled study assessing MPOD and

MPOD was significantly lower in patients with retinopathy compared

(2019).389

microvascular density on OCTA in a cohort of Type 1

with controls (p<0.001). OCTA vessel density were significantly lower

diabetes patients with retinopathy (N=59, total of 82 eyes).

in diabetes patients than in controls (p<0.001).

The control group (N= 40; total of 80 eyes examined).
Hu et al,

RCT: Controlled trial including non-proliferative diabetic

Plasma lutein/zeaxanthin concentrations in diabetic retinopathy patients

(2011).15

retinopathy patients (N=61) & non-diabetic controls

were lower than those in normal controls. Lutein/zeaxanthin intake can

(N=60).

improve VA, contrast sensitivity & macular oedema in diabetic
retinopathy patients.
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Chous et al,

RCT: Type 1 (N=27) and Type 2 (N=40) diabetes with no

Significant improvement in MPOD (p values: 0.008 to <0.0001); visual

(2015).21

diabetic retinopathy or mild to moderate non-proliferative

function on all measures (p values: 0.008 to <0.0001); plasma lipids (p

DiVFuSS

diabetic retinopathy versus placebo.

values ranging from 0.01 to 0.0004), hs-CRP (p=0.01) and diabetic

Intervention group received 2 daily doses of a xanthophyll,

peripheral neuropathy (Fisher’s exact test, p=0.0024). These effects

antioxidant and plant extract supplement.

were observed without an effect on glycaemic control.

Abbreviations: MPOD, macular pigment optical density; MP, macular pigment; CAREDS, carotenoids in age related eye disease study; HFP heterochromatic flicker photometry;
HbA1c, glycated haemoglobin; DR, diabetic retinopathy; OCT, optical coherence tomography; mfERG; multifocal electroretinography; DHA, docosahexaenoic acid; IL-6,
interleukin 6; OCTA, optical coherence tomography angiography; RCT, randomised control trial; VA, visual acuity; DiVFuSS, the diabetes visual function supplement study; hsCRP, high sensitivity – C reactive protein.
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6.3 Literature search methods
For the purpose of this review, partly because of the relative dearth of higher level
RCT evidence, we have appraised all forms of published research, even lower level
evidence sources, to ensure that the scientific and clinical implications of the available
evidence might be synthesised into useful treatise, which accurately reflects what is
known about this area, and what remains to be elucidated. All relevant published
articles from human and animal studies which reported on the relationship between
MP and diabetes (Type 1 & Type 2), were identified for the first stage of the review,
up until the year 2019. Secondly, the review focused on identifying publications which
investigated the relationship between the metabolic perturbations typically associated
with diabetes, and Type 2 diabetes in particular (e.g. adiposity/dyslipidaemia) and MP.
Pre-selected keywords including: ‘lutein’, ‘zeaxanthin’, ‘macular pigment’,
‘diabetes’, ‘diabetes AND MP’, ‘diabetes AND lutein/zeaxanthin’, ‘BMI’, ‘body fat
AND diabetes’, ‘adipose’, ‘high density lipoprotein AND diabetes, ‘triglycerides
AND diabetes’, ‘oxidative stress’, ‘inflammation’, ‘hypertension AND MP’, ‘insulin
resistance’, ‘hyperinsulinemia’, were entered into academic databases and search
engines including PubMed, Google Scholar, Mendeley, Scopus, Cochrane Library and
the ISRCTN registry to define our search of the literature relating to MP and diabetes
up until 2019. Although many supporting publications were retrieved, in total, only
eight animal studies (Table 6.1) and eleven human studies (Table 6.2) were included
to help clarify our current understanding of the links between diabetes and MP. A total
of thirteen papers on adiposity and MP (Table 6.3) and seven papers on MP and
dyslipidaemia (Table 6.4) were included to help analyse the relationship between
MPOD and the metabolic correlates of Type 2 diabetes (adiposity and dyslipidaemia).
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The overall findings suggest that MP is lower in diabetes, Type 2 diabetes in particular;
and that supplementation with macular carotenoids and/or other antioxidants may
confer protection against diabetic eye disease. To elucidate the causal mechanisms and
metabolic perturbations which might possibly explain the lower MP levels observed
in diabetes, we will first explore the condition diabetes mellitus itself, including its
association with oxidative stress and inflammation; and subsequently present the
evidence linking adiposity and dyslipidaemia with Type 2 (or poorly controlled Type
1) diabetes and MPOD.
6.4 Diabetes mellitus
Diabetes mellitus is a group of metabolic disorders caused by the complex interaction
of genetics, environmental factors and lifestyle choices.390 Diabetes is characterised
by a deficiency of insulin and/or systemic insulin resistance. Over the past number of
decades, the number of people with diabetes, particularly Type 2 diabetes, has
increased dramatically, making it a critical and universal public health challenge.391
Type 1 diabetes usually develops in normal-weight children, teenagers and younger
adults, and is an autoimmune condition involving the selective destruction of
pancreatic β cells, ultimately resulting in complete deficiency of insulin.392
Conversely, Type 2 diabetes is linked to a sedentary lifestyle and being overweight,
and is characterised by systemic insulin resistance and subsequent pancreatic
endocrine dysfunction, which results in attenuated insulin synthesis as well as
inhibition of its cellular effects.390 Whilst diabetes is characterised by having higher
than normal blood glucose levels, the pathogenesis and development of Type 1 and
Type 2 diabetes differ; therefore, the relationship between MPOD and the different
forms of diabetes should not be generalised. At presentation, Type 2 diabetes is most
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often accompanied by other co-morbidities including overweight/obesity, insulin
resistance, hypertension and dyslipidaemia, features which are less common in Type
1 diabetes at diagnosis, but which may occur as complications of Type 1 diabetes later
in the course of the disease. Oxidative stress and inflammation are implicated in both
Type 1 and Type 2 diabetes; however, research has shown that these metabolic
disturbances are very pronounced in Type 2 diabetes.393-397 The oxidative stress,
inflammation, adiposity and dyslipidaemia which characterise diabetes, may have
independent relationships with MPOD, and therefore constitute plausible causal
mechanisms in diabetic eye disease. These pathological mechanisms merit further
exploration and will be discussed in more detail herein.
6.4.1 Oxidative stress and diabetes
Chronic hyperglycaemia induces oxidative stress in patients with diabetes.398
Oxidative stress, defined as the excessive production of ROS, results in oxidative
injury when the redox balance is upset; i.e. where the level of oxidative species
exceeds the capacity of the anti-oxidant defence system to neutralise them.355,

399

Reactive oxygen species can include free radicals, which are partially reduced oxygen
species containing one or more unpaired electrons (for example, superoxide anion or
hydroxyl radical); and species with their full complement of electrons in an unstable
or reactive state (for example, singlet oxygen or hydrogen peroxide).400 The body’s
natural defence against oxidative damage is neutralisation by endogenous
antioxidants,401 which include enzymatic antioxidants such as SOD, CAT and GPx,
and non-enzymatic antioxidants such as GSH. Our endogenous antioxidant defence
system, however, is incomplete without exogenous antioxidant nutrients including
vitamin C, vitamin E, carotenoids (beta carotene, lutein, zeaxanthin & meso150

zeaxanthin) and polyphenols.177 Exogenous antioxidants, such as those available in
dietary fruit and vegetables, are therefore necessary to balance redox status. Through
normal physiological processes, antioxidants inhibit or quench free radical reactions
and can delay or inhibit cellular damage.399 When these processes are overwhelmed,
however, as in Type 2 diabetes, ROS will readily react with lipids, proteins and nucleic
acids, resulting in impaired cell function or cell death.402-404

The retina is already at an increased risk of oxidative stress and damage, given its high
oxygen demand and consumption, its exposure to visible light irradiation and its high
concentration of PUFAs in the photoreceptor outer segments.405 These risks increase
when the generation of free radicals and ROS is stimulated by environmental
factors,406, 407 short-wavelength light exposure,408 and other internal stresses including
inflammation,409 and hyperglycaemia.403, 404, 410 While PUFAs in the photoreceptor
outer segment are thought to protect against oxidative and inflammatory damage, they
can potentially act as a substrate for the propagation of free radicals as they provide a
readily available source of electrons.291, 406 With increasing age, systemic antioxidant
levels decline and ROS levels increase in most tissues, and this is associated with a
number of neurodegenerative diseases, including AMD and diabetes.291, 411,9

Hyperglycaemia, oxidative stress and changes in redox homeostasis are fundamental
events in the pathogenesis of diabetic retinopathy. Various mechanisms have been
suggested to contribute to the formation of reactive oxygen-free radicals.
Hyperglycaemia causes tissue damage through five major pathways, namely increased
flux of glucose and other sugars through the polyol pathway; increased intracellular
formation of AGEs; increased expression of the receptor for AGEs (RAGEs) and its
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activating ligands; activation of PKC isoforms; and activity of the hexosamine
pathway.412 Over activation of these pathways can lead to damage of cellular
organelles and enzymes, increased lipid peroxidation, and development of insulin
resistance.413,

414

Several lines of evidence indicate that all five mechanisms are

activated by a single upstream event: mitochondrial overproduction of ROS.415
Locally, the occurrence of these metabolic changes, results in defective angiogenesis
and the activation of a number of pro-inflammatory pathways which stimulate an
influx of leukocytes which can alter vascular permeability in the retina.378 The role of
hyperglycaemia in diabetic microvascular complications in the eye has been
established by large-scale prospective studies in Type 2 diabetes (UKPDS).416 Beyond
elevations in blood glucose, however, ROS formation is also increased by elevations
in FFAs (a common feature of Type 2 diabetes), through their direct effect on
mitochondria.417

While, oxidative stress is increased in diabetes, the activities of antioxidant defence
enzymes responsible for scavenging free radicals and maintaining redox homeostasis
(SOD, CAT, GPx) are concomitantly diminished in the retina of both Type 1 and Type
2 diabetes.355, 401, 418 The activity of non-enzymatic antioxidants is also depressed
during hyperglycaemia-induced oxidative stress.418 Redox balance is important, as its
disruption can cause antioxidants to become pro-oxidative, potentially precipitating
damage to the retina. It cannot be assumed, however, that a single reductive or
antioxidant treatment would be sufficient to reverse the underlying pathophysiological
mechanisms of diabetic retinopathy. Antioxidant protection in the retina is provided
mainly from vitamins C and E, carotenoids, GPx, SOD and CAT enzymes, and GSH
compound,419 and many of these antioxidants are aided by micronutrients (e.g. copper,
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zinc, selenium) which act as cofactors.420 The carotenoids lutein and zeaxanthin are
very effective quenchers of singlet molecular oxygen and lipid peroxy radicals,
however, in the process, these carotenoids are themselves oxidised to their
corresponding radical cations.250 These cations must be reduced to regenerate the
original carotenoid, thereby allowing their reuse as an antioxidant. Vitamin E (𝛼tocopherol) reduces oxidised carotenoids, which leaves tocopherol oxidised.420
However, oxidised tocopherol can be reduced and regenerated by vitamin C (ascorbic
acid) and GSH, which are themselves further reduced by copper and zinc.5, 421 Dietary
lutein, zeaxanthin and vitamins E and C, as well as endogenous antioxidant enzymes,
therefore, act in concert with one another to lower the levels of ROS (via ROS
detoxification) and to recycle oxidised lipid antioxidants (via re-reduction).

The presence of oxidation products of the macular carotenoids in human and primate
retinal tissue indicates that lutein, zeaxanthin and meso-zeaxanthin play an important
antioxidant role there.45 Zeaxanthin appears to be a more potent anti-oxidant than
lutein,270 with meso-zeaxanthin being even more efficacious, but only in conjunction
with its binding protein.271 Li et al.

272

, demonstrated that a 1:1:1 ratio mixture of

lutein, zeaxanthin and meso-zeaxanthin quenches more singlet oxygen than any of
these carotenoids individually at the same total concentration,272, 422 suggesting that
they are most effective when acting synergistically with one another. Diet is a major
lifestyle factor which can greatly influence the incidence and progression of Type 2
diabetes. Some dietary and lifestyle modifications associated with enhanced
antioxidant supply could therefore be an effective prophylactic means to prevent or
limit oxidative stress in diabetic eye disease. Type 2 diabetes is associated with a
sedentary lifestyle and being overweight, therefore, patients with Type 2 diabetes may
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not only be exposed to diets which are high in fat and low in antioxidants,423 and to
the increased oxidative stress imposed by their diabetes;6, 7, 9 but may also be subject
to greater chronic oxidative stress as a result of their obesity itself.424 The cooccurrence of these phenomena consequently demands an even greater supply of
exogenous antioxidants (vitamin C, E, carotenoids lutein, zeaxanthin & mesozeaxanthin) to balance redox status and to combat this state of chronic oxidative stress
to which the diabetic retina is exposed. While the control of blood glucose is critical
in patients with diabetes, neuroprotective strategies and novel antioxidant treatments
should also be considered to target the specific aetiologies and underlying
pathophysiological mechanisms of the condition, and to ultimately protect against the
vascular pathologies of diabetes. It is logical that natural antioxidants (lutein,
zeaxanthin and meso-zeaxanthin) may have beneficial implications for diabetic
retinopathy in this context. However, larger trials involving intensive assessment of
oxidative stress, antioxidant defence activities and their effects on one another in the
diabetic state are necessary before empirical supplementation of these carotenoids can
be recommended clinically.
6.4.2 Inflammation and diabetes
Diabetic retinopathy has traditionally been considered a disease of the retinal
microvasculature, associated with oxidative stress induced by hyperglycaemia. More
recently, however, inflammation has been cited as a deleterious factor in the
development of diabetic complications,10 and is now also implicated in the
pathogenesis of many ocular diseases including AMD, 425 and diabetic retinopathy.426
Numerous interplays exist between inflammation and oxidative stress and vice
versa.427 Hyperglycaemia increases the levels of pro-inflammatory proteins,10 and it is
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now believed that inflammatory processes underlie many of the functional changes in
retinal vasculature observed histologically in early diabetic retinopathy, such as
pericyte loss, microaneurysms, and occluded and degenerated capillaries.194

While inflammation is normally a protective response to tissue stress, hyperglycaemia
leads to a dysregulation of inflammation, which ultimately becomes chronic.
Oxidative stress triggers inflammatory responses, and inflammation also enhances the
production of ROS, which creates a self-perpetuating cascade towards oxidative tissue
damage.428 The increased expression of many inflammatory proteins in diabetic
retinopathy is regulated through the activation of pro-inflammatory transcription
factors including NF-κB.429 Activation of NF-κB leads to the synthesis of proinflammatory molecules such as IL-1, IL-6, TNF-alpha, c-Jun N-terminal kinase-1
(JNK-1), inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-β) and growth
factors such as VEGF.378, 429

In the retina, the microvascular endothelium forms an effective barrier to control the
movement of blood, fluid and proteins across the vessel wall. This barrier is formed
by tight junctions, which consist of over 40 different proteins and various
inflammatory mediators including VEGF, TNF𝛼, PKC, IL-1𝛽, and IL-6.194,

430

Dysfunction of these proteins is highly correlated with the pathogenesis of bloodretinal barrier breakdown and increased vascular permeability, which leads to diabetic
macular oedema, a major cause of vision loss in diabetic retinopathy.431 Inflammatory
processes can induce oxidative stress, and similarly, oxidative stress can induce
inflammation through the activation of multiple pathways. The coincident overactivation of inflammation and oxidative stress can therefore deplete cellular
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antioxidant capacity and reduce MP levels in the eye.4, 291

The expression of various pro-inflammatory cytokines, such as TNF-α, IL-1 and IL6, are also increased from visceral adipose tissue (more common in Type 2 diabetes),
and this has been linked to systemic inflammation and accompanying insulin
resistance.432 The inhibition of signalling downstream of the insulin receptor is a
primary mechanism through which inflammatory signalling leads to insulin
resistance.10 Several cross-sectional studies have shown that insulin resistance and
Type 2 diabetes are associated with higher levels of C-reactive protein (CRP), IL-6
and TNF-alpha, all markers of subclinical inflammation.433-435 Various longitudinal
studies have also shown that elevated levels of CRP and IL-6 are linked to the later
development of Type 2 diabetes.436, 437

Inhibition of different inflammatory mediators, including NF-kβ, IL-1β, VEGF and
cyclooxygenase-2 (Cox-2), has been shown to limit the degeneration of retinal
capillaries characteristic of early stage diabetic retinopathy.438 There is evidence to
suggest that lutein and zeaxanthin may prevent the development of diabetic
retinopathy by suppressing ROS induced by inflammation.377 Li et al. 283 investigated
the anti-inflammatory effects of lutein on Muller cells in a murine model. Treatment
with lutein led to lower production of the pro-inflammatory factors NF-kB, IL-1β and
Cox-2, suggesting an anti-inflammatory role for lutein in protection against retinal
ischemic/hypoxic injury.283 In another study, the protective effects of lutein and
zeaxanthin against photo-oxidative damage to RPE cells were investigated.
Supplementation with carotenoids modulated the inflammatory responses in these
cultured RPE cells in response to photo-oxidation.439
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The effects of zeaxanthin on diabetes induced retinal oxidative damage and
inflammation have also been investigated in diabetic rats.14 It was found that
zeaxanthin significantly inhibits diabetes-induced retinal oxidative damage and
elevations in VEGF and its adhesion molecule, abnormalities which are commonly
associated with the pathogenesis of diabetic retinopathy.14 Clinical findings have
highlighted the inverse association between lutein and IL-6 in coronary artery disease
patients.440 A recent novel RCT, the diabetes visual function supplement study
(DiVFuSS),21 explored the effects of a nutritional supplement (which included lutein
and zeaxanthin) on patients with Type 1 and Type 2 diabetes, and suggested that the
preparation used mitigated the damaging effects of systemic inflammation on ocular
function, and that these effects may have been mediated by enhancements in MPOD.
Chronic low grade inflammation and oxidative stress co-exist in diabetes, particularly
Type 2 diabetes but also poorly controlled Type 1 diabetes. Therefore, findings from
DiVFuSS, which achieved significant increases in MPOD (27% mean increase in
DiVFuSS group vs. 2% mean decrease in placebo group), as well as reductions in
plasma high-sensitivity (hs)-CRP (60% mean decrease in DiVFuSS group vs. 11%
mean decrease in placebo group), may be due in part to the inclusion of compounds
which in combination, specifically target both inflammation and oxidative stress, and
therefore, which block some of the oxidative and/or inflammatory pathways
responsible for the progression of diabetic retinopathy.21 The inclusion of many
compounds in this test formula and the fact that both types of diabetes patients (Type
1 & 2) were examined renders interpretation of the outcome more difficult, however,
these findings are promising as they clearly show that MPOD can be augmented in
patients with Type 2 diabetes.21
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While it is clear that oxidative stress and inflammation are implicated in the initiation
and development of diabetic retinopathy, it remains unclear whether the pathological
effects of oxidative stress/inflammation are mediated through MPOD depletion in
Type 2 diabetes. The current body of evidence which directly links lower MP levels
with other metabolic correlates of diabetes, namely adiposity and dyslipidaemia; will
now be explored to elucidate the possible mechanisms by which these metabolic
factors mediate their effects on MPOD. It is important to note that both increased
adiposity and dyslipidaemia (primarily reduced HDL) may adversely affect MP by
compromising the availability,16, 17, 54, 441 and transport,18, 19 of dietary carotenoids to
the retina. It follows that a condition such as Type 2 diabetes, which unfavourably
affects these parameters, may have deleterious effects on MPOD, with clinically
relevant outcome effects. An analysis of the literature is presented describing these
putative mechanisms: (a) evidence in relation to MPOD and body fat/adiposity (n =13,
Table 6.3); and (b) evidence concerning MPOD and dyslipidaemia (n =7, Table 6.4).
6.4.3 Type 2 diabetes, MPOD & adiposity – the evidence.
Diabetes mellitus is a chronic disorder which can alter carbohydrate, protein, and fat
metabolism. Weight gain, following excessive calorie intake, results in the body
becoming markedly resistant to the action of insulin. Despite initial impairment in
insulin action, glucose tolerance can remain normal for some time because there is a
compensatory increase in insulin secretion by pancreatic β-cells, which results in a
well-compensated metabolic state, a condition known as hyperinsulinemia. There is
now mounting evidence to indicate that persistently elevated plasma insulin levels can
contribute to the development of hypertension, plasma lipid abnormalities and
atherosclerosis.442 The escalating rates of insulin secretion as a result of advancing
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obesity, however, cannot be maintained and Type 2 diabetes ensues.

Intra-abdominal fat appears to be an important determinant of insulin sensitivity
compared with subcutaneous fat.443 Visceral and subcutaneous fat differ in their
phenotypic, physiological and functional aspects, as there are a greater number of
macrophages, T lymphocytes and pro-inflammatory molecules in visceral versus
subcutaneous fat in obese individuals. Abdominal adipose tissue produces a variety of
adipocytokines including IL-1, IL-6, IL-8, TNF-alpha, leptin and resistin, therefore,
the abdominal adipose mass acts as an important mediator of inflammation in
diabetes.444 Obesity also leads to an increased size of adipocytes. The death of
adipocytes, which is rare in healthy people, is very common in obese individuals and
has been linked to adipocyte hypoxia. The accumulation of macrophages in the
adipose tissue of obese individuals, not only eliminates the dead cells but also further
increases their synthesis of inflammatory mediators IL-8, IL-6, IL-1, TNF-alpha.444
The resultant inflammation becomes chronic, therefore, obesity is considered a lowgrade inflammatory condition which in turn leads to an increase in oxidative stress.
Plasma 8-hydroxy-21–deoxyguanosin (8-OHdG), a known sensitive marker of
oxidative DNA damage and of total systemic oxidative stress in vivo, has been shown
to be positively correlated with BMI in people with Type 2 diabetes mellitus.370 Overexpression of oxidative stress and the concomitant reduction in antioxidant defence,
damages cellular structures,367 often resulting in further inflammatory responses.
Antioxidant defences may be lower in overweight/Type 2 diabetes patients, due to
their lower intake of antioxidant rich foods (e.g. fruits and vegetables), their increased
utilisation of these molecules (e.g. increased inflammation/ROS in insulin dependent
tissue such as the retina) and their impaired generation of other supportive anti159

oxidants,367 factors which may collectively lead to MPOD depletion.

The diminished response to insulin in Type 2 diabetes also leads to increased lipolysis
in adipocytes. Enlarged adipocytes release FFAs and adipocytokines,418, 442 therefore,
greater amounts of FFAs reach the liver via the portal vein, resulting in fatty liver
infiltration. Mobilised FFAs are oxidised by vascular endothelium to generate ROS.
Elevations of FFAs in plasma also inhibit insulin suppression of hepatic glucose
production, leading to an increase in glucose production by the liver.445 This in turn,
results in both insulin resistance and inflammation in the major insulin target tissues
(skeletal muscle, liver and endothelial cells). Abnormal levels of lipids, fatty acids,
and various adipocytokines from adipose tissue therefore initiate a vicious cycle of fat
damage, inflammation, worsening insulin resistance, impaired β-cell insulin secretion
and ultimately Type 2 diabetes.442, 446 The chronic low grade inflammation, associated
with obesity and Type 2 diabetes leads to increased oxidative stress and further
inflammation, putting a greater demand on antioxidant defences.

Apart from its pro-inflammatory and pro-oxidant effects, adipose tissue is also a major
body store for carotenoids such as lutein and zeaxanthin. Higher levels of body fat
have been shown to be related to lower levels of circulating carotenoids,347 making
these pigments less available to retinal tissue.68 Furthermore, a randomised controlled
weight loss trial found that a significant weight loss in the intervention group was
related to increases in plasma lutein.447 Higher BMI 448 and higher body fat percentage
16

have both been linked with an increased risk of AMD. Studies have reported an

inverse relationship between adiposity and BMI and MPOD,52, 54 with the observed
relationships largely attributable to participants with a BMI > 29 kg/m2.54 One study
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found that higher body fat percentage, even within relatively healthy limits, was
associated with lower retinal tissue lutein and zeaxanthin status,53 suggesting that
adiposity may affect the nutrient status of the retina. Gender differences in MPOD
have also been reported,16, 17 which may imply differences in metabolism of MP, or
reflect differences in adipose tissue storage of these dietary carotenoids between men
and women. Competitive absorption by a larger overall fat mass (percentage fat mass
is generally higher in women),449 or specifically by greater abdominal fat mass (which
is more common in men),450 may reduce lutein and zeaxanthin uptake by the retina.
Concentrations of carotenoids differ according to body site, with levels demonstrably
higher in abdominal fat,67 which may explain the differences in MPOD currently
observed between men and women.16, 17 Since adipose tissue may trap lutein and
zeaxanthin

53

individuals who are overweight or obese (Type 2 diabetes) may

consequently have lower concentrations of carotenoids lutein and zeaxanthin available
at the macula.

Overall the research appears to suggest that obesity has a negative impact on MPOD,
however, there is also some evidence to the contrary. One study found that mean
MPOD values did not differ significantly between subjects with various types of
obesity and ideal weight subjects.364 Our previous study 7 is the only one to date which
has examined the relationship between BMI and MPOD in a group with diabetes. This
study found that MPOD was significantly lower and BMI was significantly higher in
patients with Type 2 diabetes, compared to Type 1 and non-diabetic controls,
highlighting the possibility that different relationships exist between MPOD status and
Type 1 and 2 diabetes. The higher BMI levels observed in Type 2 diabetes are
reflective of excess adiposity which acts as a store for lutein and zeaxanthin. However,
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as described previously, obesity is also independently associated with increased
oxidative stress,69, 367, 368 and with inflammation 372 which exacerbates oxidative stress,
and may therefore have multiple depletive effects on MP. Unfortunately the crosssectional nature of this study 7 means that it cannot elucidate the extent or nature of
any causal relationships between BMI and MPOD in these Type 2 subjects.

The different presenting features of Type 1 and 2 diabetes and the interplay of their
disease components with MPOD status (e.g. adiposity), may mean that the mechanistic
relationship between these conditions and MPOD status, is not uniform across both.
The fact that much of the research to date includes both diabetic groups may obfuscate
any relationships present. Although, the evidence to date is somewhat conflicting,
there appears to be a theoretical basis for a relationship between the characteristic body
fatness of Type 2 diabetes and lower levels of MPOD. A summary of the studies
investigating the association between MPOD and adiposity are outlined in Table 6.3.
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Table 6.3: Summary of studies linking MPOD and body fat.
Author &

Design

Sample

Results

Johnson et al

Study 1: 15 week modified diet to increase

1. N = 7 (4 women & 3

1. Only plasma zeaxanthin increased from baseline and

(2000).17

lutein & zeaxanthin intake with plasma, buccal

men).

only at week 4. Adipose tissue lutein peaked at week 8.

mucosal cell and adipose samples taken at 0, 4,

2. N = 21 (13 women & 8

2. Significant negative correlations found between

8 & 15 weeks and 2 months post-intervention.

men).

adipose tissue, lutein concentrations and MP for women.

Year

Study 2: A cross-sectional analysis of

A positive effect was seen in men.

relationships.
Broekmans et Cross-sectional design looking at plasma and

376 healthy adults.

Regression models showed a positive significant

al (2002).63

Plasma (N=376)

association between MP density and plasma lutein,

Adipose (N=187)

plasma zeaxanthin, and adipose lutein concentrations in

adipose tissue concentrations in relation to MP.

men after adjustment for age, but no relation in women.
This effect remained in men after further correction.
Hammond et

Cross-sectional study investigating MPOD,

680 healthy adults.

Inverse association between MPOD and BMI (p <

al (2002).54

BMI, body fat percentage, dietary intake and

Body fat (N=400)

0.0008) and body fat (p < 0.01).

plasma carotenoid concentrations.

Dietary (N = 280)
Plasma (N = 280)

Nolan et al

Cross-sectional study investigating MPOD,

100 healthy adults.
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Significant inverse relationship between MPOD and body

(2004).16

body fat percentage, dietary carotenoid intake

Males (N= 45)

fat percentage in males (p<0.05) but not in females

and plasma levels.

Females (N=55)

(p=0.14).

Mares et al

Cross-sectional study investigating MPOD,

Subsample of women who

MPOD is directly related to dietary intake and plasma

(2006).384

dietary intake of lutein & zeaxanthin and other

participated in CAREDS.

levels of lutein & zeaxanthin. Higher abdominal fat is

predictors of MP levels.

N=1698 women aged 53-

related to lower MPOD.

86 years.
Moeller et al

Intervention in a sub-sample of the Women’s

394 healthy adults.

Lower MPOD was associated with above median WC.

(2009).451

Health Initiative to increase lutein and

Intervention (N = 1581)

This explained 2.7% of the variation.

zeaxanthin through dietary modification.

Control/usual diet (N =
236).

Kirby et al

Randomised controlled weight loss trial.

(2011). 447

104 subjects with BMI

Significant weight loss in the intervention group

>28 kg/m2; Intervention

(p<0·0001), was related to plasma increases in lutein.

group (N= 54); Control
group (N= 50).
Gupta et al

Clinical study; MPOD was compared to

161 healthy adults.

Mean MPOD values did not differ significantly in various

(2012).364

various anthropometric measurements

Males (N= 82)

types of obesity when compared with normal subjects.

including WHtR, WC, WHpR and BMI.

Females (N= 79).

Prospective cohort study.

Subset of TILDA

Nolan et al
(2012).52

Obese individuals had significantly lower MPOD (mean

participants with MPOD & = 0.190) than either overweight individuals (mean =
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BMI measures N = 4281

0.208; p < 0.01) or those with normal weight (mean =

adults aged over 50.

0.213; p < 0.01).

Bovier et al

Cross-sectional study investigating MPOD,

100 healthy adults.

Significant inverse relationship between body fat

(2013).53

assessment of body composition and plasma

Males (N=39)

percentage (total and regional) and MPOD (p<0.01).

lutein/zeaxanthin status.

Females (N=61).

Scanlon et al

Cross-sectional study to assess MPOD in Type

102 diabetic participants,

BMI was significantly higher and MPOD lower in Type 2

(2015).7

1 and Type 2 diabetic participants and BMI,

of which Type 1 (N=34) &

vs Type 1 diabetics and healthy controls. BMI was not

dietary intake and plasma carotenoid

Type 2 (N=68), and 48

directly correlated with MPOD.

concentrations.

healthy controls.

Khan et al

Cross-sectional study investigating MPOD,

114 adults with

MPOD was inversely related to body fat % (p=0.04) and

(2018).452

whole body adiposity (% Fat) and intellectual

overweight and obesity

positively associated with IQ (p=0.01) and fluid

ability.

(≥25 kg/m2).

intelligence (p=0.01).

Edwards et al

Cross-sectional study investigating MPOD,

101 adults with

MPOD was not significantly associated with body fat %

(2019).453

body fat % (DXA) and event related brain

overweight and obesity

in this study (p>0.07). MPOD was associated with mean

potentials.

(≥25 kg/m2).

and peak amplitude (N2) (p<0.04) and latency (P3)
(p<0.01) of neuroelectric indices.

Abbreviations: MPOD, macular pigment optical density; MP, macular pigment; BMI, body mass index; CAREDS, carotenoids in age-related eye disease study; kg/m2 , kilogram
per metre squared; WC, waist circumference; WHtR, waist-to-height ratio; WHpR, waist-to-hip ratio; TILDA, the Irish longitudinal study of aging; IQ, intelligence quotient; DXA,
dual-energy X-ray absorptiometry.
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6.4.4 Type 2 diabetes, MPOD and dyslipidaemia – the evidence
Insulin resistance and obesity, metabolic abnormalities commonly associated with
Type 2 diabetes, may themselves lead to disturbances in the production and clearance
of plasma lipoproteins.158 Dyslipidaemia is often characterised by low levels of HDL
and hypertriglyceridemia. In addition, LDL particles are converted to smaller, more
atherogenic lipoproteins.160 A number of factors are likely to be responsible for
diabetic dyslipidaemia and these include insulin’s effects on liver apoprotein
production, dysregulation of LPL, impaired action of CETP and the peripheral action
of insulin on adipose and muscle.158 Hormone sensitive lipase and LPL are two
enzymes which regulate mobilisation and deposition of fatty acids in adipose tissue in
a reciprocal manner.454 Reduced insulin action leads to increased lipolysis in
adipocytes with increased FFA release, which can mediate many adverse metabolic
effects, most notably further insulin resistance

446

and dyslipidaemia.158 In diabetes

greater amounts of fatty acids returning to the liver are reassembled into TGs and
secreted in VLDL.455 In the presence of increased concentrations of VLDL in
circulation, CETP will exchange VLDL TGs for cholesteryl ester in the core of HDL,
which results in smaller HDL particles, which are more rapidly cleared from
plasma.456 This explains the hypertriglyceridemia and reduced HDL commonly
observed in Type 2 diabetes.158 Cholesteryl ester transfer protein also exchanges
VLDL triglyceride for cholesteryl ester in the core of LDL and the net effect is a
decrease in the size and an increase in the density of LDL particles.158 In vitro, small
dense LDL can be oxidised more easily, and it binds to LDL receptors less avidly,
than normal LDL. As a result diabetic patients are at an increased risk of
cardiovascular disease. Many clinicians measure LDL density and/or size to predict
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risk of cardiovascular disease. An increase in waist circumference (WC) and waistheight ratio (WHpR) has been found to be associated with small dense LDL
particles.158,

457

Therefore, intra-abdominal fat is a critical determinant of an

atherogenic lipoprotein profile, including disruptions in the distribution of cholesterol
in the different lipoprotein fractions.443

The characteristic lipid profile in an individual with Type 2 diabetes (increased plasma
VLDL, increased TGs, decreased plasma HDL and less commonly, an increase in
LDL-cholesterol),158 may have important implications for MP levels in the eye, as
studies have shown that the carotenoids lutein and zeaxanthin are primarily
transported by HDL in plasma.18, 19 High density lipoprotein is a known ligand for SRB1, and this suggests a “piggy back” mechanism of lutein and zeaxanthin uptake into
the retina via RPE cells which is mediated by SR-B1.326 This hypothesis is supported
by evidence from lutein deficiencies observed in the retina of chickens with a genetic
HDL defect but not in other organs, implying a major role for HDL in the receptormediated transport of lutein to the eye.18 It has been argued that the subspecies of HDL
containing apolipoprotein E supplies lipids and lipid soluble lutein and zeaxanthin to
the retina, and that by increasing HDL, retinal lutein levels may be simultaneously
augmented.441

Omega-3 long chain-PUFA supplementation may also lead to increases in plasma
HDL.458 Recent epidemiological studies indicate that increased dietary long chainPUFA intakes enhance MPOD,459 and that DHA facilitates the accumulation of lutein
in the blood and macula. The mechanism by which DHA increases MPOD may relate
to its effect on the transport and uptake of lutein into the macula by mediating changes
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in lipoprotein levels.460 Putatively, this effect could also be mediated by the antiinflammatory effects of DHA, but this is conjectural and no direct evidence supports
this effect within the retina.

One observational study found that the correlation between MPOD, plasma lutein,
zeaxanthin and lipids differed depending on the age profile of participants. 461 In
younger adults, MPOD was found to be influenced by plasma lutein, whereas in older
adults, circulating lipids were an added determining factor.461 Mares et al.,384 queried
whether any association with plasma lipids is truly strong enough to play a meaningful
role in the pathogenesis of MPOD depletion. One study which used a diabetic cohort,
involving a small group of 43 participants (14 controls, 17 with diabetes but without
retinopathy and 12 with diabetes and with mild non-proliferative retinopathy), found
no significant correlation between MPOD and plasma lipid levels.6 Our own research
group, however,7 reported lower levels of MPOD in Type 2 versus Type 1 diabetes
and noted significantly lower HDL values within the Type 2 group, with raising the
possibility that lower HDL levels may have contributed to this difference. More
recently, the DiVFuSS study 21 has demonstrated significant improvements in plasma
LDL cholesterol level (9% mean decrease in the intervention group vs 1% mean
increase in placebo group); HDL cholesterol (7% mean increase in the intervention
group vs 3% decrease in placebo group); and TGs (8.6% mean decrease in the
intervention group vs 2% mean increase in placebo group), suggesting a positive effect
of the study formulation on plasma lipids. Whilst this effect was likely attributable to
other non-carotenoid components of the supplement, the synchronous increase in
MPOD observed in the intervention group may have been partially mediated by these
favourable changes in lipid profile and their consequential impact on carotenoid
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transport to the retina.18, 19, 71 In the broader context, the evidence from this study is
sufficiently robust to prompt further lines of investigation into the role of MP
supplementation either in isolation or as a multi-component supplement in diabetes.
The research to date, however, is not conclusive and it remains unclear from the
limited amount of observational and RCT data, whether plasma lipids (primarily HDL)
play a meaningful role in determining MPOD status. Given the theoretical basis for an
association between lipid profile and MP status, and the fact that lipid profile is often
altered deleteriously in diabetes, further investigation is warranted. The relationship
between dyslipidaemia and lower levels of MP is outlined in Table 6.4.
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Table 6.4: Summary of studies linking MPOD with plasma lipids.
Author & Year

Design

Sample

Results

Mares et al (2006).384

Cross-sectional study on women.

Sub sample of women who

Plasma lutein & zeaxanthin correlated with plasma

MPOD measured by HFP.

participated in the CAREDS

cholesterol (r = 0.17) but adjustment for this did not affect

(N = 1698).

the direct association between plasma levels and MPOD.

Cross-sectional study with 3 test

43 Type 2 diabetes participants

No significant associations were observed with lipid

groups: non-diabetic controls,

with and without retinopathy

levels and MP (p = 0.08).

diabetic participants without

matched to controls.

Lima et al (2010).6

retinopathy & diabetic
participants with retinopathy.
Loane et al (2010).71

Renzi et al (2012).462

Cross-sectional study on healthy

Total no of subjects: N=302.

A significant and positive association between plasma

men & women, without ocular

N= 181 with negative family

HDL and plasma concentrations of lutein. A significant

disease, aged between 20 -70

history of AMD;

inverse association between plasma TG concentration and

years.

N=121 with positive family

both plasma lutein concentration and MPOD in those

history of AMD.

with a positive family history of AMD.

Cross-sectional study on young

Relations between plasma

HDL were significantly (p < 0.05) related to MPOD (r =

healthy subjects. MPOD

lutein & zeaxanthin, MPOD

0.33), to plasma lutein (r = 0.36) and to plasma

measured by HFP.

and lipoprotein levels (N=108). zeaxanthin (r = 0.26). MPOD was also significantly
related to TC (r = 0.19).
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Olmedilla-Alonso et

Cross-sectional study assessing

Healthy men and women aged

MP only correlated with plasma lutein & zeaxanthin

al (2014).461

plasma concentrations and intake

(20-35 and 45 -65 years) (N =

when expressed in terms of cholesterol + TGs (p = 0.012)

of lutein and zeaxanthin and

108).

or LDL (p = 0.017). In the older group relationships were

MPOD using HFP.
Nagai et al (2015).463

also seen with LDL (p = 0.002) and HDL (p = 0.004).

Cross-sectional study assessing

55 healthy volunteers (110

MPOD was positively correlated with plasma

plasma concentrations of

eyes) aged 23-53 years.

concentrations of lutein (p=0.00001), zeaxanthin

carotenoids and lipoproteins.

(p=0.0005) and dietary lutein intake (p=0.002). Plasma

MPOD was measured using HFP.

oxidised LDL was inversely correlated with MPOD (p =
0.006), after adjusting for age, sex, and plasma lutein.

Chous et al (2015).21

DiVFuSS RCT: Type 1 and Type

Total group (N=67); Type 1

Significant improvement in MPOD (p values: 0.008 to

2 diabetes with no diabetic

(N=27); Type 2 (N=40).

<0.0001) and visual function on all measures (p values:

retinopathy or mild to moderate

Intervention DiVFuSS

0.008 to <0.0001); Mean LDL, HDL and TG levels

non-proliferative diabetic

supplement (N=39); Type 1

within the intervention group at 6 months were -9%,

retinopathy versus placebo.

(N=16); Type 2 (N=23).

+7%, -8.6% respectively versus +1%, -3%, -2%

Intervention group received 2

Placebo (N=28); Type 1

respectively in the placebo group.

daily doses of a xanthophyll,

(N=11); Type 2 (N=17).

antioxidant and plant extract
supplement.
Abbreviations: MPOD, macular pigment optical density; HFP, heterochromatic flicker photometry; CAREDS, carotenoids in age related eye disease study; MP, macular pigment;
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AMD, age-related macular degeneration; TG, triglyceride; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; DiVFuSS, the diabetic visual and
function supplementation study; RCT, randomised control trial.
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6.5 Causal mechanisms and metabolic perturbations associated with lower
macular pigment in diabetes
The candidate causal mechanisms explored herein as contributors to lower MPOD
levels in diabetes relate primarily to Type 2 diabetes (or poorly controlled Type 1).
The complex inter-relationship between oxidative stress/inflammation and the
metabolic correlates of diabetes (adiposity, dyslipidaemia, insulin resistance,
hyperinsulinemia and hyperglycaemia); and their associations with MPOD, both
individually and as a whole, represent a significant scientific challenge. In summary,
our analysis indicates that MPOD might be depleted through at least four causal
mechanisms previously described, all of which are outlined in Figure 6.2.
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Figure 6.2: Metabolic perturbations and supply deficiencies contributing to MP
depletion in diabetes.
Abbreviations: MPOD, macular pigment optical density; ROS, reactive oxygen
species.
6.5.1 Dietary determinants of MPOD in diabetes
First and foremost, patients with Type 2 diabetes may experience lower levels of MP
as a result of poor dietary intake of antioxidant nutrients (lutein, zeaxanthin and mesozeaxanthin). Lutein and zeaxanthin are not synthesised de novo in humans, therefore,
a diet rich in fruit and vegetables is necessary to enhance MP levels in the eye.22 While
the exact cause of diabetes is still not fully understood, dietary factors have garnered
particular attention over the last number of years. In fact, some research indicates that
up to 74% of Type 2 diabetes cases are directly attributable to obesity.464

Many studies have reported a positive association between a high intake of sugars and
the development of Type 2 diabetes.465-467 Research has also found an association
between high fat intakes and Type 2 diabetes and impaired glucose tolerance,468, 469
with some literature suggesting that high-fat, low-carbohydrate diets are associated
with the onset of Type 2 diabetes.468 A global change in dietary intake has occurred
over recent decades resulting from an increased use of sweeteners such as fructose and
sucrose by the food industry.470 Recent evidence suggests a causal link between the
high intake of sugar-sweetened soft drinks and obesity and diabetes. This is thought
to arise from the large amount of fructose in these soft drinks, which impairs insulin
sensitivity and raises blood glucose levels and BMI to dangerous levels.466, 471 Fructose
consumption increases postprandial TG concentrations within hours,472 which
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suggests that postprandial hypertriglyceridaemia is one of the earliest metabolic
perturbations associated with fructose consumption. The most likely mechanism for
this hypertriglyceridaemia is increased hepatic de-novo lipogenesis, which in turn
upregulates VLDL production and secretion,473 factors which have a knock on
suppressive effect on HDL, a known transporter of carotenoids to the eye.18, 19

Studies have also found an inverse correlation between the intake of green leafy
vegetables and risk of developing Type 2 diabetes; 214, 474 and that the consumption of
fruits and vegetables may protect against the development of Type 2 diabetes, as they
are rich in micronutrients, fibre and antioxidants,474 dietary components also known
to enhance MPOD. A recent meta-analysis revealed that a higher intake of fruit,
especially berries and green leafy vegetables, yellow vegetables and cruciferous
vegetables or their fibre, is associated with a lower risk of Type 2 diabetes. 214 Health
benefits have also been observed with the Mediterranean diet,475, 476 a diet which
contains an abundance of fruit and vegetables. While, the beneficial effects of fruits
and vegetables on diabetes risk are likely to be multiple, these foods are the primary
dietary source of carotenoids including lutein and zeaxanthin, highlighting their
consumption as a key determinant of MPOD. Lower levels of MPOD in diabetes,
might also be associated with high intakes of fried foods and fat,477 alcohol,478 red and
processed meat,479 sugar-sweetened beverages,465,

466

and high glycaemic index

foods,480 all of which have been linked with higher levels of visceral fat and increased
WC. Numerous studies have shown that obesity (in particular, central obesity) can
increase the risk of Type 2 diabetes.481

While the body’s natural defence against oxidative damage and inflammation is
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neutralisation by endogenous antioxidants (enzymatic & non enzymatic), in
association with exogenous antioxidants (vitamin C, vitamin E, carotenoids, βcarotene, lutein, zeaxanthin and meso-zeaxanthin),177, 419 these antioxidant defences
may be compromised in diabetes. Hence, it is clear that both over utilisation and under
supply of antioxidant nutrients may contribute to lower levels of MP in the diabetic
retina.

Based on the outlined associations between nutritional and dietary factors and the
components of the metabolic syndrome which may contribute to MPOD depletion, we
outline dietary factors which: 1) may exacerbate the metabolic correlates associated
with Type 2 diabetes (Table 6.5 a) and 2) may help to prevent or resolve the metabolic
perturbations associated with Type 2 diabetes (Table 6.5 b).

Overall, western dietary habits are a significant factor in the development of the
metabolic syndrome. The continuous over-provision of energy via dietary
carbohydrate and lipid, when unmatched by physical activity-induced energy
expenditure, leads to a state of excess adiposity, chronic low grade inflammation, and
oxidative stress and dyslipidaemia; features associated with Type 2 diabetes and which
may lead to MPOD depletion.

The importance of diet cannot be overemphasised in diabetes management. Given the
variety of mechanisms which may contribute to MPOD depletion and the broader
ocular risks associated with such MPOD depletion in diabetes, a comprehensive
dietary approach is therefore necessary to optimise ocular health and MPOD status.
The generous provision of brightly coloured fruits and vegetables which are rich in a
177

broad range of antioxidants including the target carotenoids lutein, zeaxanthin and
meso-zeaxanthin represents an obvious recommendation. This, however, should be
complimented by the inclusion of wholegrain fortified breakfast cereals for their
folate, vitamin D and anti-obesogenic fibre content; and with plenty of oily fish to
provide further vitamin D and omega-3 essential fatty acids to attenuate inflammation
and correct or prevent hypertriglyceridaemia. These foods should be used to displace
those which are high in fat, saturated fat, refined sugar and fructose; for example oily
fish should replace red or processed meats at several main meals each week, fruit or
raw vegetables should be used to replace snack foods high in fat, saturated fat, transfat and refined sugar (e.g. baked goods and confectionery); and low fat fortified milk
should replace sugar-sweetened soft drinks. Starchy carbohydrates should be evenly
distributed over the day to achieve better glycaemic control, with sterol or stanol
enriched products used to reduce plasma LDL and consequently enhance LDL: HDL
ratio. Finally, from a broader lifestyle perspective, these individuals should be advised
to moderate their alcohol consumption to no more than two standard drinks per day
with several alcohol-free days each week, and to engage in moderate intensity exercise
(e.g. walking) on most days of the week to enhance their insulin sensitivity and
optimise their blood glucose and lipoprotein profiles. Table 6.5 a. outlines the dietary
factors causally associated with the metabolic correlates of Type 2 diabetes, and Table
6.5 b. outlines the dietary factors associated with protection against the metabolic
perturbations of Type 2 diabetes.
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Table 6.5: Dietary factors associated with the metabolic correlates of Type 2 diabetes.
Metabolic correlates

a. Causal dietary factors associated with the

of Type 2 diabetes.
Oxidative Stress

metabolic correlates of Type 2 diabetes.

b. Preventative dietary factors associated with the
metabolic correlates of Type 2 diabetes.

High protein (red meat),479 high fat (saturated fat).482,

Whole grains (fibre),485 nuts (fibre, omega-3 PUFA).486

483

Fruit and vegetables (antioxidants vitamin C & E, β carotene,

High carbohydrate (refined sugar, fructose).465, 466, 484

lycopene, quercetin, resveratrol, flavonoids, lutein, zeaxanthin &
meso-zeaxanthin). 5, 15, 21, 22, 214, 250, 259, 474, 476, 487, 488
Fish (omega-3 PUFA),489 legumes (protein, phytochemicals).490

Inflammation

High fat (saturated fat, trans fat).491-493

Oily fish and omega-3 FAs,489 folate,497 vitamin D.498

High carbohydrate (refined sugar, fructose).484, 494, 495

Fruit & Vegetables (antioxidants vitamin C & E, β carotene,

Alcohol.496

lycopene, quercetin, resveratrol, flavonoids, lutein, zeaxanthin &
meso-zeaxanthin).377, 487

Obesity

Excessive energy consumption.499

Diet & exercise,504 high dietary fibre.505

High fat (saturated).500-503

High fruit and vegetable (antioxidants vitamin C & E, β carotene,

High carbohydrate (refined sugar, fructose).465, 466

lycopene, quercetin, resveratrol, flavonoids, lutein, zeaxanthin &
meso-zeaxanthin),487 high milk intake.506
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Dyslipidaemia

High fat (saturated fat, trans fat),507-509 high

High dietary fibre,505 omega-3 FAs,514, 515

carbohydrate (refined sugar, fructose),510, 511

plant stanols/sterols,516 physical activity.458, 513

Sodium,510 alcohol (especially binges),512 low physical
activity.513

Abbreviations: PUFA, polyunsaturated fatty acid; FA, fatty acid.
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6.6 Limitations
It is important to note the significant limitations which currently prevail in the
reviewed literature. The heterogeneity of studies is a major drawback. Small sample
sizes, the merging of Type 1 and Type 2 diabetes patients in statistical analyses,
and the complex interplay of diabetes and its accessory factors (adiposity,
dyslipidaemia, oxidative stress and inflammation) with MPOD status are also
challenging. While there is some preliminary positive evidence, primarily from
animal studies

14, 20

and the DiVFuSS trial,21 that higher MP levels may be

protective against retinal damage, there is limited evidence that low MPOD levels
are detrimental to ocular health in diabetes, and the actual benefits of higher MPOD
in terms of retinal disease development and/or progression in diabetes remain to be
elucidated.
6.7 Conclusion
This review outlines our present understanding of the relationship between diabetes
and MPOD. Macular pigment appears to be generally lower in diabetic populations
compared to healthy controls,6 and this is noted particularly amongst patients with
Type 2 diabetes.7 Impaired defence against ROS at the retina may not only be
attributable to lower intake of foods rich in carotenoids and other antioxidants (e.g.
fruit, vegetables, legumes) however, but may also arise from the increased
utilisation of these antioxidants in diabetes (via chronic inflammation and oxidative
stress). Adiposity, particularly abdominal fatness, is closely linked to Type 2
diabetes, and is a significant factor in the condition’s pathogenesis. Excess fat tissue
may not only compete with the retina for uptake of dietary carotenoids, but may
also contribute to increased oxidative stress and inflammation, factors which may
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negatively impact MP levels in the eye. Similarly, the hyperglycaemia which is
characteristic of diabetes, also contributes to inflammation and oxidative stress, and
their depletive effects on MPOD. Dyslipidaemia, more common in poorly
controlled diabetes, is a metabolic correlate which may adversely affect the
transport and assimilation of carotenoids into retinal tissue, by limiting the
availability of their principal carrier HDL. The chronic low-grade inflammation and
increased oxidative stress observed in patients with Type 2 diabetes may also
increase the use of these carotenoids at the molecular level, and in so doing, may
elevate our dietary requirement for them.

In view of the limited evidence available, supplementation with lutein, zeaxanthin,
and/or meso-zeaxanthin, either with or without other antioxidants, represents a
fertile area for future interventional research. It is important to recognise, however,
that in order to minimise the risk of MPOD depletion and/or ocular damage in
diabetes, it is not sufficient to simply supplement with macular carotenoids. Rather,
our review suggests the need for a more holistic evaluation of diet and lifestyle in
relation to MPOD in diabetes. In this context, inflammation and oxidative stress,
the dual pathogenic driving forces of diabetes which occur independent of
hyperglycaemia, may be amenable to dietary intervention and nutritional
supplementation. The incorporation of a number of dietary modifications (e.g.
enhanced antioxidant, vitamin D and omega-3 fatty acid intake; and reduced fat,
saturated fat, trans- fat and refined sugar consumption); alongside lifestyle changes
such as increased physical activity; may not only address the under-supply of
macular carotenoids, but may also abrogate the competitive storage, transport,
inflammatory and oxidative features of Type 2 diabetes, which may compromise
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MPOD status. The safety and low cost of such interventions further commend their
potential value as a therapeutic adjunct in diabetic eye disease, and may come to
represent an essential element of ocular care for this important and expanding
patient group.
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7. IDENTIFICATION OF SURROGATE BIOMARKERS FOR THE
PREDICTION OF PATIENTS AT RISK OF LOW MACULAR
PIGMENT IN TYPE 2 DIABETES.
7.1 Abstract
Purpose
This cross-sectional study compared MP levels among persons with Type 2
diabetes relative to healthy controls. Additionally, a range of behavioural,
anthropometric, clinical and plasma measures were explored as possible predictors
of low MPOD in diabetes.
Methods
Two health status groups; Group 1: Type 2 diabetes (n=188), and Group 2: Healthy
controls (n=2,594) completed a full MP assessment using c-HFP, as part of TILDA.
Clinical [blood pressure; cataract status; MPOD] and anthropometric [waist (cm);
weight (kg); hip (cm)] measurements were taken, and a blood sample drawn for
analysis of plasma biomarkers [lipoproteins; inflammatory markers (CRP and
vitamin-D)].
Results
One-way analysis of variance revealed lower MPOD in subjects with Type 2
diabetes relative to controls (p=0.047). Amongst participants with diabetes, those
with low plasma vitamin D (≤50 nmol/L) had significantly lower mean MPOD
compared to those with sufficient plasma vitamin D levels (>50 nmol/L)
(0.173(0.148) vs. 0.226(0.145); p=0.006). Concomitantly, MP was significantly
lower in diabetes participants with raised plasma TG over HDL lipoprotein ratio
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(TG/HDL); values >1.74 mmol/L (0.172 (0.140) vs 0.215 (0.152); p=0.039).
Macular pigment was also significantly lower in diabetes participants with
hypertension (>140/90 mmHg); (0.177(0.130) vs 0.228(0.166); p=0.043). Body
mass index, WHtR, and WC were all significantly negatively correlated with
MPOD (Pearson’s correlation, p<0.05 for all). Significant correlates of MPOD in
the multivariate regression model included smoking, cataract, and vitamin D, which
collectively contributed 18.5% of the overall variability in MPOD status amongst
participants with Type 2 diabetes.
Conclusions
This study provides additional evidence that low MP may indeed be a feature of
Type 2 diabetes and further identifies smoking, cataract, and vitamin D status as
plausible predictors of low MPOD amongst persons with Type 2 diabetes.
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7.2 Introduction
The prevalence of diabetes has been increasing steadily over recent decades and is
now reaching epidemic proportions.517 Type 1 and Type 2 diabetes are the two main
forms of diabetes, however, Type 2 diabetes is much more common and is estimated
to affect more than 500 million people worldwide.518 Diabetic retinopathy, a
debilitating microvascular complication of diabetes, is the most common cause of
vision loss in people with diabetes and is a leading global cause of vision
impairment and blindness among working-age adults.26

The pathogenesis of diabetic retinopathy is multifactorial and remains poorly
understood. Chronic hyperglycaemia induces oxidative stress in the retina,355 and it
is thought that hyperglycaemia causes tissue damage through a number of major
pathways, including the polyol pathway, activation of PKC, upregulation of AGE
product formation and activity of the hexosamine pathway.412 Interaction of these
biochemical pathways may cause a cascade of events, such as apoptosis, oxidative
stress, inflammation, and angiogenesis, which can lead to damage of the diabetic
retina, as reviewed by Al-Kharashi.519 It is thought that hyperglycaemia leads to a
dysregulation of inflammation, which in turn leads to an increase in the level of
pro-inflammatory proteins.372

Inflammatory processes underlie many of the functional retinal vasculature
alterations observed histologically in early diabetic retinopathy.194 Animal and
human studies have confirmed that all retinal cell types, including inner retinal
neurons, Muller cells, and astrocytes, are damaged by diabetes.204 Recognising both
the clinical and histological aspects of retinal change in diabetic macular oedema
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and diabetic retinopathy is essential to understanding the mechanisms of vision loss
in diabetes, and in developing early-stage clinical interventions that effectively
target the specific aetiologies and underlying pathological mechanisms of the
condition. In fact, insulin resistance, impaired glucose tolerance, and Type 2
diabetes may exist for many years before clinical retinal signs become evident.520

The body’s natural defence against oxidative damage and inflammation is the
neutralisation of ROS with endogenous antioxidants, both enzymatic and nonenzymatic.401 These endogenous antioxidants work with exogenous antioxidants
(vitamin C, vitamin E, and carotenoids such as β-carotene, lutein, zeaxanthin, and
meso-zeaxanthin),177 together balancing redox status. The carotenoids, lutein,
zeaxanthin, and meso-zeaxanthin, collectively known in the eye as MP; confer
potent antioxidant and anti-inflammatory effects at the macula.5,283 These
carotenoids are uniquely concentrated in the inner and central layers of the primate
macula, and while there have been numerous studies looking at the role of
carotenoids and other nutrients in the prevention of AMD, reviewed elsewhere,226
the association between diabetes and MPOD levels, however, has received
somewhat less attention.

The evidence that does exist, however, suggests that the relationship is worth
exploring in more detail. Plasma concentrations of lutein and zeaxanthin have been
observed to be significantly lower in patients with diabetic retinopathy.15
Furthermore, MP has been found to be significantly lower in patients with diabetes,6
with one study reporting lower levels of MP in Type 2 versus Type 1 patients.7 It is
also possible that MP may confer therapeutic benefits in diabetic eye disease. A
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number of studies have explored the effect of MP supplementation in diabetes.
Although the evidence is far from definitive, improvements in structural and
functional measures of ocular health in response to macular carotenoid
supplementation have been found. The earliest of these studies reported
improvements in vision and macular oedema following supplementation. 15 The
DiVFuSS study suggested that a nutritional supplement containing lutein and
zeaxanthin mitigated the damaging effects of systemic inflammation on ocular
function and that these beneficial effects may have been mediated by enhancements
in MPOD.21 Improvements in visual function have also been observed in patients
with diabetes following supplementation, including in contrast sensitivity 521 and in
electrophysiological indices of retinal function.387

The reasons why MPOD levels might be adversely affected in diabetes are yet to
be elucidated, but a number of factors might be important. At presentation, Type 2
diabetes is most often accompanied by other co-morbidities including
overweight/obesity, insulin resistance, hypertension and dyslipidaemia,522 which
may adversely affect MP by compromising the availability,54 transport,18
assimilation,18 and maintenance/retention of dietary carotenoids in the retina. De
novo synthesis of carotenoids is not possible in humans, therefore, the chronic lowgrade inflammation,372 and pro-oxidative environment,355 associated with Type 2
diabetes may negatively impact MPOD levels in the eye.

Macular pigment levels can be measured in vivo, but are not routinely measured in
clinical practice. Given the possibility that higher levels of MP may be beneficial
for vision and ocular health in diabetes, the investigation of surrogate indicators of
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MP status that are more readily and routinely measured is merited. The capacity of
such an alternate biomarker to expedite the identification and treatment of patients
at risk of low MP could be particularly important given that retinal damage can
occur long before visual signs of diabetic retinopathy are evident. This study was
designed, therefore, to compare MPOD in participants with and without Type 2
diabetes and, more importantly, to explore a range of behavioural, anthropometric,
clinical and plasma biomarkers as possible predictors of risk for low MPOD among
individuals with Type 2 diabetes.
7.3 Methods
Study population
The Irish Longitudinal Study on Ageing is a large prospective cohort
study examining the social, economic and health factors which influence healthy
ageing in older adults resident in Ireland.523 Cross-sectional data from TILDA was
analysed in this study. A stratified clustered sample of 8,175 individuals,
representative of the population of Ireland, aged 50 years and over, participated in
Wave 1 of this study, which took place between October 2009 and July 2011. The
study design of TILDA has been described in detail elsewhere.523, 524 Health and
lifestyle data were captured in participants’ own homes using computerised aided
personal interview (CAPI).525, 526 The presence or absence of eye pathology was
determined using the CAPI with the question ‘’has a doctor ever told you if you had
any of the following conditions: diabetes, AMD, cataracts or glaucoma’’.
Participants were also asked whether they had ever been told by a doctor if they had
high cholesterol or high blood pressure. Participants were asked to record all
medications that they took on a regular basis, including those related to diabetes,
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such as oral hypoglycaemic agents and/or insulin, which were coded using the
Anatomic Therapeutic Classification (ATC) system. Participants were asked if they
currently smoked or had ever smoked cigarettes regularly (daily for at least a year),
and were categorised as never smoked, past smokers or current smokers. The
International Physical Activity Questionnaire was used to classify participants’
level of physical activity into low, moderate or high levels. All participants were
invited to attend a health assessment in one of two locations, Dublin or Cork.
Macular pigment measurement was only conducted on participants who attended a
health centre, therefore, a number of participants were automatically excluded from
the current analysis: i.e. if they were unable to travel to a health centre or opted for
a home assessment instead (n=875) and/or refrained from having either a home or
health assessment (n=2,025). A total of 5,275 individuals participated in a health
assessment, carried out by trained research nurses (Figure 7.1). This research
adhered to the tenets of the Declaration of Helsinki and was approved by the
Technological University Dublin Research Ethics Committee. All participants
provided written informed consent prior to participation in the study.
Diabetes classification
Diabetes type was classified into ‘no diabetes’, ‘pre-diabetes’, ‘diagnosed diabetes’
and ‘undiagnosed diabetes’. Diagnosed diabetes was identified from the CAPI with
the question ‘has a doctor ever told you that you have diabetes or high blood sugar?’
and also from prescribed diabetes medications at the time of the interview,
identified using the ATC codes ‘A10A’ for insulin and ‘A10B’ for oral
hypoglycaemic medications. A blood sample was provided for plasma analysis.
Glycated haemoglobin, a long-term indicator of glycaemic control, was measured
and participants were further classified as having ‘pre-diabetes,’ and ‘undiagnosed
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diabetes’ against American Diabetes Association cut-off values.24 The TILDA
protocol for blood sample collection, processing and storage has been described
previously.525 Eleven respondents who reported a doctor’s diagnosis of diabetes
before the age of 40 and who were on insulin therapy at the time of interview were
excluded from analysis due to the suspicion that they might have Type 1 diabetes,
in line with previously published data
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(Figure 7.1). Duration of disease was

quantified by asking those with a previous diagnosis ‘how old they were when first
diagnosed?’
Macular pigment optical density assessment
Corrected VA was measured in both eyes using the ETDRS LogMAR chart at a
distance of 4 metres, using the participant’s existing prescription where necessary.
The eye with the best VA was chosen for the MP assessment or if there was equal
vision in both eyes, the right eye was chosen. The MPOD was measured by HFP
centrally at 0.5° of retinal eccentricity using the Macular Metrics Densitometer
(Macular Metrics, Rehoboth, MA). This device was modified specifically for the
TILDA study from a device originally described by Wooten et al.334 The established
method employed for measuring MP has been described in detail previously.56 In
brief, the subject viewed a stimulus that alternated between a wavelength which is
absorbed by MP and one that is not. To account for the fact that participants may
have different temporal (i.e. flicker) rates, the HFP task was customised for each
subject, according to their age.335 If a fixed flicker frequency was used instead then
a subject with a low flicker sensitivity (i.e. low critical flicker fusion frequency)
would experience a large null flicker zone. While this does not prevent the test from
being completed, it could lead to an over or underestimation of MPOD. Conversely,
a subject with a high critical flicker fusion frequency may not be able to eliminate
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flicker and this would make the test more difficult to complete. A ‘bracketing’
protocol was adapted in the TILDA study to allow quick but accurate customised
MPOD measurements to be obtained, both centrally at 50 and peripherally at 70.56
The examiner pre-set the radiance dial, either at the lowest blue light intensity
(ascending measurement) or the highest blue light intensity (descending
measurement), and a total of 6 measurements were taken. In other words, the
examiner pushed a button that alternated the blue/green ratio until the subject
reported no flicker or that flicker had started. The radiance value obtained was
recorded for the 6 measurements in the MPOD log form (central measurement
where MP peaks). The examiner then selected the target and fixation point required
to measure MPOD at 7° retinal eccentricity (parafoveal target at 7°), where MP is
optically undetectable, and another 6 measurements were taken. All radiance values
obtained (12 in total) were used to calculate MPOD by taking the log ratio of MP
peripherally (7 0 ) from the log ratio of MP centrally (0.50 ) and in this way the
MPOD value at 0.5° was generated for that subject. Of the 5,275 participants who
attended a health assessment, 2,782 were deemed suitable for the current analysis
and successfully completed an MPOD assessment (participants with diabetes,
n=188; non-diabetic controls, n=2,594). A number of subjects were excluded from
the overall MPOD analysis (n=2,493) and possible reasons for this included: poor
fixation, technical issues, poor VA (VA 6/18 Snellen (≤ 0.5 LogMAR)) and retinal
pathology (AMD, glaucoma). Because Type 1 and 2 diabetes are considered
different clinical conditions, the presenting features of the condition (adiposity,
dyslipidaemia, oxidative stress, and inflammation) may not be uniform across both
and may have different relationships with MPOD, therefore, a number of
participants with suspect Type 1 diabetes (n=11), were excluded from the current
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study. Participants with pre-diabetes (HbA1c: 5.7 - 6.4%) were also excluded from
the current analysis (n=111). Of the 8,500 participants that took part in Wave 1 of
TILDA, 188 Type 2 diabetes participants and 2,594 controls were deemed suitable
for the study (Figure 7.1).

Figure 7.1: Flowchart illustrating the selection of study participants and reasons
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for exclusion from the original participant group.
Abbreviations: AMD, age-related macular degeneration; MPOD, macular pigment
optical density, n, number of participants; TILDA, The Irish Longitudinal Study on
Ageing; VA, Visual Acuity.
Anthropometric assessment
Height (cm) and weight (kg) were measured to one decimal place as described in
detail elsewhere.525 Body mass index was calculated from measured height and
weight as: weight (kg)/height (m2). Waist circumference and hip were measured to
the nearest cm. Waist-to-height ratio and WHpR were calculated based on these
measured data. Cut-offs were applied to classify participants as obese or non-obese
for the following variables (BMI; WC; WHtR, and WHpR).527
Blood pressure
Two blood pressure (BP) measurements were taken using the OMRONTM digital
automatic BP monitor (Model M10-IT) with arm cuff.525 Seated mean systolic
(mmHg) and mean diastolic (mmHg) BP were used for analysis. The participant
was defined as hypertensive if mean seated systolic BP exceeded 140 mmHg or
mean seated diastolic BP exceeded 90 mmHg.
Plasma analysis
Respondents were not asked to fast before the health assessment. Blood was
extracted using defined phlebotomy protocols,525 and analysed for a complete lipid
profile, which included TC, HDL, LDL, and TGs, measured in mmol/L.
Triglyceride over HDL ratio (TG/HDL), TC/HDL ratio and non-HDL cholesterol
(TC minus HDL) were calculated for subsequent analyses. Cut-offs were applied
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to indicate high or ideal plasma lipid levels as per 2016 European Society of
Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines.528 Research
suggests that inflammation plays a role in the development of Type 2 diabetes,10, 529
therefore, anti-inflammatory marker plasma vitamin D [(25(OH)D); nanomoles per
litre (nmol/L)] and inflammatory marker CRP, [micrograms per litre (μg/l)] were
also measured. Respondents were considered vitamin D deficient if plasma levels
were ≤50 nmol/L, and sufficient if plasma levels were >50 nmol/L as per the
Institute of Medicine (IOM) vitamin D guidelines.530 A threshold of >3.00 μg/l for
high and ≤ 3.00 μg/l as ideal was used for plasma CRP.531
Statistical analysis
The statistical software package SPSS for Microsoft Windows (version 23.0; IBM
Corp., Armonk, NY) was used for all analyses. To account for the fact that the study
response rate varied among different subgroups of the population, inverse
probability weights were calculated for the main sample using the Quarterly
National Household Survey (2010).532 Participation rates for the health centre
assessment also varied according to geographic location, health, education, age, and
smoking, therefore, a specific “health centre weighting” was applied. A more
detailed description of the weighting procedure used in TILDA is described by
Barrett et al.532

Our data are presented as mean ± standard deviation throughout. These data were
tested for normality using the Kolmogorov-Smirnov test. For group comparison
between participants with diabetes and non-diabetic controls, ANOVA was used to
test for differences in means for normally distributed parameters, while the KruskalWallis test was used to test differences between group medians for non-normally
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distributed parameters. For categorical data, cross-tabulation with Chi-square
analysis was used. The distribution of MPOD was skewed, therefore, a square root
transformation of the MPOD data was performed (Figure 7.2 and 7.3). The derived
data were normally distributed and used as the dependent variable for subsequent
statistical analyses of MPOD on the diabetes group. For ease of interpretation, mean
and SD of MPOD data is presented as the non-transformed original measure for
Type 2 diabetes participants. Pearson’s product-moment correlation tests were
performed to assess the relationship between normalised MPOD and other study
variables where appropriate. Boxplots and scatterplots were used to graphically
highlight statistical findings. Multiple linear regression was used to investigate the
un-confounded associations between behavioural, anthropometric, clinical and
plasma biomarker indicators and normalised MPOD. The level of statistical
significance was set at p<0.05 for all analyses.
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Figure 7.2: Distribution of MPOD as normal optical density value with data
positively skewed [Mean =0.221; Std. Dev =0.160; N=2,782].
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Figure 7.3: Distribution of MPOD using a square root transformation now
normally distributed [Mean = 0.437; Std. Dev = 0.175; N=2,872].
7.4 Results
Two thousand seven hundred and eighty-two subjects, analysed as part of Wave 1
of TILDA, were divided into two study groups: Group 1: Non-diabetic controls
(n=2,594) and Group 2: Type 2 diabetes (n=188). Respondents ‘diagnosed with
diabetes’ and those with ‘undiagnosed diabetes’ were grouped together and
classified as having Type 2 diabetes for subsequent analyses. Characteristics of the
study population according to their diabetes status are presented in Table 7.1. Group
average MPOD was 10.3% lower in participants with Type 2 diabetes [mean
MPOD =0.20 (0.148)] compared with non-diabetic controls [mean MPOD = 0.223
(0.161)], and this difference was statistically significant [t (2780) = -1.989,
p=0.047)]. Participants with Type 2 diabetes also differed from the control group
across all other demographic, behavioural, anthropometric, clinical and plasma
parameters examined (p<0.0001 for all), with the exception of education (primary,
secondary or third level), alcohol intake, and plasma TC/HDL ratio (p>0.05 for
these variables; Table 7.1).

Participants with diabetes were older, and more likely to be male with a current or
past history of tobacco use. In general terms, the behavioural, clinical and
anthropometric profile of these participants was poorer than that observed in the
control group, with lower levels of physical activity, greater levels of obesity and
higher prevalence of hypertension and cataract. Similarly, plasma analysis revealed
that participants with diabetes were typically more hyperglycaemic, more
dyslipidaemic and displayed lower anti-inflammatory marker elevation (plasma
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vitamin D) and greater inflammatory marker elevation (CRP), than the control
group.
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Table 7.1: Characteristics of the study population according to diabetic status.
Variable

Normal Controls

Type 2 Diabetes

p

(n=2594)

(n=188)

61.40(7.62)

64.73(8.32)

0.0001*

50-64

68.12%

51.06%

0.0001‡

65-74

24.94%

35.64%

>75

6.94%

13.30%

Male

43.79%

64.89%

Female

56.21%

35.11%

Primary

18.81%

22.34%

Secondary

41.69%

44.68%

Third level

39.59%

32.98%

Current

13.42%

14.89%

Past

39.36%

47.87%

Demographic Factors
Age years (Mean (SD))
Age category years † (%)

Sex (%)
0.0001‡

Education (%)
0.174 ‡

Behavioural Factors
Smoking (%)
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0.027 ‡

Never

47.22%

37.23%

Yes

78.83%

72.87%

No

18.47%

22.87%

NA

6.51%

3.72%

Low

37.90%

54.25%

Moderate

30.07%

28.19%

High

32.03%

17.55%

BMI (kg/m2)

27.98 (4.42)

32.32 (6.25)

0.0001*

WC (cm)

93.19 (12.83)

105.47 (13.74)

0.0001*

WHtR

0.56 (0.070)

0.63 (0.08)

0.0001*

WHpR

0.894 (0.083)

0.96 (0.08)

0.0001*

Hypertensive (untreated)

5.82%

2.66%

0.0001‡

Hypertensive (treated)

24.79%

52.19%

Normotensive

69.39%

44.15%

0.223 (0.161)

0.20 (0.148)

0.047††

6.51%

13.83%

0.0001‡

Alcohol (%)
0.130 ‡

Exercise (%)
0.0001‡

Anthropometric & Clinical Biomarkers

MPOD** (Mean (SD))
Cataracts (%)
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Plasma Biomarkers
TC (mmol/L)

5.24 (1.04)

4.27 (1.06)

0.0001*

HDL (mmol/L)

1.59 (0.44)

1.27 (0.33)

0.0001*

LDL (mmol/L)

3.01 (0.92)

2.24 (0.89)

0.0001*

TG (mmol/L)

1.66(1.03)

1.94 (1.11)

0.0001*

TC/HDL Cholesterol Ratio

3.46 (0.91)

3.473 (0.92)

0.675*

TG/HDL Cholesterol Ratio

1.19 (0.961)

1.68 (1.12)

0.0001*

Non-HDL Cholesterol (TC-HDL) Ratio

3.65 (0.946)

2.99 (0.95)

0.0001*

Vitamin D (nmol/L)

59.91 (25.86)

51.90 (22.72)

0.0001*

CRP (μg/l)

2.83 (6.95)

5.23 (11.94)

0.0001*

HbA1c (%)

5.06 (0.27)

6.22 (0.934)

0.0001*

‡ Chi-square test; *Kruskal–Wallis test; ††One-way analysis of variance (ANOVA);
MPOD sqrt; P values reflect the probability associated with the given F statistic. Sig., significance.
†Age: the age division corresponds to groupings used in previously published cohort studies. 52
**MPOD, P values are reported using MPOD square root transformation (sqrt).
Abbreviations: BMI-body mass index; kg/m2- kilograms per metre squared; NA – non-applicable; WC-waist circumference; cm - centimetres; WHtR-waist-to-height
ratio; WHpR-waist-to-hip ratio. HbA1c-glycated haemoglobin; TC-Total cholesterol; HDL-High-density lipoprotein; LDL-Low-density lipoprotein; TGTriglycerides; Non HDL- Total cholesterol minus HDL; CRP-C-reactive protein; mmHg- millimetres of mercury; mmol/L -millimoles per litre; nmol/L -nanomols
per litre; μg/l-micrograms per litre. Normotensive (≤140 mmHg systolic; ≤90 mmHg diastolic); Hypertensive (>140 mmHg systolic; >90 mmHg diastolic).
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Biomarker associations with MPOD among participants with diabetes
(1) Demographic and behavioural factors
Smoking was the only demographic or behavioural factor significantly associated
with lower MPOD (F (2,185) = 6.019, p = 0.003). Post hoc analysis revealed that
participants who never smoked had significantly higher normalised MPOD
(mean=0.235(0.148)) compared with current smokers (mean=0.124(0.113); t (96);
= 3.58, p=0.001). There was also a significant difference in MPOD between past
(mean=0.19[0.151] and current smokers (t (116); = 2.268, p=0.025). However,
there was no significant difference in MPOD between non-smokers and past
smokers (t (158) = 1.723, p=0.087); [Figure 7.4 (A)].
(2) Anthropometric and clinical biomarkers
MPOD was negatively correlated with BMI, WC, and WHtR (Pearson’s correlation
= -0.202, -0.161, -0.189 respectively, p<0.05 for all), but not with WHpR
(Pearson’s r = -0.111, p>0.05). Cut-offs were applied to classify participants as
obese and non-obese for all anthropometric measures, including BMI, WC, WHtR,
and WHpR.527 Macular pigment optical density, however, was not significantly
different in individuals with excess compared with normal adiposity indices for all
anthropometric measures (p>0.05 for all; Table 7.2). Although MPOD tended to be
lower in subjects with cataracts, and in those with elevated WHtR and WHpR (all
trending towards significance), only hypertension emerged in the univariate linear
regression analysis as associated with lower MPOD [Table 7.2; Figure 7.4 (B)].
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Table 7.2: MPOD according to anthropometric and clinical biomarkers in a diabetic population (normalised MPOD).
Variable

n

Mean (SD)

25th

50th

75th

(188)

MPOD

Ideal (≤30)

122

0.200 (0.148)

0.087

0.177

0.304

Excess (>30)

66

0.199 (0.150)

0.075

0.180

0.262

Ideal (≤102 M, ≤88 F)

55

0.224 (0.140)

0.110

0.208

0.337

Excess (>102 M, >88 F)

132

0.191 (0.151)

0.076

0.162

0.264

Ideal (≤1.00 M, ≤0.85 F)

84

0.222 (0.153)

0.090

0.210

0.305

Excess (>1.00 M, >0.85 F)

103

0.183 (0.142)

0.072

0.138

0.259

Ideal (≤0.57 M, ≤0.53 F)

45

0.237 (0.164)

0.088

0.228

0.379

Excess (>0.57 M, >0.53 F)

142

0.189 (0.142)

0.086

0.172

0.267

Normotensive (≤140/90)

83

0.228 (0.166)

0.090

0.210

0.324

Hypertensive (>140/90)

105

0.177 (0.130)

0.075

0.138

0.259

sig
p

Anthropometric & Clinical Biomarkers
BMI (kg/m2)
0.964††

WC (cm)
0.101††

WHpR
0.075††

WHtR
0.073††

Blood pressure (mmHg)
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0.043††

Diabetic retinopathy
Yes

10

0.151 (0.134)

0.047

0.091

0.231

No

152

0.204 (0.149)

0.088

0.180

0.296

Yes

26

0.150 (0.108)

0.087

0.180

0.304

No

161

0.206 (0.153)

0.054

0.118

0.231

0.256††

Cataracts
0.068††

†† ANOVA was used to check for MPOD differences among anthropometric and physical biomarkers. P values are reported using MPOD square root transformation (sqrt)
(normalised MPOD) and reflect the probability associated with the given F statistic. Sig., significance.
The following cut-offs were applied to indicate ideal or excess obesity measures and normotensive/hypertension for the following variables: BMI-body mass index; [ideal ≤ 30;
excess > 30 kg/m2 - kilograms per metre squared; WC-waist circumference; ideal ≤ 88 F; ≤ 102 M; excess > 88 F; >102 M cm - centimetres; WHtR-waist-to-height ratio; ideal
≤ 0.53 F; ≤ 0.57 M; excess >0.57 F; >0.53 M; WHpR-waist-to-hip ratio; ideal ≤ 0.85 F; ≤1.00 M; excess > 0.85 F; >1.00 M; M=Male; F=Female;
mmHg systolic; ≤90 mmHg diastolic); Hypertensive (>140 mmHg systolic; >90 mmHg diastolic).
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527

Normotensive (≤140

(3) Plasma biomarkers
Macular pigment optical density was significantly lower among participants with a
raised TG/HDL ratio [Mean=0.172 (0.140)] compared to those with ideal levels
(Mean =0.215(0.152); t (185); = 2.080, p=0.039; Table 7.3; Figure 7.4 (C)). One
way analysis of variance revealed no significant difference in MPOD between those
with high and low TC, HDL, LDL, TGs, non-HDL, and TC/HDL (p= 0.287-0.946)
(see Table 7.3). Participants who were vitamin D deficient had significantly lower
MPOD [mean = 0.173(0.148)] compared to participants who had sufficient levels
[mean = 0.226 (0.145); t (185), = -2.796, p=0.006; Table 7.3; Figure 7.4 (D)].
Figure 7.5 shows a significant positive relationship between normalised MPOD and
plasma vitamin D (r=0.218, p=0.003). There was no significant association between
MPOD and plasma CRP levels (Table 7.3).
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Table 7.3: MPOD according to plasma biomarkers in a diabetic population (normalised MPOD).
Variable

n

Mean (SD)

25th

50th

75th

(188)

MPOD

Ideal (≤ 5.00)

141

0.207 (0.152)

0.088

0.182

0.304

Ideal (> 5.00)

46

0.177 (0.138)

0.068

0.163

0.260

Ideal (> 1.6)

27

0.203 (0.138)

0.089

0.184

0.275

Low (≤ 1.6)

160

0.199 (0.151)

0.085

0.173

0.296

Ideal (≤ 2.6)

127

0.20 (0.147)

0.076

0.179

0.297

High (>2.6)

10

0.195 (0.151)

0.087

0.174

0.276

Ideal (≤1.7)

97

0.203 (0.147)

0.099

0.177

0.285

High (>1.7)

90

0.195 (0.151)

0.069

0.179

0.301

Ideal (≤ 3.4)

132

0.202 (0.146)

0.088

0.178

0.303

High (>3.4)

55

0.194 (0.157)

0.072

0.172

0.263

sig
p

Plasma Biomarkers
TC (mmol/L)
0.287††

HDL (mmol/L)
0.785††

LDL (mmol/L)
0.946††

TG (mmol/L)
0.491††

Non-HDL Cholesterol Ratio
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0.671††

TG/HDL Cholesterol Ratio
Ideal (≤1.74)

118

0.215 (0.152)

0.100

0.181

0.314

High (>1.74)

69

0.172 (0.140)

0.053

0.119

0.248

Deficient (≤ 50)

96

0.173 (0.148)

0.056

0.181

0.234

Sufficient (> 50)

91

0.226 (0.145)

0.103

0.209

0.336

Ideal (≤ 3.0)

113

0.213 (0.158)

0.088

0.181

0.298

High (> 3.0)

74

0.178 (0.130)

0.069

0.167

0.262

(≤ 6.00)

77

0.203 (0.160)

0.081

0.173

0.295

(> 6.00)

97

0.190 (0.139)

0.081

0.177

0.259

0.039††

Vitamin D (nmol/L)
0.006††

CRP (μg/l)
0.120††

HbA1c (%)
0.728††

††ANOVA was used to check for MPOD differences among plasma biomarkers. P values are reported using MPOD square root transformation (sqrt) (normalised MPOD) and
reflect the probability associated with the given F statistic. Sig., significance.
The following cut-offs were applied to plasma levels: HDL, high-density lipoprotein; [high risk ≤1.6; low risk >1.6 millimoles per litre (mmol/L)]; LDL, low-density lipoprotein;
[high risk > 2.6; low risk ≤ 2.6 mmol/L]; TC, total cholesterol; [high risk > 5.00; low risk ≤ 5.00 mmol/L]; TG, triglycerides; [high risk >1.7; low risk ≤1.7 mmol/L];TG/HDL,
triglyceride to high density lipoprotein ratio; [high risk >1.74; low risk ≤1.74 mmol/L]; TC/HDL, total cholesterol to high-density lipoprotein ratio; [high risk >3.5; low risk
≤3.5 mmol/L]; Non-HDL, total cholesterol minus high-density lipoprotein; [high risk >3.4; low risk ≤ 3.4 mmol/L] as per 2016 ESC/EAS guidelines;528 plasma vitamin D
(25(OH) D) levels in nanomoles per litre (nmol/L) [deficient ≤50; sufficient >50 nmol/L] as per IOM vitamin D guidelines;530 plasma CRP levels in micrograms per litre (μg/l)
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[high > 3.00 μg/L; ideal ≤3.00 μg/L];531 and HbA1c (glycated haemoglobin) in millimoles per mol (mmol/mol) [high > 6.00 %; ideal ≤ 6.00 %] as per American Diabetes
Association guidelines.527
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Figure 7.4: Box plots of MPOD differences by (A) Smoking status (B) Hypertension status (C) Triglyceride over High Density
Lipoprotein ratio (D) Vitamin D 25(OH) D plasma levels (ANOVA).
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Figure 7.5:

Scatterplot showing a significant positive relationship between

normalised MPOD and Vitamin D (25(OH) D) plasma levels.
Multivariate model
Demographic and behavioural factors
Smoking remained a strong, negative predictor of MPOD after adjusting for
covariates. Current smoking was significantly associated with lower MPOD (Beta
coefficient = - 0.097; p=0.022; Table 7.4).
Anthropometric and physical biomarkers
The presence of cataract remained the only clinical parameter to be negatively
associated with MPOD in a diabetic population after adjusting for covariates (Beta
coefficient = - 0.078; p<0.049). None of the other anthropometric or clinical
parameters (WHtR, hypertension, diabetic retinopathy or duration of disease)
remained significantly associated with MPOD in this model (p>0.05 for all).
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Plasma biomarkers
Vitamin D remained a significant and positive predictor of MPOD in the
multivariate model, although this was a subtle effect (Beta coefficient = 0.001;
p=0.029). None of the other plasma biomarkers (TG/HDL, HbA1c or CRP)
remained significantly associated with MPOD (p>0.05 for these variables).

The correlates of MPOD identified as significant in the multivariate regression
model (smoking, cataracts, and low vitamin D status) contributed 18.5% of the
overall variability in MPOD status amongst patients with Type 2 diabetes,
(F(13,146) = 2.545, p=0.003; R2 = 0.185).
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Table 7.4: Multivariate relationship between behavioural, anthropometric, clinical, plasma biomarkers and MPOD in a diabetic population
(n=188); (F (13,146) = 2.545, p=0.003; R2 = 0.185).
Independent Variable

Unstandardised
Beta Coefficient

Std error

T

p

Constant

0.428

0.197

2.175

0.031

Age

0.001

0.002

0.700

0.485

Sex* (Female)

-0.007

0.025

-0.259

0.796

Past

-0.028

0.031

-0.913

0.363

Current

-0.097

0.042

-2.316

0.022

WHtR

-0.192

0.183

-1.046

0.297

Cataracts‡ (Yes)

-0.078

0.039

-1.988

0.049

Vitamin D (nmol/L)

0.001

0.001

2.204

0.029

CRP (μg/l)

0.001

0.001

1.382

0.169

TG/HDL Cholesterol Ratio

-0.015

0.013

-1.170

0.244

HbA1c (%)

-0.006

0.017

-0.373

0.710

Duration (years)

0.003

0.003

1.093

0.276

Retinopathy†† (Yes)

-0.092

0.058

1.585

0.115

Hypertension ‡‡ (No)

0.035

0.027

1.302

0.195

Smoking†
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R2 = 0.185; F = 2.545; p= 0.003. Dependent variable = MPOD sqrt (normalised MPOD); Std. Error, Standard Error.
*Male = control group; † Never smoked = control group; ‡ No Cataracts = control group; ††No Diabetic Retinopathy = Control group; ‡‡ Hypertension= Control group.
Abbreviations: CRP - C-reactive protein; HbA1c- glycated haemoglobin; μg/l – micrograms per litre; nmol/l – nanomoles per litre; WHtR- waist to height ratio; TG/HDLtriglyceride to high-density lipoprotein ratio.
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7.5 Discussion
Consistent with previous investigations

6, 7

this study provides further evidence that

patients with Type 2 diabetes have significantly lower MPOD, compared with nondiabetic controls. Additionally, MPOD was inversely associated with a range of
behavioural,

clinical

and

anthropometric

biomarkers

including

smoking,

hypertension, and bodyweight. Body mass index, WHtR, and WC were all negatively
associated with MPOD on univariate analysis, in the Type 2 diabetes group, (Pearson’s
r, p<0.05 for all). Some novel relationships were observed among the plasma
biomarkers, with low plasma vitamin D and raised TG/HDL ratio associated with low
MPOD levels; findings not previously reported. Current smoking, the presence of
cataract and low plasma vitamin D persisted as predictors of low MPOD in the
multivariate model, after adjusting for all other covariates, albeit collectively
explaining just 18.5% of the variability in MPOD.

Our finding that hypertensive participants with diabetes had significantly lower
MPOD compared to normotensive participants with diabetes is important given that
hypertension is an established risk factor for the development and progression of
diabetic retinopathy.533 The association between MP and hypertension is not well
documented; however, one study has reported a link between lower MPOD and selfreported diagnosis of high blood pressure.52 Chronic hypertension causes vascular
endothelial shear stress and circumferential wall stress.151 This, in turn, leads to
endothelial damage, increased ROS production and activation of inflammatory
cascades.534 One recent study found lower levels of GSH and increased levels of 8OHdG, a marker of oxidative stress, in diabetes patients with hypertension, supporting
the hypothesis that oxidative stress increases considerably in hypertension, especially
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as a diabetic co-morbidity.535 Endogenous antioxidants become depleted when both
conditions coexist, which leads to an increased need for exogenous antioxidants (i.e.
vitamins C and E, carotenoids lutein, zeaxanthin, and meso-zeaxanthin) to balance
redox status, which may explain our observation that hypertension in the presence of
Type 2 diabetes may have an added negative impact on MPOD status on univariate
analysis. While we did not reach statistical significance in multivariate analyses, future
studies with larger cohorts could further investigate this finding.

The inverse relationship observed between adiposity and MPOD confirms previous
findings among patients with Type 2 diabetes.7 Adipose tissue, visceral fat in
particular; may act as a sink/reservoir for macular carotenoids,54 thereby influencing
carotenoid concentrations in plasma,347 and subsequent retinal uptake.18 Distribution
of body fat is also a significant factor, as it has been shown that concentrations of
lutein and zeaxanthin are higher in abdominal fat,67 and abdominal adiposity is
characteristic in Type 2 diabetes. Excess visceral fat also contributes to inflammation
and oxidative stress due to the increased production of adipocytokines (IL-1, IL-6, IL8, and TNF-alpha).372 The chronic low-grade inflammation, associated with obesity
and Type 2 diabetes leads to increased oxidative stress and further inflammation,
putting a greater demand on antioxidant defences. Antioxidant defences may also be
lower in overweight/Type 2 diabetes patients, due to their lower intake of antioxidantrich foods (e.g. fruits and vegetables), their increased utilisation of these molecules
(e.g. increased inflammation/ROS in insulin-dependent tissue such as the retina) and
their impaired generation of other supportive anti-oxidants, reviewed by Savini et
al,367 which may collectively lead to MPOD depletion.68 Dietary intake of lutein and
zeaxanthin was not, however, assessed as part of the TILDA study (this limitation is
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discussed further below).

Of interest, and to our knowledge a novel finding; is that MPOD was significantly
lower for participants with a raised TG/HDL ratio. This observation is important given
that Type 2 diabetes patients commonly display an altered lipoprotein profile, termed
diabetic dyslipidaemia (i.e. raised TGs and low HDL), and that diabetes patients in the
current study had indeed significantly higher TGs and significantly lower HDL plasma
lipid levels than the non-diabetic control group. The characteristic lipid profile of
individuals with Type 2 diabetes,158 may have important implications for MP levels in
the eye, as dietary carotenoids are transported on circulating lipoproteins.18 The
general consensus is that xanthophylls associate with HDL,327 and that HDL levels are
therefore important for the efficient delivery and uptake of lutein and zeaxanthin to
the eye.18 The relationship between MPOD and plasma lipid levels has previously been
investigated in patients with diabetes, with a marginal negative association between
MPOD and TGs and a marginal positive association between MPOD and HDL
observed (p<0.08 for both).6 We previously reported significantly lower levels of
MPOD in patients with Type 2 versus Type 1 diabetes, and noted significantly lower
HDL values within the Type 2 diabetes group, postulating that lower HDL levels may
have mediated this difference.7 More recently, the DiVFuSS study,21 has demonstrated
significant improvements in plasma LDL, HDL, and TGs, in a group of patients with
diabetes who participated in a 6-month RCT. The coincident increase in MPOD
observed in the intervention group may have been partially mediated by these
favourable changes in lipid profile.18 We acknowledge, however, that the lack of
dietary information on carotenoid intake is a limitation of the current study, (discussed
in further detail below), as MPOD is influenced by both lutein and zeaxanthin intake
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as well as transport and assimilation (i.e. mediated by HDL) in the target tissue. This
information would have added to the interpretation of our findings. While we found
that lower MPOD was associated with raised plasma TG/HDL levels on univariate
analysis (p=0.039), plasma TG/HDL did not remain as a predictor of MPOD in
multivariate analyses. Future studies, however, based on a larger number of diabetic
participants could further investigate this finding.

Our findings in relation to smoking are not surprising given that smoking is associated
with increased oxidative stress, not only through the increased systemic production of
ROS but also through a weakening of the antioxidant defence systems.65 The reported
associations between cigarette smoking and diabetic retinopathy, however, are more
variable, with some studies reporting an association,536 while others have found no
such relationship.537 Chronic hyperglycaemia causes oxidative stress, so the increased
production of ROS in diabetes may be compounded further by smoking, another
important source of free radicals. Exposure to cigarette smoking causes profound
oxidative damage to human RPE cells.538 Interestingly, we found no difference in
MPOD between previous smokers and non-smokers, perhaps indicating that MPOD
repletion is possible in diabetes patients through smoking cessation.

Cataract status remained a predictor of low MPOD in the multivariate model in line
with previous observations.260,

539

The marginal statistical significance of this

association in the univariate model (p=0.068) was more than likely limited by the
small sample size in the current study (n=26 with cataracts). The evidence that
carotenoids, lutein, and zeaxanthin, are protective against the development of cataract,
however, is well documented

260, 539

suggesting the possibility of a causal role for
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MPOD depletion in the pathogenesis of cataract development in diabetes. With
ageing, there is a natural decrease in the production of antioxidants and antioxidant
enzymes and a concomitant increase in phototoxic chromophores in the lens.250
Phototoxic reactions, whether caused by endogenous or exogenous singlet oxygen
photo-sensitisers, lead to a modification of lens proteins, which eventually causes
opacification of the lens (i.e. cataractogenesis) (reviewed by Roberts & Dennison 250).
The phototoxic reaction damage can be prevented by the appropriate antioxidant
quenchers. Lutein and zeaxanthin both accumulate in the lens

540

and research has

shown a lower prevalence of nuclear cataract amongst those with higher intakes of
xanthophylls.539 Furthermore, findings from the AREDS2 revealed that participants in
the lowest quintile of dietary lutein/zeaxanthin intake experienced slower cataract
progression with carotenoid supplementation.260 Although the development of cataract
is an age-related phenomenon, other factors appear to influence their progression
including poor diet, smoking, UV light exposure, and metabolic factors. In the current
study, a greater percentage of patients with diabetes had cataract (13.83%) compared
with controls (6.51%), (p<0.0001). Cataract status does not appear to relate to MPOD
levels among non-diabetic individuals,52 suggesting a relationship that is particular to
cataract in the presence of Type 2 diabetes, which may impact MPOD levels in this
patient group. To our knowledge, this is the first study to report an association between
low MPOD and the presence of cataract in diabetes.

That vitamin D emerged as a positive predictor of MPOD in Type 2 diabetes after
controlling for other covariates represents a particularly novel and interesting finding.
Although the best-known function of vitamin D is to help the body absorb and use
calcium, other important roles include protection of the eye during inflammation,
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oxidative stress, fibrosis, and angiogenesis.541 Vitamin D insufficiency is common
amongst the general population, and particularly amongst those who are obese, 542 or
who have diabetes.543 Our findings support this observation as both the control and
Type 2 diabetes group had mean vitamin D levels which fell well below the optimal
recommended level,544 and as the participants with Type 2 diabetes had significantly
lower plasma vitamin D compared with the control group (p<0.0001). Vitamin D
receptors are expressed in the eye, including the RPE,545 which suggests that vitamin
D is biologically relevant to the eye.307 Research shows that human adult RPE cells
(ARPE-19) also express the 1α-hydroxylase enzyme required to convert 25(OH) D to
its biologically active 1,25 (OH)2 D form.546

The ability to inhibit neovascularisation has also led researchers to examine vitamin
D’s involvement in diabetic retinopathy development.547 Plasma vitamin D
concentrations have previously been found to be inversely related to the severity of
retinopathy in patients with diabetes,307 with this study suggesting that the
measurement of serum 1,25(OH) 2 D3 concentrations might be helpful in predicting
retinopathy progression, and that a detailed ophthalmologic examination is indicated
for diabetes patients whose plasma vitamin D levels are low.307 The DiVFuSS study
recently examined the effects of supplementation with a novel multi-component
nutritional supplement, which included vitamin D and the antioxidants lutein and
zeaxanthin, on ocular health and visual function in a group of participants with
diabetes.21 Individuals receiving the DiVFuSS formula improved on all measures of
visual function, and although not statistically significant (p=0.07), four subjects were
downgraded from moderate to mild non-proliferative diabetic retinopathy following
the intervention, while one subject on placebo was upgraded from mild to moderate
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non-proliferative diabetic retinopathy over the same period.21 Positive outcomes from
DiVFuSS may in part be due to supplementation with a compound that specifically
targets both inflammation and oxidative stress. It is plausible that these findings may
have been mediated by enhancements in MPOD (27% mean increase in DiVFuSS
group vs 2% mean decrease in placebo group), and by vitamin D’s attenuating effect
on inflammation with reductions in plasma hs-CRP (60% mean decrease in DiVFuSS
group vs 11% mean decrease in placebo group).21 Although CRP levels were
significantly higher in participants with diabetes [mean =5.23(11.94)], compared with
non-diabetic controls [mean=2.83(6.95)], (p=0.0001), in our study, MPOD was not
significantly different in diabetic participants with an elevated CRP level compared
with ideal levels (p=0.120; Table 7.3). These findings, however, warrant further
investigation.
7.6 Limitations
There are a number of important limitations to the current study which should be
recognised. Firstly, the use of self-reported data is not ideal. Diabetes diagnosis was
based on respondent’s recall rather than health records. Concomitantly, respondents
were not explicitly asked what type of diabetes they had. Instead, patient medications
(self-reported) and age at diagnosis were used to account for possible Type 1 cases,
which may have led to some misclassification. The presence or absence of cataract
was also based on patient’s recall rather than direct examination. Secondly, small
patient numbers in some of the sub-group analyses may have limited the statistical
power to detect associations that may exist (Type II error possibility). It is worth noting
that the prevalence of diagnosed and undiagnosed Type 2 diabetes in these older adults
resident in Ireland was found to be relatively low compared to other populations (8.6%
and 0.9% respectively), which would account for low participant numbers in the
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current study.130,

520

Another limitation was that dietary intake of the macular

carotenoids was also not assessed, therefore, it was not possible to control for potential
confounding from variable intake of lutein and zeaxanthin. Macular pigment
constituent carotenoids cannot be synthesised de novo in humans, therefore, lower
levels of MPOD may be experienced in participants with poor dietary intake of
antioxidants. Mares et al,384 found that MPOD was directly related to dietary intake of
carotenoids, lutein, and zeaxanthin, but even more strongly with plasma levels,
suggesting that unmeasured physical and medical factors may also influence the
uptake, distribution and utilisation of lutein and zeaxanthin.384 The absence of plasma
analysis of lutein and zeaxanthin was also a weakness in our study.

Furthermore, it is worth noting that measures of MP are subject to genetic variation.
Macular pigment optical density is a multi-factorial phenotype, associated with
variation in genes related to carotenoid transport, uptake, and metabolism, and may be
independent of known dietary and health influences in MPOD.72 The MP determinants
reported herein (current smoking, presence of cataracts and vitamin D status)
explained 18.5% of the overall variability in MPOD, in participants with diabetes. Diet
is an important determinant of MPOD, therefore, cautionary interpretation of our
findings is advised. Finally, while the current study used a large, nationally
representative population, MPOD was only measured on participants who were able
to attend a health centre.

Despite these drawbacks, there were a number of strengths to the current analysis. The
design of the TILDA study is a particular strength, in particular, the selection of
participants from which our diabetes and controls were drawn, which was
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representative of the Irish population aged 50 and over. Plasma lipoproteins (HDL,
TG/HDL) and inflammatory markers (vitamin D, CRP) were analysed and blood
pressure was measured, which represents an advance on previous research carried out,
research which was based on self-reported doctors’ diagnosis of high cholesterol and
hypertension.52 The additional use of HbA1c helped identify undiagnosed and prediabetes cases. Finally, anthropometric measures such as WHtR and WHpR were used
to analyse overweight/obesity in conjunction with BMI and WC.
7.7 Conclusion
Overall our findings suggest that individuals with Type 2 diabetes have lower MP
relative to healthy controls, although the clinical importance of the observed level of
difference is questionable. Future studies with larger cohorts could further investigate
this finding, as the difference in MPOD, although significant (p=0.047), was marginal.
Hyperglycaemia and other anthropometric, metabolic and clinical correlates
associated with diabetes (e.g. excess adiposity, dyslipidaemia, hypertension, and
cataract), may relate to a state of chronic oxidative stress and inflammation, processes
which also underlie many of the functional alterations in the retinal vasculature in
diabetic retinopathy. Both over utilisation (i.e. in response to elevated oxidative
stress/inflammation) and undersupply of antioxidant nutrients (dietary deficiency,
excess adiposity, and dyslipidaemia) may contribute to lower levels of MP in the
diabetic retina. Clinical benefits may be realised through the early identification of
MPOD depletion in Type 2 diabetes. Given the borderline statistical significance of
many of our findings, more work needs to be done to verify and refine our
understanding of the observed relationships. The MPOD difference of 0.053 OD in
participants with sufficient vitamin D (>50nmol/L) versus deficient levels (≤50
nmol/L), although significant (p<0.006), is not clinically meaningful as it stands.
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Macular pigment optical density measurement is not routinely available, however, the
capacity of commonly-measured surrogate plasma biomarkers (HDL, TG/HDL,
vitamin D), and anthropometric measurements (WHtR, WC) to identify people with
diabetes at risk of low MP merits further consideration. The novel and important
findings reported herein should now be subject to further research, to better understand
the nature of any relationships that may exist.
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8. INVESTIGATION OF SURROGATE BIOMARKERS ASSOCIATED
WITH LOWER MACULAR PIGMENT IN A GROUP OF OLDER IRISH
ADULTS.
8.1 Abstract
Purpose
Macular pigment confers potent antioxidant and anti-inflammatory effects at the
macula but its optical density in the eye is not routinely measured in clinical practice.
This study explored a range of anthropometric, clinical, and plasma measures which
are commonly measured and which may be associated with lower MPOD, in a large,
population-based sample of older adults.
Method
Two thousand five hundred and ninety four subjects completed a full MP assessment,
as part of Wave 1 of TILDA. The MPOD was measured using c-HFP. Clinical [blood
pressure], plasma [lipoproteins, inflammatory markers] and anthropometric [waist
(cm), hip, (cm), height (cm) weight (kg)] biomarkers were measured for each
participant.
Results
Mean (SD) MPOD for the study group was 0.223 (0.161) with a range of 0 to 1.08.
One way analysis of variance revealed that MPOD was significantly lower among
participants with: low plasma HDL (p =0.038), raised plasma TG/HDL ratio (p=0.003)
and raised TC/HDL ratio (p=0.030). Subjects with an elevated WC had significantly
lower MPOD [mean = 0.216(0.159)] compared to those with an ideal WC [mean =
0.229(0.162); p=0.034]. Significant correlates of MPOD on mixed linear model
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analysis included education, smoking status and WC.
Conclusions
Higher abdominal fat is associated with lower MPOD in this representative sample of
older Irish adults. While altered lipoprotein profiles (low HDL, raised TG/HDL ratio,
raised TC/HDL ratio), may affect the transport, uptake and stabilisation of carotenoids
in the retina, these plasma biomarkers were not predictive of low MPOD after
adjustment for abdominal circumference. Although WC emerged as a possible
anthropometric predictor of lower MPOD, its effect size appears to be small and
clinical applicability questionable.
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8.2 Introduction
The concept that MP may have a protective role in neurodegenerative eye conditions
such as AMD, glaucoma and diabetes is well documented.4, 353, 548 The macula is
particularly important for central high resolution vision and blindness results when
this area is lost to disease. The carotenoids lutein, zeaxanthin, and meso-zeaxanthin,
collectively known as MP, accumulate at the macula to the exclusion of all other
dietary carotenoids. Macular pigment has a unique distribution within the retina,
selectively located within the fibres of Henle in the fovea and in the inner nuclear layer
of the parafovea,43, 549 implying that MP plays an important role in vision and macular
health, and that it is biologically relevant to the eye.44, 45

The selective absorption of short-wavelength light prior to photoreceptor light capture
means that MP plays an important role in visual performance in healthy eyes.2
Concomitantly, through its optical filtration and antioxidant properties, MP protects
the retina from photo-oxidative damage, thereby, reducing the risk of various eye
diseases, including AMD 5 and diabetes.15, 21 Decreased MPOD appears to be a risk
factor for the development of these diseases,6, 7, 55 and numerous studies investigating
the effects of MP augmentation have also reported beneficial effects in diseased eyes.5,
15, 218

While the aetiopathogenesis of conditions such as AMD and diabetes remain a

matter of debate, there is growing consensus that oxidative damage,291,

355

and

associated inflammation 10, 242 play a significant role. The macular carotenoids exhibit
neuroprotective functions at the macula,4, 230 and it has been shown that lutein and
zeaxanthin can affect immune responses, reduce inflammation and have antiangiogenic properties in the eye.4, 550, 551 Therefore, the density of MP, offers potential
as a clinical biomarker of retinal health.
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Macular pigment levels can be measured in vivo, but the relevant instrumentation is
not commonly available in clinical practice. Other indirect techniques for assessing
MP status such as dietary and plasma analysis have limited practical application and
are not used in clinical practice. Previous investigators have examined and identified
possible predictors of MPOD, and found associations with dietary intake,384 plasma
cholesterol and lipoprotein status,18, 71 metabolic status,6, 7 overweight/obesity status,52
and smoking.52 Many of these studies, however, were based on opportunistic sampling
and restricted to small sample sizes,6, 7, 71 or relied on self-reported data.52 While one
study investigated determinants of MPOD on a larger older cohort (n=1698), this
research was conducted on female subjects only.384

Consequently, there is merit in exploring the association between MPOD and more
commonly measured clinical and biometric parameters, which might be used to
identify patients at risk of low MP, so that practitioners can implement strategies for
preventative intervention. While self-reported data provide a reasonable measure of
overall health status, concerns exist regarding the magnitude of bias from using these
measures in analysis.552, 553 This study was designed, therefore, to address some of the
limitations of previous investigations by examining the predictive capacity of a range
of measured (rather than self-reported) clinical (blood pressure), plasma (lipoproteins,
inflammatory markers) and anthropometric (abdominal fat) parameters in a large
representative group of older men and women.523
8.3 Methods
Study design and population
Cross-sectional data from Wave 1 of TILDA were analysed in this study, which was
229

conducted during the period between October 2009 and July 2011. A sample of 8,175
individuals representative of the population of Ireland aged 50 years and older
participated in the study, as described in detail elsewhere.523, 524 In brief, information
on health behaviours and lifestyle patterns were captured by trained professional
interviewers in participants’ own homes using CAPI.525 Participants were then invited
to take part in a health assessment.526 Macular pigment measurement was only
conducted on participants who attended a health centre (Figure 8.1). In total 5,275
consented to and participated in the health centre based assessment. The current study
was approved by the Technological University Dublin Research Ethics Committee
and all experimental procedures adhered to the tenets of the Declaration of Helsinki.
All participants provided written informed consent prior to participation in the study.
Demographic, health and lifestyle factors
Demographic, health, and lifestyle factors were captured for the study group. The
presence or absence of eye pathology was determined using the CAPI with the
question ‘’has a doctor ever told you if you had any of the following conditions:
diabetes, AMD, cataracts or glaucoma?’’. Participants were asked if they currently
smoked or had ever smoked cigarettes regularly (daily for at least a year), and were
categorised as never smoked, past smokers or current smokers. Blood pressure was
measured and participants were defined as hypertensive if mean seated systolic BP
exceeded 140 mmHg or mean seated diastolic BP exceeded 90 mmHg.
Macular pigment optical density assessment
Macular pigment optical density was measured by c-HFP using the Macular Metrics
Densitometer (Macular Metrics, Rehoboth, MA). This device was modified
specifically for the TILDA study and the method of measurement has been described
230

in detail elsewhere.56 In brief, MPOD was measured centrally at 0.5° (i.e. 1° stimulus)
and peripherally at 7o (parafoveal target at 7°). Macular pigment assessment was
carried out on the eye with the best VA or if there was equal vision in both eyes the
right eye was chosen.56 Corrected VA was measured using the ETDRS LogMAR chart
at a distance of 4 metres using participants’ existing prescription where necessary.
Participants with a VA worse than 0.5 LogMAR were excluded from the analysis
(Figure 8.1).
Anthropometric assessment
Height (cm) and weight (kg) were measured to one decimal place using a Seca wall
mounted measuring rod and Seca electronic floor scales, as described in detail
elsewhere.525 Body mass index was calculated from measured height and weight as:
weight (kg)/height (m2), with obesity classified as a BMI > 30 kg/m2.363 Waist and hip
circumferences were measured to the nearest cm. Ideal WC was defined as a WC of ≤
88 cm in women and ≤ 102 cm in men, while central obesity was defined as a WC >
88 cm in women and > 102 cm in men. Waist-to-height ratio and WHpR were
calculated based on measured data. Cut-off thresholds for ideal and excess WHtR were
taken as less than or greater than 0.53 in women and 0.57 in men respectively. For
WHpR a cut off threshold of less than or greater than 0.85 in women and less than or
greater than 1.00 in men defined ideal and elevated WHpR.527, 554
Plasma analysis
A blood sample was provided for plasma analysis using defined phlebotomy protocols,
which are described in detail elsewhere.525, 526 Respondents were not asked to fast
before the health assessment and plasma was analysed for a complete lipid profile,
including TC, HDL, LDL and TGs, each measured in mmol/L. Triglyceride over HDL
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ratio, TC/HDL ratio and non-HDL cholesterol were calculated from measured data.
Cut-offs were applied to indicate high/low or ideal plasma lipid levels as per 2016
ESC/EAS guidelines (Table 8.2).528 Plasma vitamin D levels [(25(OH)D); nmol/L]
were also measured and participants were considered vitamin D deficient if plasma
levels were ≤50 nmol/L and sufficient if plasma levels were >50 nmol/l as per IOM
vitamin D guidelines.530 Inflammatory marker CRP [μg/l] and HbA1c (%) were also
measured. A threshold of > 3.00μg/l for high and ≤ 3.00μg/l for ideal was used for
plasma CRP 531 and a cut off of ≤ 5.00% and > 5.00% was used for HbA1c.
Statistical analysis
The statistical software package SPSS for Microsoft Windows (v.25.0; IBM Corp.,
Armonk, NY) was used for analysis. To account for the fact that the study response
rate varied between different subgroups of the population, inverse probability weights
were calculated for the main sample (CAPI participants) using the Quarterly National
Household Survey 2010. The probability of participation in the health centre also
varied according to health, education, age and smoking, therefore, a specific ‘health
centre weight’ was created. A detailed description of the weighting procedures used
in TILDA is given elsewhere.532

Demographic data for eligible study participants were compared to those of the overall
health centre population using Chi-square analyses, to explore if they differed from
the representative sample. Data for the study group were tested for normality using the
Kolmogorov-Smirnov test. One-way analysis of variance was used to test for
differences in means for normally distributed parameters. For categorical data, crosstabulation with Chi-square analysis was used. Pearson’s product-moment correlation
tests were performed to assess the relationship between normalised MPOD and other
232

study variables where appropriate. A mixed linear model analysis (fixed effect) was
carried out to estimate the independent association between putative predictor
variables (behavioural, clinical, anthropometric, and plasma biomarker parameters)
and normalised MPOD. Data are presented as mean ± standard deviation throughout.
The level of statistical significance was set at p< 0.05 for all analyses.
8.4 Results
In total, 8,175 individuals aged 50 years and older participated in the study. Of these,
5,275 consented to and participated in the health centre based assessment as part of
Wave 1 of TILDA. For various reasons, 2,681 were excluded from the current
analysis, leaving an overall study population of 2,594 (Figure 8.1). The main reasons
for exclusion related to unsuccessful MPOD measurement or the presence of retinal
pathology. Participants were identified with AMD, cataracts and glaucoma from the
CAPI. The presence or absence of diabetes was identified from prescribed diabetes
medications at the time of the interview (identified using the ATC codes ‘A10A’ for
insulin and ‘A10B’ for oral hypoglycaemic medications), from the CAPI and/or from
measured HbA1c [HbA1c > 6.4% (diabetes); 5.7 - 6.4% (pre-diabetes)], as per
American Diabetes Association cut-off values.24
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Figure 8.1: Flowchart illustrating the selection of study participants and reasons for
exclusion from the original participant group.
Abbreviations: AMD, age related macular degeneration, MPOD, macular pigment
optical density, VA, visual acuity, TILDA, the Irish Longitudinal Study on Ageing.

A Chi-square test of independence was performed to examine the relationship between
the centre population (n=5,275) and participants with a valid MPOD assessment
(n=2,594). The age profile of study participants [mean age = 61.95 (8.47) years; range
50 to 93 years] was similar to the overall health centre assessed population [mean age
= 61.40 (7.62) years; range 51 to 86 years] and there was no significant difference in
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sex or education status between the two groups (p=0.882 and p=0.768 respectively).
Mean (SD) MPOD for the study group was 0.223 (0.161) with a range of 0 to 1.08.
Differences in normalised MPOD by demographic (age group, sex, education status),
health and lifestyle variables (smoking, hypertension, physical activity and cataracts)
were examined. Participants were divided into three age groups: 50-64 years (mean
MPOD =0.223[0.160]); 65 to 74 years (mean MPOD=0.223[0.164]); and 75 years and
over (mean MPOD =0.216[0.151]). Age was not significantly associated with MPOD
on one-way ANOVA (p=0.852). Additionally, age as a continuous variable was not
significantly associated with MPOD (r=-0.003, p=0.883). Our findings concur with
previously reported statistically significant associations between gender, educational
status and smoking with MPOD in the TILDA dataset (p<0.05 for all), despite a
slightly different study sample (participants with AMD, glaucoma, diabetes and prediabetes were excluded from the current analysis of older individuals, but not in a
previous study).52
Clinical, anthropometric and biomarker associations with MPOD
(1) Clinical factors
We found no correlation between measured hypertension status (with or without
treatment) and MPOD in the current study [n= 2,591; t=1.105; p=0.331].
(2) Anthropometric factors
The MPOD was significantly and negatively correlated with all anthropometric
measures (BMI; WC; WHtR and WHpR) on univariate analysis (Pearson’s r = -0.047;
-0.073; -0.060; -0.081 respectively, p<0.05 for all). Waist circumference, however,
emerged as the only anthropometric variable associated with lower MPOD on binary
univariate analysis. Participants with an elevated WC had significantly lower MPOD
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[Mean =0.216(0.159)] compared to participants with ideal WC [Mean = 0.229(0.162);
n=2,589; t=2.119; p=0.034; Table 8.1; Figure 8.2], although the differences were not
clinically meaningful, as illustrated in Figure 8.2. MPOD did not differ significantly
according to any other anthropometric measures (p>0.05 for all; Table 8.1).
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Table 8.1: The MPOD according to anthropometric biomarkers in the study population (n=2594); (normalised MPOD).
Variable

n

Mean (SD)

(2594)

MPOD

25th

50th

75th

Sig
p

Anthropometric Biomarkers
BMI (kg/m2)
Ideal (≤30)

1387

0.223[0.161]

0.100

0.191

0.310

Excess (>30)

1203

0.223[0.160]

0.101

0.195

0.316

Ideal (≤102 M, ≤88 F)

1433

0.229[0.162]

0.105

0.196

0.319

Excess (>102 M, >88 F)

1158

0.216[0.159]

0.096

0.187

0.301

Ideal (≤ 1.00 M, ≤0.85 F)

1637

0.225[0.158]

0.105

0.195

0.314

Excess(>1.00 M, >0.85 F)

954

0.219[0.165]

0.093

0.189

0.307

Ideal (≤0.57 M, ≤0.53 F)

1307

0.228[0.161]

0.107

0.197

0.317

Excess (>0.57 M, >0.053 F)

1282

0.219[0.162]

0.095

0.188

0.306

0.829

WC (cm)
0.034*

WHpR
0.133

WHtR
0.079

One way ANOVA was used to check for MPOD differences among anthropometric and physical biomarkers. P values are reported using MPOD
square root transformation (sqrt) (normalised MPOD) and reflect the probability associated with the given F statistic. Sig., significance.
The following cut-offs were applied to indicate ideal or excess obesity measures and normotensive/hypertension for the following variables:
BMI-body mass index; [ideal ≤ 30; excess > 30 kg/m2 - kilograms per metre squared; WC-waist circumference; ideal ≤ 88 F; ≤ 102 M;
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excess > 88 F; >102 M cm - centimetres; WHtR-waist-to-height ratio; ideal ≤ 0.53 F; ≤ 0.57 M; excess >0.57 F; >0.53 M;
WHpR-waist-to-hip ratio; ideal ≤0.85 F; ≤1.00 M; excess > 0.85 F; >1.00 M; M=Male; F=Female.
Abbreviations: BMI- body mass index; cms - centimetres; F-female; kg-kilogram; M-male; MPOD-macular pigment optical density;
WC-waist circumference; WHpR – waist-to-hip ratio; WHtR – waist-to-height ratio.
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Figure 8.2: Violin plot of MPOD differences according to waist circumference status
(ANOVA).
(3) Plasma biomarkers
Participants with ideal plasma levels of HDL had significantly higher MPOD than those with
low HDL levels [n=2587; t=-2.077; p=0.038; Table 8.2; Figure 8.3 (A)]. The MPOD was also
significantly lower among participants with a raised TG/HDL ratio [n=2587; t = 2.994,
p=0.003; Table 8.2; Figure 8.3 (B)] and among participants with a raised TC/HDL ratio
[n=2574; t=2.166; p =0.030; Table 8.2; Figure 8.3 (C)]. The magnitude of all statistically
significant differences were not, however, clinically important, as illustrated in Figure 8.3.
One-way analysis of variance revealed no significant difference in MPOD levels for any other
plasma biomarkers (p>0.05 for all); Table 8.2).
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Table 8.2: The MPOD according to plasma biomarkers in the study population (n=2594), (normalised MPOD).
Variable

n

Mean (SD)

25th

50th

75th

(2594)

MPOD

Ideal (≤5.00)

1040

0.224[0.161]

0.109

0.192

0.315

High (>5.00)

1549

0.222[0.160]

0.096

0.192

0.312

Ideal (>1.6)

1126

0.229[0.160]

0.104

0.203

0.323

Low (≤1.6)

1463

0.218[0.161]

0.096

0.183

0.305

Ideal (≤2.6 )

833

0.222[0.157]

0.109

0.190

0.314

High (>2.6)

1756

0.223[0.162]

0.098

0.193

0.312

Ideal (≤1.7)

1625

0.224[0.161]

0.102

0.192

0.313

High (>1.7)

961

0.220[0.161]

0.097

0.191

0.312

Ideal (≤3.4)

1044

0.224[0.159]

0.108

0.190

0.314

High (>3.4)

1541

0.222[0.162]

0.098

0.194

0.311

1187

0.233[0.163]

0.106

0.204

0.322

Sig
p

Plasma Biomarkers
TC (mmol/L)
0.735

HDL (mmol/L)
0.038*

LDL (mmol/L)
0.965

TG (mmol/L)
0.487

Non HDL (mmol/L)
0.715

TG/HDL Cholesterol Ratio
Ideal (≤0.87)
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0.003*

High (>0.87)

1402

0.214[0.158]

0.095

0.182

0.304

Ideal (≤3.5)

1483

0.229[0.164]

0.105

0.200

0.319

High (>3.5)

1093

0.214[0.156]

0.096

0.180

0.300

Low (≤ 50)

963

0.223[0.159]

0.107

0.191

0.305

Optimal (> 50)

1609

0.222[0.162]

0.096

0.192

0.314

Low (≤ 3.0)

1927

0.224[0.158]

0.103

0.196

0.314

High (>3.0)

644

0.218[0.170]

0.093

0.181

0.305

≤ 5.00

1206

0.221[0.159]

0.101

0.188

0.309

>5.00

1388

0.225[0.162]

0.101

0.196

0.316

TC/HDL Cholesterol Ratio
0.030*

Vitamin D (nmol/L)
0.654

CRP (μg/l)
0.186

HbA1c (%)
0.633

One way ANOVA was used to check for MPOD differences among plasma biomarkers. P values are reported using MPOD square root
transformation (sqrt) (normalised MPOD) and reflect the probability associated with the given F statistic. Sig., significance.
The following cut-offs were applied to plasma levels: HDL, high density lipoprotein; [high risk ≤1.6; low risk >1.6 millimoles per
litre (mmol/L)]; LDL, low density lipoprotein; [high risk > 2.6; low risk ≤ 2.6 mmol/L]; TC, total cholesterol; [high risk > 5.00;
low risk ≤ 5.00 mmol/L]; TG, triglycerides; [high risk >1.7; low risk ≤ 1.7 mmol/L];TG/HDL, triglyceride to high density lipoprotein
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ratio; [high risk >0.87; low risk ≤ 0.87 mmol/L]; TC/HDL, total cholesterol to high density lipoprotein ratio; [high risk >3.5;
low risk ≤ 3.5 mmol/L]; Non-HDL, total cholesterol minus high density lipoprotein; [high risk >3.4; low risk ≤ 3.4 mmol/L]
as per 2016 ESC/EAS guidelines;528 plasma vitamin D (25(OH) D) levels in nanomoles per litre (nmol/L) [deficient ≤ 50;
sufficient >50 nmol/L] as per IOM vitamin D guidelines;530 plasma CRP levels in micrograms per litre (μg/l) [high risk > 3.00 mg/L;
low risk ≤ 3.00 μg/l];531 and HbA1c (glycated haemoglobin) in millimoles per mol (mmol/mol) [high > 5.00 %;
ideal ≤ 5.00 % (42.1 mmol/mol) as per American Diabetes Association guidelines.24
Abbreviations: CRP - C-reactive protein; HbA1c- glycated haemoglobin; HDL-high density lipoprotein; LDL-low density
lipoprotein; μg/l – micrograms per litre; MPOD-macular pigment optical density; non HDL –TC-HDL; nmol/L – nanomoles
per litre; TC-total cholesterol; TC/HDL- total cholesterol over high density lipoprotein; TG-triglyceride; TG/HDL- triglyceride
over high density lipoprotein.
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Figure 8.3: Violin plots of MPOD differences by (A) High Density Lipoprotein (HDL);
(B) Triglyceride over High Density Lipoprotein (TG/HDL) Ratio and (C) Total
Cholesterol over High Density Lipoprotein (TC/HDL) Ratio (ANOVA).
Mixed linear model effects
A mixed linear model analysis was carried out on normalised MPOD versus
demographic, behavioural, anthropometric and plasma biomarker independent
variables. Low education, current smoking and elevated WC were significant
predictors of MPOD in this regression model (Table 8.3). None of the plasma
biomarkers (HDL, TG/HDL, TC/HDL, Vitamin D, CRP or HbA1c) were significantly
associated with MPOD in this model (P >0.05 for all variables; Table 8.3).
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Table 8.3: Mixed linear model effects; relationship between demographic, behavioural, anthropometric and plasma biomarkers, and
MPOD in a normal population.
Parameter

Estimate

Std. error

T

(normalised MPOD)
p

Constant

0.448

0.085

5.297

0.000

Sex* (Female)

0.011

0.008

1.284

0.199

Secondary

0.023

0.010

2.376

0.018

Tertiary/higher

0.038

0.010

3.866

0.000

Past

-0.004

0.008

-0.588

0.557

Current

-0.022

0.011

-2.011

0.044

WC (cm)

-0.001

0.000

-2.415

0.016

HbA1c (%)

0.006

0.013

0.454

0.650

Vitamin D (nmol/L)

-0.000

0.000

-0.728

0.467

CRP ‡ (>3μg/l)

0.000

0.000

0.745

0.456

HDL (mmol/L)

-0.009

0.012

-0.781

0.435

TG/HDL Cholesterol Ratio

-0.001

0.005

-0.161

0.872

TC/HDL Cholesterol Ratio

-0.001

0.005

-0.145

0.885

Education

Smoking†
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Hypertension ‡‡ (mmHg) (No)
Hypertensive

0.008

0.007

1.056

0.291

Hypertensive

0.002

0.010

0.188

0.851

0.018

0.014

1.291

0.197

(not medicated)
Cataracts‡‡ (No)

Dependent variable = MPOD sqrt (normalised MPOD).
*Male = reference group; † Never smoked = reference group; ‡ CRP (≤ 3mg/L= reference group); †† No Hypertension = reference group; ‡‡
Yes cataracts = reference group. WC (cms); HbA1c (%); vitamin D (nmol/L), HDL (mmol/L); TG/HDL ratio; TC/HDL ratio – as continuous variables.
Abbreviations: Std. Error - Standard Error; cms - centimetres; CRP - C-reactive protein; HbA1c- glycated haemoglobin; HDL-high density lipoprotein;
μg/l – micrograms per litre; mmHg- millimetres of mercury; nmol/L – nanomoles per litre; WC-waist circumference; TC/HDL- total cholesterol over high
density lipoprotein; TG/HDL- triglyceride over high density lipoprotein.
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8.5 Discussion
The key finding to emerge from this study is the observation that participants with
increased central adiposity, as indicated by an elevated WC, had significantly lower
MPOD compared to those with ideal measures. Macular pigment was also lower
amongst participants with an altered lipoprotein profile, i.e. in participants with raised
plasma TG/HDL ratio, raised plasma TC/HDL ratio and low plasma HDL.
Additionally, male gender, current smoking and low educational status was associated
with lower MPOD, findings which concur with previously reported analyses on a
similar cohort.52 Elevated WC, current smoking and low educational attainment
persisted as predictors of low MPOD on mixed linear model analysis, after adjusting
for all other covariates.

Consistent with most previous reports,16, 52, 54, 384 MPOD was, in fact, significantly and
negatively associated with all measures of overweight/obesity, including BMI, WC,
WHtR, WHpR, (Pearson’s r; p<0.05 for all). With cut-off levels applied to classify
participants into binary categories (obese or non-obese),527 elevated WC emerged as
the main anthropometric variable associated with lower levels of MPOD. Carotenoids,
such as lutein and zeaxanthin, are known to accumulate in adipose tissue, and in
visceral fat in particular,54,

219

therefore, distribution of body fat is an important

consideration.67 Higher WC has previously been reported to be the strongest nondietary predictor of low MPOD,384 and findings from the Third National Health &
Nutrition Examination Survey revealed that participants with higher WC values were
increasingly likely to have hypertension, diabetes, dyslipidaemia and the metabolic
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syndrome,555 metabolic correlates independently associated with lower MPOD.6, 7, 18

As an indicator of ‘abdominal’ obesity 384, 555 WC is receiving increased attention as a
more clinically relevant measure of adiposity compared with BMI. Intra-abdominal
fat may have different metabolic consequences compared with other patterns of fat
distribution or overall adiposity, as it is more biologically active. Intra-abdominal fat
is associated with inflammation due to the increased production of adipocytokines.372,
442

The associated inflammation becomes chronic, therefore, obesity is now considered

a low-grade inflammatory condition, which in turn leads to an increase in oxidative
stress.69 Chronic inflammation and associated oxidative stress exert a greater demand
on antioxidant defences within the body; defences which tend to be lower in the
obese,367 and older adults.556 Sex differences exist in relation to how body fat is
deposited,449 and there is evidence for gender-related differences in the accumulation
of carotenoids.16,

17

Interestingly, we found that MPOD was 9% lower in males

compared with females (p=0.004), possibly explained by the fact that men store more
fat in the visceral (abdominal) fat depot,555 thereby, making these pigments less
available to retinal tissue.68, 326 Thus, lower antioxidant activity may relate not only to
lower intake of antioxidants and phytochemical rich foods in older adults (e.g. fruits,
vegetables and legumes),557 reduced activity of endogenous anti-oxidative
enzymes,556,367 but also due to an increased utilisation of these molecules. Collectively,
these factors may lead to antioxidant depletion, including lower levels of MP in the
eye.4, 291
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Another interesting finding is the observation that MPOD was significantly lower in
participants with raised plasma TG/HDL ratio (>0.87 mmols/L), and in those with
raised plasma TC/HDL ratio (>3.5 mmols/L). Although these relationships did not
persist on mixed linear model analysis, the lower MPOD levels observed among
participants with low plasma HDL corroborates previous findings which identified an
association between plasma HDL and MPOD.462 Dyslipidaemia is often characterised
by low levels of HDL, raised TGs and smaller, more atherogenic LDL particles.160 As
carotenoids are bound to circulating lipoproteins, the relation between plasma levels
of the various lipoproteins and MPOD is of interest. Evidence suggests that HDL is
the major carrier of lutein to the eye.18 Furthermore, HDL is a known ligand for SRB1, and the mechanism of xanthophyll uptake by the retina appears to be entirely SRB1 dependent.326

Vitamin D deficiency has repeatedly been associated with ocular disease.306,
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Additionally, vitamin D deficiency is common world-wide, particularly so in older
adults.498, 558 Of interest, we recently reported that individuals with Type 2 diabetes
who were vitamin D deficient (≤50 nmol/L), had significantly lower MPOD, and that
vitamin D was a significant positive predictor of MPOD on multivariate analysis in
this study group.559 The current study, however, suggests that the association between
vitamin D status and MPOD does not persist among older adults who are free of ocular
pathology. Furthermore, no relationship was observed between MPOD and the
inflammatory marker CRP.
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This population-based representative study advances previously published work which
also utilised TILDA data to explore MPOD,52 as the analyses herein relied much less
on self-reported data. A large number of subjects were excluded from the overall MP
analysis (n=2,014), and possible reasons for this included: technical issues, poor
fixation and poor VA, among others. While c-HFP is one of the most common methods
of measuring MP, it is challenging to perform, particularly so for older adults. 56
Research has shown that some participants have difficulty performing this technique,
with dropout rates varying from 10 to 20%.56, 560 A Chi-square test of independence
was performed, however, comparing the centre population (n=5,275) and the smaller
sample of participants with a valid MPOD assessment (n=2,594), and this test
confirmed that there was no significant difference in age, sex or education status
between the two groups. More importantly, the attenuated number of participants in
the current study did not appear to impact on the validity of our findings as we
confirmed previously reported analyses on a similar cohort.52 Despite differences in
inclusion criteria, the relationship between education and smoking status and MPOD
observed therein and elsewhere was confirmed in our analysis.52,

384

Some

discrepancies did emerge, however. Self-reported measures of high cholesterol, for
example, were not associated with MPOD according to the previous analysis,52
whereas the analysis of direct cholesterol measures taken herein suggest that
dyslipidaemia (i.e. low plasma HDL, raised TG/HDL, raised TC/HDL) may have
implications for the delivery and uptake of MP in the eye. Additionally, while an
inverse association between self-reported high blood pressure and MP was also
previously reported,52 we found no association between measured hypertension
(treated or untreated) and MPOD on either univariate or mixed linear model analysis.
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These direct measurements (systolic and diastolic, mmHg), would appear to outweigh
self-reported data.52 Interestingly, we recently reported that individuals with diabetes
and hypertension, had significantly lower MPOD compared to those without,559 which
suggests that when conditions co-exist the redox balance may become increasingly
upset, and that oxidative stress may increase considerably in hypertension, especially
as a diabetic co-morbidity.535 Hypertension, however, does not appear to affect or
deplete MP, in older adults, who are free of ocular pathology.

A number of variables did not persist as predictors of MPOD on mixed linear analysis,
(i.e. sex, and plasma lipoproteins), despite significant outcomes on univariate analysis.
While gender (male) and lipoprotein (low HDL, raised TG/HDL, raised TC/HDL)
status contribute to lower levels of MP, it appears that WC status is a more robust
predictor of low MPOD. It is important to note, however, that the small difference in
mean MPOD between participants with and without elevated WC suggests that any
effect size is likely to be modest and not particularly useful in terms of predictive
capacity from a clinical perspective.
Macular pigment was measured using c-HFP, a technique that has been validated in
older subjects 335, 560 and found to be reliable.560 Macular pigment measurements have,
however, shown a degree of variability across studies.59,
Stringham et al,

335

335, 384, 561

For example,

measured the density of MP in patients with intermediate AMD,

using a similar device and retinal eccentricity (0.50), and the mean optical density was
(0.37±0.24). Subjects in CAREDS had an average MP level of (0.36±0.22) right eye
and (0.34±0.21) left eye, and these participants were of a similar age.384 We
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acknowledge that the mean MPOD in the current study was notably lower than
previously reported.335, 384 While, we found no correlation between age and MPOD in
the current study, our findings suggest that older Irish adults have lower MP levels on
average. It is worth noting that the prevalence of conditions which might affect MPOD
levels is relatively high in Ireland, including AMD,562 glaucoma,563 and Type 2
diabetes.130 The lower levels of MP observed in the current study, may, therefore,
reflect the combined influence of inadequate dietary intake and increased utilisation of
these phytonutrients.556 Given the variety of mechanisms which may contribute to
macular pigment depletion, and the ocular risks associated with such depletion in this
age group, the importance of diet cannot be over-emphasised. The provision of
coloured fruit and vegetables which are rich in a broad range of antioxidants including
the target carotenoids lutein and zeaxanthin and/or supplementation with these
nutrients represents an obvious recommendation, given the putative protection that this
pigment confers against age-related vision loss. These recommendations should now
be subject to further research.
8.6 Limitations
Limitations of the current study include the failure to assess dietary intake or plasma
levels of the carotenoids lutein and zeaxanthin as MPOD is influenced by both intake
and individual efficacy of absorption.70 It is also worth noting that the high variability
and lower levels of MPOD observed across different people may also be subject to
genetic variation

72

a factor that is not accounted for in our analysis. Information on

supplement usage was also not assessed, which would have added to the interpretation
of our findings, particularly those in relation to vitamin D and MPOD.

252

Despite these limitations, there were a number of strengths to the current analysis.
Plasma lipoproteins and inflammatory markers were analysed and blood pressure was
measured, an advance on previously used self-reported data.52 Participants with
comorbidities, AMD, glaucoma and diabetes, were eliminated from the current
analysis and HbA1c was used to help identify undiagnosed and pre-diabetes cases.
The use of measured rather than self-reported anthropometric data for WC, WHtR and
WHpR is a further strength of the study. Finally, the representative study design of the
TILDA study, the unique sampling method which includes both males and females,
and the detailed exclusion criteria, we believe that our findings and the conclusions
drawn from our findings concerning MPOD are representative of the older Irish
population.
8.7 Conclusion
In conclusion, we report that elevated WC and dyslipidaemia may have important
implications for the storage, delivery and uptake of lutein and zeaxanthin in the eye.
Determinants of MPOD (i.e. education status, tobacco use, WC), remain statistically
significant following mixed linear model analysis. Although no strong predictor of
MPOD status emerged in this analysis, the capacity of more commonly-measured
surrogate biomarkers to help identify people at risk of low MP merits further
consideration. Given the marginal statistical significance of many of our findings,
further research is necessary to refine our understanding of the observed relationships
as MP is not routinely measured in clinical practice.
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9. SUMMARY, CONCLUSIONS AND DIRECTION FOR FUTURE WORK
9.1 Summary and conclusions
This work was designed to explore the optical density of MP in patients with diabetes
mellitus and to compare their levels with those of normal healthy controls. The
findings reported and the conclusions drawn herein are based on the outcomes of two
cross-sectional, case-controlled studies, one of which investigated MPOD in
participants with Type 1 and Type 2 diabetes in a hospital setting; and the other, which
explored MPOD amongst Type 2 diabetes participants in TILDA, a large, randomlyselected population representative of older adults in Ireland. Although the optical
density of MP can be measured in vivo it is not routinely measured in clinical practice.
Therefore, as part of this research, surrogate biomarkers for the prediction of MPOD
in patients at high risk of MPOD depletion (i.e. Type 2 diabetes and older adults) were
investigated and identified in the TILDA cohort. A literature review of the evidence
describing macular carotenoid depletion in diabetes (particularly Type 2 diabetes) was
also performed, to identify the causal mechanisms by which diabetes mellitus and its
metabolic perturbations contribute to lower MP levels. The conclusions and future
research proposed as a result of the outcomes of this work are as follows.
Macular pigment is lower in Type 2 diabetes
Consistent with previous investigators who have explored the relationship between
MPOD and diabetes, 6, 9 this research provides further evidence that low MP may
indeed be a feature of diabetes. Furthermore, the current work demonstrates that
MPOD is significantly lower in those with Type 2 diabetes participants compared to
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those with Type 1; this represents an entirely novel finding. Overall, the behavioural
(smoking), clinical (blood-pressure, presence of cataracts), anthropometric (body
weight, BMI, WHtR) and plasma (lipoproteins, inflammatory markers) parameters of
participants with Type 2 diabetes were poorer than those observed in non-diabetic
controls. Hyperglycaemia and other anthropometric, metabolic and clinical correlates
associated with diabetes may, therefore, constitute readily measurable proxies for the
presence of chronic oxidative stress, inflammation and other pathological processes
which underlie many of the functional alterations observed in diabetic retinopathy,
and which also appear to be responsible for MPOD depletion in diabetes.
Surrogate biomarkers for the prediction of patients at risk of low macular pigment in
Type 2 diabetes.
Tobacco use and the presence of cataract were significantly associated with lower
MPOD levels amongst participants with diabetes. Metabolic comorbidities
characteristic of Type 2 diabetes (i.e. overweight/obesity, dyslipidaemia and
hypertension) were also significantly negatively associated with MPOD. The
combined effect of increased lutein/zeaxanthin sequestration by excess adipose
tissue, increased inﬂammation and elevated oxidative stress associated with
overweight/obesity (i.e. BMI, WHtR, WC), appear to explain, at least in part, the
lower MPOD levels observed in these Type 2 diabetes participants. Unfavourable
lipoprotein status (i.e. raised TG/HDL) may also contribute to lower MPOD, as MP
carotenoids are primarily transported by HDL in plasma,18, 71 and mechanisms
governing their retinal capture and/or stabilisation in the retina are also subject to
HDL inﬂuence.71 Furthermore, hypertension, especially as a co-morbidity of
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diabetes, appears to further deplete MPOD levels due to its role in elevated oxidative
stress.535 The borderline statistical significance of these findings, however, means
that more work needs to be done on larger, purposively selected study populations to
verify and refine our understanding of how these factors affect MPOD levels.

Vitamin D emerged as a positive predictor of MPOD in participants with Type 2
diabetes which is again, a novel finding. In addition, MP levels were significantly
lower in participants with Type 2 diabetes who were deficient in vitamin D (i.e. ≤
50nmol/L). Vitamin D status does not appear to be associated with MPOD in older
adults who are free of ocular pathology (i.e. AMD, glaucoma, diabetes/pre-diabetes).
These findings suggest that the chronic low-grade inflammation and oxidative stress
associated with Type 2 diabetes may indeed explain the lower MPOD levels
observed in those with this condition and that the low vitamin D status associated
with these pathological processes may itself be used as a predictor of low MPOD in
patients with diabetes (Type 2). Findings from the DiVFuSS trial 21 are promising
and appear to suggest that supplementation with a compound which specifically
targets both inflammation and oxidative stress (i.e. vitamin D and carotenoids,
lutein/zeaxanthin and meso-zeaxanthin) may be beneficial in protecting against the
mechanisms underlying diabetic retinopathy.21 Furthermore, in line with previous
research,307 a dilated eye examination might be recommended for diabetes patients
whose low plasma vitamin D levels indicate an elevated risk of diabetic retinopathy.
Further research is, however, needed to articulate the links between inflammatory
status, disease progression and the ameliorative effects of supplementation with
carotenoids and other vitamins (i.e. vitamin D) amongst those with diabetes.
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Current findings suggest that the exogenous antioxidants lutein, zeaxanthin and
meso-zeaxanthin, become depleted in diabetes. Although no strong predictor of
MPOD depletion emerged, the capacity of more commonly used everyday measures
to help identify patients at risk of low MPOD in diabetes, such as anthropometric
status (WC, WHtR) and plasma biomarkers (TG/HDL, vitamin D) merits further
consideration. Further research should now be undertaken to refine our
understanding of these observed relationships.
Causal mechanisms putatively associated with lower macular pigment in diabetes
mellitus.
A review of the evidence pertaining to MP levels in diabetes mellitus suggests that
MP is lower in diabetes (Type 2 diabetes in particular). Candidate causal mechanisms
to explain the lower MP levels reported include oxidative stress, inflammation,
overweight/obesity and dyslipidaemia. In summary, hyperglycaemia, oxidative stress
and changes in redox homeostasis are fundamental events in the pathogenesis of
diabetic retinopathy. The body’s natural defence against oxidative damage is
neutralisation by endogenous antioxidants (enzymatic and non-enzymatic), supported
by exogenous antioxidants (i.e. vitamin C, vitamin E, carotenoids lutein, zeaxanthin
and meso-zeaxanthin). While oxidative stress is increased in diabetes, the activities of
the antioxidant defence system are concomitantly diminished. In addition,
inflammation is involved in the development of diabetic complications. Inflammatory
processes underlie many of the functional changes in retinal vasculature observed
histologically in early diabetic retinopathy. Oxidative stress triggers inflammatory
responses and inflammation also enhances the production of ROS. Locally, the
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occurrence of these metabolic changes can lead to MPOD depletion in the eye.
Adipose tissue (more common in Type 2 diabetes) is another source of inflammation
and also a major body store for carotenoids, lutein and zeaxanthin. Competitive
storage by increased visceral fat may not only compete for retinal uptake but also
independently increase oxidative stress and inflammation, thereby, reducing
antioxidant capacity and MP levels in the eye. Finally, reduced insulin action in Type
2 diabetes may also increase the risk of dyslipidaemia. The characteristic lipid profile
of an individual with diabetes (i.e. increased TGs and low HDL) may have important
implications for the delivery and uptake of MP in the eye.

Impaired defence against ROS at the retina may not only be attributable to the
increased utilisation of these antioxidants in diabetes (via chronic inflammation and
oxidative stress) but may also arise as a result of increased adiposity (visceral fat in
particular) and dyslipidaemia (i.e. low HDL, raised TGs), metabolic correlates which
may adversely affect MP by compromising the availability, transport, and assimilation
of these dietary carotenoids in the eye. Furthermore, lower intake of foods rich in
carotenoids and other nutrients (i.e. fruit, vegetables, legumes), is common in Type 2
diabetes. Overall, dietary advice focused on enhanced antioxidant supply and the
optimal provision of anti-inflammatory nutrients (e.g. vitamin D, omega-3 essential
fatty acids), along with lifestyle modifications such as increased physical activity to
better manage bodyweight and plasma lipids, may be an effective prophylactic means
to control oxidative stress/inflammation in diabetic eye disease and potentially slow
the progression of diabetic retinopathy.
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Surrogate biomarkers for the prediction of patients at risk of low macular pigment in
older Irish adults.
Finally, given the possibility that higher levels of MP may be beneficial for vision
and ocular health, and that MPOD is not routinely measured in clinical practice, a
range of behavioural, anthropometric, clinical and plasma measures were also
explored as possible predictors of low MPOD amongst a cohort of non-diabetic older
adults. Several findings emerged from this investigation. Of note, low educational
status, current smoking and elevated WC were all significant predictors of lower
MPOD in this non-diabetic cohort. That an elevated WC (>102cm in males, >88cm
in females) was independently associated with lower MPOD levels is particularly
interesting, given that participants with higher WC values are also more likely to
have hypertension, diabetes, dyslipidaemia and the metabolic syndrome,555
metabolic correlates independently associated with lower MPOD. 6, 7, 18 This lends
credence to the theory that central adipose sequestration of carotenoids plays a role
in MPOD depletion, and adds further support to the recommendation that WC be a
routine measure in identifying patients at risk of low MPOD. However, further
research is needed in this area as the difference in MPOD (0.013 OD), while
statistically significant, was not at a level deemed clinically significant.

Macular pigment was significantly lower amongst non-diabetic participants with low
plasma HDL, raised plasma TG/HDL ratio, and raised TC/HDL ratio. Of interest,
dyslipidaemia can often precede the overt appearance of Type 2 diabetes by several
years.171 These findings suggest that the characteristic lipid profile of individuals
who are overweight or obese, or who have emerging metabolic disease or established
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Type 2 diabetes,158 (i.e. raised TGs and low HDL), may indeed have important
implications for MP levels in the eye. While plasma lipoprotein biomarkers were not
predictive of low MPOD on regression analysis, these preliminary findings warrant
further investigation to fully elucidate any relationships which might exist.

Eye-care practitioners are well-positioned to help motivate patients towards dietary
modification (for example enhanced carotenoid and vitamin D intake) and lifestyle
changes (such as increased physical activity). Notably, formal educational status was
a positive predictor of MPOD amongst older subjects. It is well known that
educational status is a marker for overall socioeconomic status (SES),564 and that
lower SES is associated with a constellation of risk factors thought to mitigate the
accumulation of carotenoids at the macula, (i.e. tobacco use,65 overweight/obesity,16,
17, 54

dyslipidaemia,18 oxidative stress,552 and inflammation).553 Furthermore, research

has shown that people who are less educated with lower incomes consume more
energy-dense, micronutrient-dilute food, compared with their higher
SES counterparts, who have higher fruit and vegetable intake.565 Current smoking
emerged as a significant predictor of low MPOD in both Type 2 diabetes participants
and amongst older, non-diabetic adults. Apart from its association with lower overall
antioxidant intakes and increased oxidative stress and antioxidant utilisation,
smoking is also a significant, yet preventable, direct cause of trauma to the eye which
can lead to blindness. Given the emerging evidence that MP is important for vision
and ocular health,4 and that smoking is an established modifiable risk factor for
AMD,49, 62 more effort is needed to increase patient awareness of the harmful effects
of smoking on the eye. Clinical practitioners can play an important role in educating
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patients on the importance of carotenoid intake (i.e. fruit, vegetables, legumes) and
of smoking cessation, lifestyle changes which may help to maintain healthy eyes in
the long-term.

Given the ready availability of such data, the use of commonly measured proxies to
help identify people at risk of low MP is worth exploring. The marginal statistical
significance of many of our findings in this area means that further research is
necessary to refine our understanding of these observed relationships. In time, this
may contribute to the establishment of a checklist to be used in the screening and
identification of individuals at high risk of MPOD depletion and its consequent
ocular pathologies.
9.2 Strengths and limitations of the current research
The different presenting features of Type 1 and Type 2 diabetes and the interplay of
their disease components with MPOD were analysed and compared with non-diabetic
controls in the initial study. There were several strengths to this analysis. The MPOD
was measured using c-HFP method, dietary intake of carotenoids was quantified,
plasma lipids (TC, HDL, TG, and LDL) and HbA1c were measured, to explore the
influence of potential explanatory factors on central MPOD in diabetes (Type 1 and
Type 2). There were, however, a number of limitations which should also be
recognised. While c-HFP technique is considered the gold standard psychophysical
method for measuring MPOD, the clinical densitometer can only take two
measurements, centrally and peripherally, therefore, providing no information on the
spatial distribution of MP. Although, dietary intake of lutein and zeaxanthin was
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quantified, the FFQ used in this study was designed for an American population
(among Irish participants), which was not ideal. The lack of plasma carotenoid
analysis was also a drawback. Body mass index was used to assess overweight/obesity,
however, this measure alone does not provide a precise indicator of adiposity, visceral
fat in particularly (more commonly found in Type 2 diabetes). Therefore, future
studies investigating the link between MPOD and obesity should encompass more
refined methods of body fat assessment including WC, WHtR and WHpR.
Inflammatory markers (i.e. vitamin D and CRP) were also not analysed as part of this
study. Finally, small patient numbers in some of the sub-group analyses may have
limited our ability to detect statistical effects.

Findings from this study, however, helped inform the type of analysis performed in
the TILDA study. There were a number of strengths to the TILDA study. The design
of the study itself was a particular strength. Diabetes participants and non-diabetic
controls were drawn from a large randomly selected sample, representative of the Irish
population aged 50 and over. Plasma lipoproteins including the various lipoprotein
fractions (TC/HDL, TG/HDL, non-HDL) and inflammatory markers (vitamin D,
CRP) were analysed and blood pressure was measured. The additional use of HbA1c
helped identify undiagnosed and pre-diabetes cases. Overall, the detailed exclusion
criteria used was a key strength of the study. Anthropometric measures such as WHtR,
WHpR and WC, were also used to analyse overweight/obesity, an advance on previous
analysis which used BMI only. There were, however, also a number of weaknesses to
the study, which are worth noting. Firstly, the use of self-reported data was not ideal,
particularly concerning diagnosis of diabetes (Type 1 vs Type 2), duration of disease
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and the presence of cataract (all self-reported). Customised-HFP was used to measure
MPOD, which requires significant patient training to produce meaningful results,
particularly for older participants. A large number of subjects had to be excluded from
the current study (n=2,014) due to their inability to successfully complete MPOD
measurements. In addition, small participant numbers in some of the diabetic subgroup analyses may have limited statistical power to detect associations (i.e. Type II
error). Furthermore, dietary intake of lutein and zeaxanthin and plasma analysis of
carotenoids were not assessed, therefore, it was not possible to control for potential
confounding from the variable intake of lutein and zeaxanthin.

Finally, the review paper provided an in-depth analysis of the causal mechanisms and
metabolic perturbations putatively associated with lower MP in diabetes (Type 2
diabetes in particular).This article provided a holistic evaluation of diet (and/or
supplementation) and lifestyle in relation to MPOD and diabetes and the latest
available evidence was explored. Some limitations which prevailed, however,
included small sample sizes in the reviewed literature and the merging of Type 1 and
Type 2 diabetes patients in statistical analyses. Additionally, the complex interplay of
diabetes and its metabolic correlates (adiposity, dyslipidaemia, oxidative stress and
inflammation) with MPOD status represented a particular challenge.
9.3 Directions for future work
Macular pigment has a unique concentration within the retina and is biologically
relevant to the protection of the eye.44, 45 While existing evidence suggests that MP is
protective against the onset and progression of diabetic retinopathy based on animal
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studies,14, 20, 186 and one RCT,21 the potential protective effects of MP against diabetic
retinopathy in humans need be clarified, particularly in cases where MP levels are low.
Therefore, the findings of this current work should now prompt and inform the
development of a well-designed, placebo-controlled clinical trial to help us further
understand the relationship which exists between MPOD and diabetes, and the
implication of this relationship for ocular health.

Future studies should measure carotenoid intake and MPOD levels in a range of
patients with diabetes (Type 1 & Type 2), at various stages of the disease (i.e. no
retinopathy, non-proliferative, proliferative, with or without diabetic macular
oedema), and compare their clinical outcomes, carotenoid intake and MPOD levels
with those of individuals not afflicted with the condition. Disease progression and
macular health should be monitored prospectively (ideally over 2 years or more). As
dietary estimation of carotenoids and antioxidants is complex and challenging, this
work should also be extended to embrace placebo-controlled supplementation trials
with both ocular carotenoids in isolation (lutein, zeaxanthin and meso-zeaxanthin
alone) or as part of a multi-component antioxidant/anti-inflammatory preparation.
Clinical outcome measures should include MPOD augmentation, structural
parameters of the macula (as assessed with OCT) and disease progression.

Insulin resistance, impaired glucose tolerance and Type 2 diabetes can exist for many
years before retinal signs become evident in diabetes, therefore, it is important that
both the clinical (HbA1c, lipids, BP and inflammatory markers) and histological
(structural) aspects of the condition are recognised and monitored. There is merit in
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exploring the association between MPOD and more commonly assessed parameters
such as behavioural (tobacco use), anthropometric (WC, WHtR), plasma (HDL,
TG/HDL, vitamin D and CRP) and clinical (blood pressure, presence of cataracts)
measures. This could help to determine whether MPOD levels and specifically the risk
of low MPOD status, can be predicted using these data. Also, whether clinical
interventions designed to alter these parameters and the course of the disease itself can
also elicit more favourable MPOD status and ocular health outcomes.

Clinical health benefits may be realised through the early identification of MPOD
deficits in diabetes patients and through the implementation of appropriate
interventions (supplementation with carotenoids and other nutrients) which may help
to prevent or slow the progression of diabetic retinopathy. Importantly, a combination
of lifestyle behaviours such as the avoidance of smoking, physical activity, and the
adoption of a healthy dietary pattern (i.e. increased fruit and vegetable intake) may not
only lower the prevalence of Type 2 diabetes but may also protect against the
cumulative pathological mechanisms which precipitate diabetic retinopathy.
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APPENDICES
Appendix 1: Macular Pigment and Diabetes Consent Form

Macular Pigment Optical Density Study and Diabetes
We are currently recruiting for an observational study looking at the levels of macular
pigment in a diabetes population at the Mater Hospital, in conjunction with the Dublin
Institute of Technology. The main aim is to examine whether the levels of macular
pigment are correlated with diabetes, and also the level of diabetic retinopathy that
each individual may have, and assess whether changes in the levels of these pigments
affect visual acuity. Participation in this study is entirely voluntary and non‐
participation does not affect your current treatment at the Mater Hospital. All results
will be examined anonymously.
Participation involves photographing the back of the eye with a special non‐invasive
instrument which measures the levels of macular pigment. As these levels can be
affected by dietary intake, we will also conduct a food intake questionnaire to control
for this. We envisage performing these tests and questionnaires at the time of your
screening/OPD clinic visit. Should you wish to participate in this important research
study please sign on the dotted line below as consent.
Paul Connell
Consultant Vitreoretinal Surgeon Mater Hospital. Date: …………………………
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Appendix 2: Diabetes & Macular Pigment Study - Data Capture Form
EXCLUSION CRITERIA:


Ocular diseases other than non-proliferative diabetic retinopathy



Previous ocular surgery or ocular trauma



Best corrected vision < 6/18



Taking MP supplements (e.g. Macushield, Ocuvite Lutein, Vitalux,
Vision Ace, Lutein Omega 30, etc)

Date (D/M/Y): ______________________
Location: ____________________________________________
Name: ________________________________________________
MRN: ________________________________
Sex: M / F

DOB (D/M/Y): __________________________

Race: ______________________________
Current smoker: Y / N

Previous smoker: Y / N

BMI (kg/m2): ________________________
Type of diabetes:

Duration of diabetes (years):

None: ____ Type 1: ____
Type 2: _____

Study group:

Right visual acuity:

____ Non-diabetic (control)
____ Diabetes, no DR
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____ Diabetes, non-proliferative DR

Left visual acuity:

Study Eye:
Right eye: ____
Left eye: ____

Previous laser treatments Medications for diabetes:
for DR:
Right eye: Y / N

____ Insulin
Date: ____ Oral hypoglycaemics

____________________
Multivitamin supplements? Y / N
Left eye: Y / N

Date:

_____________________

Specify:____________________________________

Systemic comorbidities:

Most recent blood data recording:

Date (D/M/Y):

HbA1C (%):
Triglycerides (mmol/L):
HDL cholesterol (mmol/L):
LDL cholesterol (mmol/L):
Total cholesterol (mmol/L):

MPOD Right: ____________ SD: _____________ MPOD Left: ____________SD:
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Appendix 3: Lutein and Zeaxanthin FFQ:
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Appendix 4: TILDA Documentation
TILDA. (2019). The Irish Longitudinal study on Ageing (TILDA) Wave 1,
2009-2011. [dataset]. Version 1.9. Irish Social Science Data Archive.
SN:0053-01. www.ucd.ie/issda/data/tilda/wave1
Tilda Data Documentation: https://tilda.tcd.ie/data/documentation/
TILDA Release Guide v4.1
https://www.ucd.ie/issda/t4media/0053-00_TILDA_Release_Guide_v4.1.pdf
The Design of the Irish Longitudinal Study on Ageing
https://tilda.tcd.ie/publications/reports/pdf/Report_DesignReport.pdf
Methodology:https://tilda.tcd.ie/publications/reports/pdf/w1-key-findingsreport/Chapter11.pdf
Fifty plus in Ireland 2011;First results from the Irish Longitudinal Study on
Ageing (TILDA): https://tilda.tcd.ie/publications/reports/pdf/w1-key-findings
report/Tilda_Master_First_Findings_Report.pdf
Computer Aided Personal Interview - TILDA
https://www.ucd.ie/issda/t4media/005301_TILDA_Wave1_CAPI_Questionn
aire.pdf
Wave 1 Self Completion Questionnaire
https://tilda.tcd.ie/data/documentation/doc/wave1/Wave%201%20Self%20C
ompletion%20Questionnaire.pdf
TILDA Wave 1 Derived Variables Codebook
https://www.ucd.ie/issda/t4media/005301_TILDA_Wave1_Derived_Variables_Codebook_v1.9.pdf
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